

**Independent Auditors' Report**

To the Members of  
**PI Health Sciences Limited**

**Report on the Audit of the standalone financial statements**

**Opinion**

We have audited the accompanying standalone financial statements of **PI Health Sciences Limited** ("the Company"), which comprise the balance sheet as at March 31 2025, the statement of profit and loss including the statement of other comprehensive income, the statement of cash flow statement and the statement of changes in equity for the year then ended, and notes to the standalone financial statements, including a summary of material accounting policies and other explanatory information. (hereinafter referred to as "the standalone financial statements").

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid standalone financial statements give the information required by the Companies Act, 2013, as amended ("the Act") in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at March 31, 2025, its loss including other comprehensive income, the changes in equity and its cash flows for the year ended on that date.

**Basis for Opinion**

We conducted our audit of the standalone financial statements in accordance with the Standards on Auditing (SAs), as specified under section 143(10) of the Act. Our responsibilities under those Standards are further described in the 'Auditor's Responsibilities for the Audit of the Standalone financial statements' section of our report. We are independent of the Company in accordance with the 'Code of Ethics' issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the standalone financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the standalone financial statements.

**Information Other than the Standalone financial statements and Auditor's Report Thereon**

The Company's Board of Directors is responsible for the other information. The other information comprises the information included in the Board's Report but does not include the standalone financial statements and our auditor's report thereon. Our opinion on the standalone financial statements does not cover the other information and we do not express any form of assurance conclusions thereon.



In connection with our audit of the standalone financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the standalone financial statements, or our knowledge obtained during the course of our audit or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

#### **Responsibilities of Management for the Standalone financial statements**

The Company's Board of Directors is responsible for the matters stated in Section 134(5) of the Act with respect to the preparation of these standalone financial statements that give a true and fair view of the financial position, financial performance including other comprehensive income, cash flows and changes in equity of the Company in accordance with the accounting principles generally accepted in India, including the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Act read with relevant Rules issued thereunder.

This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Those Board of Directors are also responsible for overseeing the Company's financial reporting process.

#### **Auditor's Responsibilities for the Audit of the Standalone financial statements**

Our objectives are to obtain reasonable assurance about whether the standalone financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:



- Identify and assess the risks of material misstatement of the standalone financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the Company has adequate internal financial controls with reference to standalone financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the standalone financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the standalone financial statements, including the disclosures, and whether the standalone financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

#### **Report on Other Legal and Regulatory Requirements**

1. As required by the Companies (Auditor's Report) Order, 2020 ("the Order") issued by the Central Government of India in terms of section 143(11) of the Act, we give in the Annexure A, a statement on the matters specified in the paragraph 3 and 4 of the Order.
2. As required by Section 143(3) of the Act, we report that:
  - (a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit;



- (b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books except for certain matters in respect of audit trail as stated in the paragraph 2(i)(vi) below on reporting under Rule 11(g) of the Companies (Audit and Auditors) Rules 2014 (as amended);
- (c) The balance sheet, the statement of profit and loss including the statement of other comprehensive income, the cash flow statement and statement of changes in equity dealt with by this Report are in agreement with the books of account.
- (d) In our opinion, the aforesaid standalone financial statements comply with the Indian Accounting Standards specified under Section 133 of the Act, read with relevant Rules issued thereunder;
- (e) On the basis of the written representations received from the directors and taken on record by the Board of Directors, none of the directors is disqualified as on March 31, 2025 from being appointed as a director in terms of Section 164 (2) of the Act;
- (f) With respect to the adequacy of the internal financial controls with reference to these standalone financial statements and the operating effectiveness of such controls, refer to our separate Report in “Annexure B” to this report. Our report expresses an unmodified opinion on the adequacy and operating effectiveness of the Company’s internal financial controls with reference to standalone financial statements.
- (g) In our opinion, and according to the information and explanations given to us, the Company has paid/ provided for managerial remuneration in accordance with the requisite approvals mandated by the provisions of Section 197 read with Schedule V to the Act.
- (h) The modifications relating to the maintenance of accounts and other matters connected therewith in respect of audit trail are as stated in the paragraph 2(b) above on reporting under Section 143(3)(b) of the Act and paragraph 2(i)(vi) below on reporting under Rule 11(g) of the Companies (Audit and Auditors) Rules, 2014 (as amended);
- (i) With respect to the other matters to be included in the Auditor’s Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, as amended in our opinion and to the best of our information and according to the explanations given to us:
  - i. The Company has disclosed the impact of pending litigations on its financial position in its financial statements – Refer Note 41 to the standalone financial statements;
  - ii. The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses;
  - iii. There is no amount required to be transferred, to the Investor Education and Protection Fund by the Company;



iv.

- (a) The management has represented that, to the best of its knowledge and belief, other than as disclosed in the note 50 of the standalone financial statement, no funds have been advanced or loaned or invested by the Company to or in any other person or entities, including foreign entities ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall, whether, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries;
- (b) The management has represented that, to the best of its knowledge and belief, other than as disclosed in the note 50 of the standalone financial statement, no funds have been received by the Company from any person or entity, including foreign entities ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the Company shall, whether, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries; and
- (c) Based on such audit procedures that were considered reasonable and appropriate in the circumstances, nothing has come to our notice that has caused us to believe that the representations under sub-clause iv (a) and iv (b) contain any material misstatement.

v. No dividend has been declared or paid during the year by the Company.

vi. Based on our examination, which included test checks, the Company has used accounting software for maintaining its books of account which have a feature of recording audit trail (edit log) facility and that has operated throughout the year for all relevant transactions recorded in the software, except that the audit log is not maintained in case of modification, if any, by users with specific access rights; and was not enabled to capture any direct changes at the database level. Further, during the course of our audit, we did not notice any instance of audit trail feature being tampered with.





**SS KOTHARI MEHTA**  
**& CO. LLP**  
CHARTERED ACCOUNTANTS

Additionally, the audit trail has been preserved by the company as per the statutory requirements for record retention.

For **S.S. KOTHARI MEHTA & CO. LLP**  
Chartered Accountants  
Firm registration number: 000756N/N500441



A handwritten signature in black ink, appearing to read "Amit Goel", written over the circular stamp.

**AMIT GOEL**  
Partner  
M.No: 500607

Place: New Delhi  
Dated: May 12, 2025  
UDIN: 25500607BMLATL6103

**Annexure A to the Independent Auditor's Report to the Members of PI Health Sciences Limited dated May 12, 2025 on its standalone financial statements.**

**Report on the matters specified in paragraph 3 of the Companies (Auditor's Report) Order, 2020 ("the Order") issued by the Central Government of India in terms of section 143(11) of the Companies Act, 2013 ("the Act") as referred to in paragraph 1 of 'Report on Other Legal and Regulatory Requirements' section.**

- i. (a)(A) The Company has maintained proper records showing full particulars, including quantitative details and situation of property, plant and equipment.
- (a)(B) The Company has maintained proper records showing full particulars of intangible assets.
- (b) Property, plant and equipment are physically verified by the Management according to a phased programme designed to cover all the items over a period of three years which, in our opinion, is reasonable having regard to the size of the Company and the nature of its assets. Pursuant to the programme, certain portion of the Property, Plant and Equipment has been physically verified by the management during the year and no material discrepancies have been noticed on such verification.
- (c) According to the information and explanations given to us and on the basis of our examination of the title deeds provided to us, we report that, the title deeds of the immovable properties, (other than immovable properties where the Company is the lessee and the lease agreements are duly executed in favor of the Company) are held in the name of the Company as at the balance sheet date except as disclosed below (Refer note 4 of standalone financial statements) :-

Descript ion of propert y	Gross Carryin g value (Rs. in Million)	Net Car ryin g valu e (Rs. in Mill ion)	Held in name of	Whether promoter, director or their relative or employee	Perio d held Indic ate range, where appro priate	Reason for not being held in name of company
Plot No. 969 and 969(A), Industrial Area, Sitapura Phase - III, Jaipur.	160.80	157.25	Therachem Research Medilab (India) Private Limited	Not applicable	April ,2008	Assets has been transferred on account of scheme of Amalgamation( merger) between the Company and Therachem Research Medilab (India) Private Limited with effect from June 02, 2023.



- (d) According to the information and explanations given to us, the Company has not revalued any of its property, plant and equipment (including right of use assets) and intangible assets during the year. Hence, reporting under clause 3(i)(d) of the Order is not applicable to the Company.
- (e) According to the information and explanations given to us and records provided, no proceedings have been initiated during the year or are pending against the Company as at March 31, 2025 for holding any benami property under the Benami Transactions (Prohibition) Act, 1988 (45 of 1988) and rules made thereunder.
- ii.
- (a) The management has conducted physical verification of inventory at reasonable intervals during the year. In our opinion, the coverage and the procedure of such verification by the management is appropriate and no discrepancies were noticed on verification between physical stocks and the book records that were more than 10% in the aggregate of each class of inventory.
- (b) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not been sanctioned working capital limits from banks or financial institutions during any point of time of the year. Accordingly, the requirement to report on clause 3(ii)(b) of the Order is not applicable to the Company.
- iii. According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not provided any security, given loan or made investments in companies, firms, limited liability partnerships or any other parties during the year except as given below:
- (a) Based on the audit procedures carried on by us and as per the information and explanations given to us the Company has provided loans to other parties as below:

Particular	Loan (Rs.Million)
Aggregate amount granted/ provided during the year:	
- Subsidiary	814.70
Balance outstanding as at balance sheet date in respect of above cases	
- Subsidiary	21.37

- (b) According to the information and explanations given to us and based on the audit procedures conducted by us, in our opinion, the term and condition of loans granted and investment made during the year is not prejudicial to the interest of the Company.
- (c) According to the information and explanations given to us and on the basis of our examination of the records of the Company, in the case of loans given, in our opinion, the repayment of principal and payment of interest has been stipulated. The repayment of loan has not been fallen due during the year.





- (d) According to the information and explanations given to us and on the basis of our examination of the records of the Company, there is no overdue amount for more than ninety days in respect of loans given.
  - (e) According to the information and explanations given to us and on the basis of our examination of the records of the Company, there is no loan or advance in the nature of loan granted falling due during the year, which has been renewed or extended or fresh loans granted to settle the overdue of existing loans given to same parties.
  - (f) The Company has not granted any loans or advances in the nature of loans, either repayable on demand or without specifying any terms or period of repayment to companies, firms, Limited Liability Partnerships or any other parties. Accordingly, the requirement to report on clause 3(iii)(f) of the Order is not applicable to the Company.
- iv. According to the information and explanations given to us and on the basis of our examination of records of the Company, in respect of investment made, loan given by the Company, in our opinion, the provisions of Section 185 and 186 of the Act, have been complied with. The Company has not given any security and provided guarantee during the year.
- v. In our opinion and according to the information and explanation given to us, the Company has neither accepted any deposits from the public nor accepted any amounts which are deemed to be deposits within the meaning of sections 73 to 76 of the Act and the rules made thereunder, to the extent applicable. Accordingly, the requirement to report on clause 3(v) of the Order is not applicable to the Company.
- vi. We have broadly reviewed the books of account maintained by the Company pursuant to the rules made by the Central Government for the maintenance of cost records under section 148(1) of the Act and are of the opinion that prima facie, the specified accounts and records have been made and maintained. We have not, however, made a detailed examination of the records with a view to determine whether they are accurate or complete.
- vii. a) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company is regular in depositing with appropriate authorities undisputed statutory dues including goods and services tax, provident fund, employees' state insurance, income-tax, sales-tax, service tax, duty of customs, duty of excise, value added tax, cess and other statutory dues applicable to it. According to the information and explanations given to us and based on audit procedures performed by us, no undisputed amounts payable in respect of these statutory dues were outstanding, at the year end, for a period of more than six months from the date they became payable.



- b) There are no dues of goods and services tax, provident fund, employees' state insurance, income tax, customs duty, excise duty, cess, goods and service tax and other statutory dues which have not been deposited on account of any dispute except as given below :-

Name of the statute	Nature of dues	Amount demand (Rs. in Millions)	Amount paid under protest (Rs. In Millions)	Period to which the amount relates	Forum where the dispute is pending
Income Tax Act	Income Tax	0.89	0.89	AY 19-20	CIT (Appeals)
Income Tax Act	Income Tax	0.23	0.23	AY 20-21	CIT (Appeals)
Income Tax Act	Income Tax	0.91	0.91	AY 21-22	CIT (Appeals)
Income Tax Act	Income Tax	0.64	0.64	AY 22-23	CIT (Appeals)

- viii. In our opinion, based on audit procedures and according to the information and explanations given to us, the Company has not surrendered or disclosed any transaction, previously unrecorded in the books of account, in the tax assessments under the Income Tax Act, 1961 as income during the year. Accordingly, the requirement to report on clause 3(viii) of the Order is not applicable to the Company.

ix.

- (a) In our opinion, based on audit procedures and according to the information and explanations given to us, the Company has not defaulted in repayment of inter-corporate deposits / loans and borrowing or in the payment of interest thereon to any lender.
- (b) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not been declared a willful defaulter by any bank or financial institution or government or government authority.
- (c) According to the information and explanations given to us and on the basis of our examination of the records of the Company, term loans were applied for the purpose for which the loans were obtained.
- (d) On an overall examination of the standalone financial statements of the Company, no funds raised on short-term basis have been used for long-term purposes by the Company.



- (e) According to the information and explanations given to us and on an overall examination of the standalone financial statements of the Company, we report that the Company has not taken any funds from any entity or person on account of or to meet the obligations of its subsidiaries defined under the Act.
- (f) According to the information and explanations given to us and procedures performed by us, we report that the Company has not raised loans during the year on the pledge of securities held in its subsidiaries.
- x.
  - (a) According to the information and explanations given to us and procedures performed by us, the Company has not raised any money during the year by way of initial public offer / further public offer (including debt instruments). Hence, the requirement to report on clause 3(x)(a) of the Order is not applicable to the Company.
  - (b) According to the information and explanations given to us and procedures performed by us the Company has complied with provisions of sections 42 and 62 of the Act, in respect of the preferential allotment of optionally fully convertible debenture during the current financial year. The funds raised, have been used for the purposes for which the funds were raised.
- xi.
  - (a) Based on examination of the books and records of the Company and according to the information and explanations given to us, no fraud by the Company or on the Company has been noticed or reported during the year.
  - (b) According to the information and explanations given to us, no report under sub-section (12) of Section 143 of the Act has been filed by the auditors in Form ADT-4 as prescribed under Rule 13 of the Companies (Audit and Auditors) Rules, 2014 with the Central Government.
  - (c) As represented to us by the management, there are no whistle blower complaints received by the Company during the year.
- xii. According to the information and explanations given to us, the Company is not a Nidhi Company. Accordingly, clause 3(xii) of the Order is not applicable to the Company.
- xiii. In our opinion, and according to the information and explanations given to us during the course of audit, transactions with the related parties are in compliance with section 188 of the Act, where applicable and the details have been disclosed in the notes to the financial statements, as required by the applicable Indian accounting standards. The provisions of section 177 of the Act are not applicable to the Company and hence not commented upon.
- xiv.
  - (a) Based on information and explanations provided to us and our audit procedures, in our opinion, the Company has an internal audit system commensurate with the size and nature of its business.
  - (b) We have considered the internal audit reports of the Company issued till date for the period under audit.



- xv. In our opinion and according to the information and explanations given to us, the Company has not entered into any non-cash transactions with its directors or persons connected to its directors and hence, provisions of Section 192 of the Act are not applicable to the Company.
- xvi.
- (a) The Company is not required to be registered under Section 45-IA of the Reserve Bank of India Act, 1934. Accordingly, clause 3(xvi)(a) of the Order is not applicable to the Company.
  - (b) The Company is not required to be registered under Section 45-IA of the Reserve Bank of India Act, 1934. Accordingly, clause 3(xvi)(b) of the Order is not applicable.
  - (c) The Company is not a Core Investment Company as defined in the regulations made by Reserve Bank of India. Accordingly, the requirement to report on clause 3(xvi) of the Order is not applicable to the Company.
  - (d) Based on the information and explanations provided by the management of the Company, the Group does not have any CICs, which are part of the Group. We have not, however, separately evaluated whether the information provided by the management is accurate and complete. Accordingly, the reporting under Clause 3(xvi)(d) of the Order is not applicable to the Company.
- xvii. The Company has incurred cash losses amounting to Rs.988.14 Million in the current financial year and Rs. 5.95 Million in the immediately preceding financial year.
- xviii. There has been no resignation of the statutory auditors during the year and accordingly the requirement to report on Clause 3(xviii) of the Order is not applicable to the Company.
- xix. According to the information and explanations given to us and on the basis of the financial ratios, ageing and expected dates of realization of financial assets and payment of financial liabilities, other information accompanying the standalone financial statements, our knowledge of the Board of Directors and management plans and based on our examination of the evidence supporting the assumptions, nothing has come to our attention, which causes us to believe that any material uncertainty exists as on the date of the audit report that the Company is not capable of meeting its liabilities existing at the date of balance sheet as and when they fall due within a period of one year from the balance sheet date. We, however, state that this is not an assurance as to the future viability of the Company.
- We further state that our reporting is based on the facts up to the date of the audit report and we neither give any guarantee nor any assurance that all liabilities falling due within a period of one year from the balance sheet date, will get discharged by the Company as and when they fall due.
- xx. According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company does not fulfill the threshold criteria for applicability of section 135 of the Act, hence requirement to report on clause 3(xx)(a) and 3(xx) (b) of the order is not applicable to the Company.



# SS KOTHARI MEHTA & CO. LLP

CHARTERED ACCOUNTANTS

- xxi. The reporting under Clause 3(xxi) of the Order is not applicable in respect of audit of the standalone financial statements. Accordingly, no comment in respect of the said clause has been included in this report.



For **S.S. KOTHARI MEHTA & CO. LLP**  
Chartered Accountants  
Firm registration number: 000756N/N500441

**AMIT GOEL**  
Partner  
M.No: 500607

Place: New Delhi  
Dated: May 12, 2025  
UDIN: 25500607BMLATL6103



**Annexure B to the Independent Auditor's Report to the Members of PI Health Sciences Limited dated May 12, 2025 on its standalone financial statements.**

**Report on the Internal Financial Controls under Clause (i) of Sub-section 3 of Section 143 of the Act as referred to in paragraph 2(f) of 'Report on Other Legal and Regulatory Requirements' section**

We have audited the internal financial controls with reference to standalone financial statements of the **PI Health Sciences Limited** (the 'Company') as of March 31, 2025, in conjunction with our audit of the financial statements of the Company for the year ended on that date.

**Management's Responsibility for Internal Financial Controls**

The Company's Management and the Board of Directors are responsible for establishing and maintaining internal financial controls based on the internal financial controls with reference to financial statements criteria established by the Company considering the essential components of internal control stated in the Guidance Note. These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Act.

**Auditors' Responsibility**

Our responsibility is to express an opinion on the Company's internal financial controls with reference to financial statements based on our audit. We conducted our audit in accordance with the Guidance Note and the Standards on Auditing deemed to be prescribed under Section 143(10) of the Act to the extent applicable to an audit of internal financial controls, both applicable to an audit of internal financial controls and both issued by the ICAI. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls with reference to financial statements was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system with reference to financial statements and their operating effectiveness. Our audit of internal financial controls with reference to financial statements included obtaining an understanding of internal financial controls with reference to financial statements, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls system with reference to financial statements.



### **Meaning of Internal Financial Controls over Financial Reporting**

A company's internal financial controls with reference to financial statements is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial controls with reference to financial statements includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorisations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorised acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

### **Inherent Limitations of Internal Financial Controls over Financial Reporting**


Because of the inherent limitations of internal financial controls with reference to financial statements, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls with reference to financial statements to future periods are subject to the risk that the internal financial controls with reference to financial statements may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

### **Opinion**

In our opinion, the Company has, in all material respects, an adequate internal financial controls system with reference to financial statements and such internal financial controls with reference to financial statements were operating effectively as at March 31, 2025, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note issued by ICAI.

For **S.S. KOTHARI MEHTA & CO. LLP**  
Chartered Accountants  
Firm registration number: 000756N/N500441



  
**AMIT GOEL**  
Partner  
M.No: 500607

Place: New Delhi  
Dated: May 12, 2025  
UDIN 25500607BMLATL6103

**PI HEALTH SCIENCES LIMITED**  
**Standalone Balance Sheet as at March 31, 2025**  
(All amounts in ₹ million, unless otherwise stated)

Particulars	Notes	As at March 31, 2025	As at March 31, 2024
<b>ASSETS</b>			
<b>Non-current assets</b>			
Property, plant and equipment	4	1,777.48	1,400.83
Right of use assets	5	527.44	546.76
Capital work-in-progress	6	111.63	95.21
Goodwill	7	871.61	871.61
Other intangible assets	8	1,523.01	1,592.02
Financial assets			
(i) Investments	9	5,793.77	2,063.53
(ii) Loans	10	21.37	2,188.89
(iii) Other financial assets	12	11.09	9.06
Deferred tax assets (net)	11	149.46	-
Other non-current assets	13	6.86	19.78
<b>Total non-current assets</b>		<b>10,793.72</b>	<b>8,787.69</b>
<b>Current assets</b>			
Inventories	14	100.26	134.15
Financial assets			
(i) Trade receivables	19	73.07	106.55
(ii) Cash and cash equivalents	15	298.46	376.74
(iii) Bank balances other than (iii) above	16	11.48	11.56
(iv) Other financial assets	17	4.45	144.57
Contracts assets	20	122.62	316.21
Current tax assets	18	2.94	98.05
Other current assets	13	395.82	323.48
<b>Total current assets</b>		<b>1,009.10</b>	<b>1,511.31</b>
<b>Total assets</b>		<b>11,802.82</b>	<b>10,299.00</b>
<b>EQUITY &amp; LIABILITIES</b>			
<b>Equity</b>			
Equity share capital	21	4,410.00	4,410.00
Other equity		(464.65)	225.76
<b>Total equity</b>		<b>3,945.35</b>	<b>4,635.76</b>
<b>Liabilities</b>			
<b>Non current liabilities</b>			
Financial liabilities			
(i) Borrowings	22	7,225.69	4,937.69
(ii) Lease liabilities	23	63.88	71.45
(iii) Other financial liabilities	24	-	2.20
Provisions	25	34.78	22.90
Deferred tax liabilities (Net)	11	-	143.68
<b>Total non current liabilities</b>		<b>7,324.35</b>	<b>5,177.92</b>
<b>Current Liabilities</b>			
Financial liabilities			
(i) Lease liabilities	23	12.59	12.44
(ii) Trade payables	27		
(a) total outstanding dues of micro enterprises and small enterprises		7.26	7.62
(b) total outstanding dues of creditors other than micro enterprises and small enterprises		67.68	41.67
(iii) Other financial liabilities	24	384.20	383.48
Provisions	25	3.33	1.49
Other current liabilities	26	58.06	38.62
<b>Total current liabilities</b>		<b>533.12</b>	<b>485.32</b>
<b>Total liabilities</b>		<b>7,857.47</b>	<b>5,663.24</b>
<b>Total equity and liabilities</b>		<b>11,802.82</b>	<b>10,299.00</b>

**Notes to accounts**

I to 51

The accompanying notes referred to above forms the integral part of these standalone financial statement

As per our report of even date

For S S Kothari Mehta & Co LLP  
Chartered Accountants  
Firm Reg. No. 000756/N/500441




**AMIT GOEL**  
Partner  
Membership Number: 500607



For and on behalf of the Board of Directors  
PI Health Sciences Limited

  
**Arunabha Raychaudhuri**  
Director  
DIN: 10685547

  
**Rajnish Sarna**  
Director  
DIN: 06429469

  
**Ankit Nayyar**  
Chief Financial Officer

  
**Ruchi Jayesh Sheth**  
Company Secretary

Place: New Delhi  
Date: May 12, 2025

Place: Mumbai  
Date: May 12, 2025

**PI HEALTH SCIENCES LIMITED**
**Standalone Statement of Profit & Loss for the year ended March 31, 2025**

(All amounts in ₹ million, unless otherwise stated)

Particulars	Notes	For the year ended March 31, 2025	For the year ended March 31, 2024
Revenue from operations	28	355.61	276.99
Other income	29	397.98	245.01
<b>Total Income</b>		<b>753.59</b>	<b>522.00</b>
<b>Expenses:</b>			
Cost of materials consumed	30	129.59	180.42
Changes in inventories of finished goods, work in progress and stock in trade	31	10.61	(19.92)
Employee benefit expense	32	397.70	239.45
Finance cost	33	559.18	372.13
Depreciation and amortisation expenses	34	263.66	152.71
Other expense	35	644.65	344.64
<b>Total expenses</b>		<b>2,005.39</b>	<b>1,269.43</b>
<b>Loss before tax for the year</b>		<b>(1,251.80)</b>	<b>(747.43)</b>
<b>Income tax expense</b>	36		
Current tax		-	-
Deferred tax		(354.20)	(589.05)
Income tax of earlier years		(25.61)	-
<b>Total tax expense for the year</b>		<b>(379.81)</b>	<b>(589.05)</b>
<b>Loss for the year</b>		<b>(871.99)</b>	<b>(158.38)</b>
<b>Other comprehensive income for the year</b>			
(i) Items that will not be reclassified to profit or loss			
Remeasurements gains/(losses) on defined benefit plans		5.62	(0.60)
Income tax relating to the above item		(1.41)	0.15
<b>Total comprehensive expense for the year</b>		<b>(867.78)</b>	<b>(158.83)</b>
<b>Earnings per equity share</b>	48		
1) Basic (in ₹)		(1.98)	(0.37)
2) Diluted (in ₹)		(1.98)	(0.37)
<b>Face value per share (in ₹)</b>		<b>10.00</b>	<b>10.00</b>

**Notes to accounts**


1 to 51

The accompanying notes referred to above forms the integral part of these standalone financial statement

**As per our report of even date**
**For S S Kothari Mehta & Co LLP**

Chartered Accountants

Firm Reg. No. 000756N/N500441


**AMIT GOEL**

Partner

Membership Number: 500607


**For and on behalf of the Board of Directors**
**PI Health Sciences Limited**

**Arunabha Raychaudhuri**

Director

DIN: 10685547


**Rajnish Sarna**

Director

DIN: 06429469


**Ankit Nayyar**

Chief Financial Officer


**Ruchi Jayesh Sheth**

Company Secretary

Place: New Delhi

Date: May 12, 2025

Place: Mumbai

Date: May 12, 2025



**PI HEALTH SCIENCES LIMITED**  
**Statement of Standalone Cash Flows for the year ended March 31, 2025**  
(All amounts in ₹ million, unless otherwise stated)

PARTICULARS	For the year ended	For the year ended
	Mar 31, 2025	March 31, 2024
<b>A. CASH FLOW FROM OPERATING ACTIVITIES</b>		
Loss before tax	(1,251.80)	(747.43)
<b>Adjustments for :-</b>		
Depreciation and amortisation expense	263.66	152.71
Finance costs	549.40	372.13
Provision for bad and doubtful debts & advances	2.66	1.61
Interest income on loans and bank deposits	(111.94)	(117.01)
Interest income on unwinding of security deposits	(0.04)	(0.14)
Liabilities written back	(264.70)	-
Lease income	(15.29)	-
Unrealised (gain)/loss on foreign currency transactions (net)	(14.87)	19.15
<b>Operating loss before working capital changes</b>	<b>(842.92)</b>	<b>(318.98)</b>
(Increase) / decrease in trade receivables	241.15	431.49
(Increase) / decrease in inventories	33.89	10.44
(Increase) / decrease in financial assets	58.03	(120.77)
(Increase) / decrease in other assets	(73.66)	(150.85)
Increase / (decrease) in trade payables	27.07	(13.04)
Increase / (decrease) in provisions	19.35	12.70
Increase / (decrease) in financial liabilities	179.17	122.66
Increase / (decrease) in other liabilities	19.44	(306.60)
<b>Cash used from operations before tax</b>	<b>(338.48)</b>	<b>(332.45)</b>
Income taxes (Paid)/ Refund	120.72	(0.67)
<b>Net cash used in operating activities</b>	<b>(217.76)</b>	<b>(333.12)</b>
<b>B. CASH FLOW FROM INVESTING ACTIVITIES</b>		
Payments for purchase of property, plant & equipment including capital work in progress, intangible assets, capital advances and creditors	(484.89)	(834.67)
Proceeds from maturity of / (investment) in bank deposits	0.08	(11.56)
Acquisition of businesses net of cash and bank balances of ₹ 599.33 Mn	-	(3,000.39)
Equity investment in wholly owned subsidiaries	(657.64)	(2,063.53)
Loan provided to wholly owned subsidiaries	(811.11)	(2,185.04)
Interest received	87.63	91.73
Rent received	25.74	-
<b>Net cash used in investing activities</b>	<b>(1,840.19)</b>	<b>(8,003.46)</b>
<b>C. CASH FLOW FROM FINANCING ACTIVITIES</b>		
Proceeds from issue of equity share capital	-	4,165.00
Proceeds from long term borrowings	2,000.00	9,410.00
Payment of long term borrowings	-	(4,600.00)
Payment of lease liabilities	(18.27)	(14.81)
Interest paid (net)	(2.06)	(281.02)
<b>Net cash inflow from financing activities</b>	<b>1,979.67</b>	<b>8,679.17</b>
<b>D. Net cash inflow / (Outflow) from operating, investing &amp; financing activities (A+B+C)</b>	<b>(78.28)</b>	<b>342.59</b>
<b>Opening balance of cash &amp; cash equivalents</b>	<b>376.74</b>	<b>34.15</b>
<b>Closing balance of cash &amp; cash equivalents</b>	<b>298.46</b>	<b>376.74</b>

Note: Cash and cash equivalents included in the cash flow statement comprise of the following :-

	As at Mar 31, 2025	As at Mar 31, 2024
i) Cash on hand	0.08	0.08
ii) Balance with banks :		
-In current accounts	266.32	141.66
-In fixed deposits	32.06	235.00
<b>Total</b>	<b>298.46</b>	<b>376.74</b>

The above Cash Flow Statement has been prepared under the Indirect method as set out in IND AS - 7 "Statement of Cash Flow".

Figures in brackets indicate cash outflows.

For non cash items and changes in financial liabilities, please refer note 10.

The accompanying notes referred to above forms the integral part of these standalone financial statement

As per our report of even date

For S S Kothari Mehta & Co LLP  
Chartered Accountants  
Firm Reg. No. 007660N/500441  
**MIT GOEL**  
Partner  
Membership Number: 500607



Place: New Delhi  
Date: May 12, 2025

For and on behalf of the Board of Directors  
PI Health Sciences Limited

**Arunabha Raychaudhuri**  
Director  
DIN: 10685547

**Ankit Nayyar**  
Chief Financial Officer  
Place: Mumbai  
Date: May 12, 2025

**Rajnish Sarna**  
Director  
DIN: 06429469

**Ruchi Jayesh Sheth**  
Company Secretary



**PI HEALTH SCIENCES LIMITED**
**Standalone Statement of Changes in Equity for the year ended March 31, 2025**

(All amounts in ₹ Mn, unless otherwise stated)

**a. Equity Share Capital (Refer Note 21)**

Particulars	As at March 31, 2025		As at March 31, 2024	
	No. of Shares	Amount	No. of Shares	Amount
Balance at the beginning of the year	44,09,99,946	4,410.00	2,44,99,997	245.00
Changes in equity share capital during the year	-	-	41,64,99,949	4,165.00
Balance at the end of the year	<b>44,09,99,946</b>	<b>4,410.00</b>	<b>44,09,99,946</b>	<b>4,410.00</b>

**b. Other Equity (Refer Note 21)**

Particulars	Retained earnings	Equity component of compound financial instrument	Total other equity
<b>Balance as at April 01, 2023</b>	(102.80)	-	(102.80)
Loss for the year	(158.38)	-	(158.38)
Other comprehensive expense for the year	(0.45)	-	(0.45)
<b>Total comprehensive expense for the year</b>	<b>(158.83)</b>	<b>-</b>	<b>(158.83)</b>
<b>Transaction with owners in their capacity as owners:</b>			
Issue of optionally fully convertible debentures (OFCD)	-	651.50	651.50
Deferred tax created	-	(163.97)	(163.97)
Transaction cost	-	(0.14)	(0.14)
<b>Transaction with owners in their capacity as owners:</b>	<b>-</b>	<b>487.39</b>	<b>487.39</b>
<b>Balance as at March 31, 2024</b>	<b>(261.63)</b>	<b>487.39</b>	<b>225.76</b>
Loss for the year	(871.99)	-	(871.99)
Other comprehensive income for the year	4.21	-	4.21
<b>Total comprehensive loss for the year</b>	<b>(867.78)</b>	<b>-</b>	<b>(867.78)</b>
<b>Transaction with owners in their capacity as owners:</b>			
Issue of optionally fully convertible debentures (OFCDs)	-	237.02	237.02
Deferred tax created	-	(59.65)	(59.65)
Transaction cost	-	-	-
<b>Transaction with owners in their capacity as owners:</b>	<b>-</b>	<b>177.37</b>	<b>177.37</b>
<b>Balance as at March 31, 2025</b>	<b>(1,129.42)</b>	<b>664.76</b>	<b>(464.65)</b>

The accompanying notes referred to above forms the integral part of these standalone financial statement

**As per our report of even date**

**For S S Kothari Mehta & Co LLP**

Chartered Accountants

Firm Reg. No. 000736N/N500441


  
AMIT GOEL


Partner

Membership Number: 500607




**For and on behalf of the Board of Directors  
PI Health Sciences Limited**

  
**Arunabha Raychaudhuri**  
Director  
DIN: 10685547

  
**Ankit Nayyar**  
Chief Financial Officer  
Place: Mumbai  
Date: May 12, 2025

  
**Rajnish Sarna**  
Director  
DIN: 06429469

  
**Ruchi Jayesh Sheth**  
Company Secretary

Place: New Delhi

Date: May 12, 2025

## PI Health Sciences Limited

### Notes to Standalone Financial Statements for the year ended March 31, 2025

#### 1. Corporate Information

PI Health Sciences ("the Company") is a public limited company and has its registered office at Udaisagar Road, Udaipur -313001 (Rajasthan). The principal activities of the Company are research, preparation, manufacture, distribution and sale of active pharmaceutical ingredients ("APIs") and intermediates.

#### 2. Basis of preparation

The Company has consistently applied the following accounting policies to all periods presented in the financial statements unless otherwise stated.

##### a. Statement of compliance

These financial statements have been prepared in all material aspects, in accordance with the recognition and measurement principles laid down in Indian Accounting Standard ('Ind AS') as per the Companies (Indian Accounting Standards) Rules, 2015 notified under Section 133 of the Companies Act, 2013 ('the Act') and other relevant provisions of the Act to the extent applicable. These financial statements were approved and adopted by the board of directors of the Company in their meeting dated May 12, 2025, and are subject to shareholder approval at the forthcoming Annual General Meeting of shareholders.

##### b. Basis of measurement

The financial statements have been prepared on the historical cost convention, except for the following:

- Certain financial assets and liabilities (including OFCD's) are measured at fair value;
- Net defined benefit plan assets/ (liability) are measured at fair value of plan assets less the present value of defined benefit obligations;
- Share-based payments measured at fair value.

##### c. Functional and presentation currency

Items included in the financial statements of the Company are measured using the currency of the primary economic environment in which the Company operates ("the functional currency"). The financial statements are presented in Indian National Rupee ('₹'), which is the Company's functional and presentation currency.

These financial statements are presented in INR and all values are rounded to the nearest million (INR 000,000), except when otherwise indicated.

##### d. Use of judgements and estimates

In preparing these financial statements, management has made judgements, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, the disclosures of contingent liabilities and contingent assets at the date of financial statements, income and expenses during the period. Actual results may differ from these estimates.



## PI Health Sciences Limited

### Notes to Standalone Financial Statements for the year ended March 31, 2025

Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to estimates are recognized prospectively.

Application of accounting policies that require critical accounting estimates and assumption judgements having the most significant effect on the amounts recognized in the financial statements are:

(i) **Provision for expected credit losses (ECL) on trade receivables**

The Company uses a provision matrix to calculate ECL for trade receivables. The ECL provision matrix is based on the Company's historical observed default rates. The Company adjust the historical credit loss experience with forward-looking information. At every reporting date, the historical observed default rates are updated and changes in the forward-looking estimates are analysed. The amount of ECL is sensitive to changes in circumstances and accordingly Company's actual default in the future may be different.

(ii) **Recognition of deferred tax**

Deferred tax is recorded on temporary differences between the tax bases of assets and liabilities and their carrying amounts, at the rates that have been enacted or substantively enacted at the reporting date. The ultimate realisation of deferred tax assets is dependent upon the generation of future taxable profits during the periods in which those temporary differences and tax loss carry-forwards become deductible. The Company considers expected reversal of deferred tax liabilities and projected future taxable income in making this assessment. The amount of deferred tax assets considered realisable, however, could reduce in the near term if estimates of future taxable income during the carry-forward period are reduced.

(iii) **Impairment test of financial assets (Investment in wholly – owned subsidiaries) and non-financial assets (Goodwill and Intangible assets)**

The Company assesses at each reporting date whether there is an indication that goodwill and intangible assets recognized on business combination may be impaired. If any indication exists, or when annual impairment testing for an asset is required, the Company estimates the asset's recoverable amount. An asset's recoverable amount is the higher of an asset's CGU'S fair value less cost of disposal and its value in use. Where the carrying amount of an asset or CGU exceeds its recoverable amount, the asset is considered impaired and is written down to its recoverable amount.

In assessing value in use, the estimated future cash flows are estimated based on past trends and discounted to their present value using a post-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset. In determining fair value less costs of disposal, recent market transactions are taken into account. If no such transactions can be identified, an appropriate valuation model is used. These calculations are corroborated by valuation multiples, or other fair value indicators.



## PI Health Sciences Limited

### Notes to Standalone Financial Statements for the year ended March 31, 2025

#### 3. Material Accounting Policies

##### a. Current versus non-current classification

The Company presents assets and liabilities in the balance sheet based on current/non-current classification considering an operating cycle of 12 months being time elapsed between deployment of resources and the realization/ settlement in cash and cash equivalents thereagainst.

##### b. Property, plant and equipment

###### i) Recognition and measurement

Freehold land is carried at historical cost. All other items of property, plant and equipment are measured at cost, less accumulated depreciation and accumulated impairment losses, if any. Capital work-in-progress are measured at cost less accumulated impairment losses, if any.

###### ii) Depreciation

Depreciation on property, plant and equipment is depreciated on the straight-line method based on the useful life of assets estimated by the Management which coincide with the life specified under Schedule II of the Companies Act, 2013.

The Company has estimated the useful lives as prescribed in schedule II of Companies Act, 2013, as follows:

- Plant and machinery	4 - 15 years
- Computer	3 - 6 years
- Electrical installations and equipment	4 - 10 years
- Furniture and fixtures	10 years
- Office equipment	4 - 5 years
- Vehicles	8 - 10 years

Leasehold land is being amortised over the lease period and Cost of improvement on leasehold building is being amortised over the lease period or useful life whichever is lower, unless the entity expects to use the assets beyond the lease term.

Based on assessment made by technical experts, the Management believes that the useful lives as given above best represent the period over which it expects to use these assets.



## PI Health Sciences Limited

### Notes to Standalone Financial Statements for the year ended March 31, 2025

#### c. Intangible assets

##### i) Recognition and measurement

###### Goodwill

Goodwill is not amortised but it is tested for impairment annually, or more frequently if events or changes in circumstances indicate that it might be impaired, and is carried at cost less accumulated impairment losses, if any.

###### Intangible assets acquired separately

Intangible assets that are acquired by the Company on initial recognition are measured at cost. Subsequently, intangible assets are carried at cost less accumulated amortization and accumulated impairment losses, if any.

###### Internally generated intangible assets - Research and development

Research costs are expensed as incurred. Development costs are capitalised only if the expenditure can be measured reliably, the product or process is technically and commercially feasible, future economic benefits are probable, and the Company intends to and has sufficient resources to complete development and to use or sell the asset. The expenditures to be capitalized include the cost of materials and other costs directly attributable to preparing the asset for its intended use. Other development expenditures are recognized in profit or loss as incurred.

##### ii) Amortisation

Amortization is recognized in the income statement on a straight-line basis over the estimated useful lives of intangible assets or on any other basis that reflects the pattern in which the asset's future economic benefits are expected to be consumed by the entity. Intangible assets that are not available for use are amortized from the date they are available for use.

The estimated useful life of customer contract is 20 years.

#### d. Impairment of non-financial assets

Goodwill and intangible assets that have an indefinite useful life are not subject to amortisation and are tested annually for impairment, or more frequently if events or changes in circumstances indicate that they might be impaired. Other assets are tested for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable.





## **PI Health Sciences Limited**

### **Notes to Standalone Financial Statements for the year ended March 31, 2025**

#### **e. Financial instruments**

##### **i) Initial recognition**

The Company recognises financial assets and financial liabilities when it becomes a party to the contractual provisions of the instrument. All financial assets and liabilities are recognised at fair value on initial recognition, except for trade receivables (which do not contain a significant financing component) which are initially measured at transaction price. Transaction costs that are directly attributable to the acquisition or issue of financial assets and financial liabilities that are not at fair value through profit or loss are added to the fair value on initial recognition.

##### **ii) Subsequent measurement**

###### **Financial assets carried at amortised cost**

A financial asset (which includes loans and advances, security deposits, deposits with banks and financial institutions, cash and cash equivalents, bank balance other than cash and cash equivalents, and trade receivables) is subsequently measured at amortised cost if it is held within a business model whose objective is to hold the asset in order to collect contractual cash flows and the contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding. When the financial asset is derecognised or impaired, the gain or loss is recognised in the statement of profit and loss.

###### **Financial liabilities**

Financial liabilities (which includes borrowings, trade payables and other financial liabilities (other than derivative financial instruments)) are subsequently carried at amortised cost using the effective interest method.

###### **Investment in subsidiaries**

Investment in subsidiaries is carried at cost less impairment, if any, in the separate financial statements. Where an indication of impairment exists, the carrying amount of the investment is assessed and written down to its recoverable amount.

###### **Offsetting**

Financial Assets and Financial Liabilities are offset and the net amount is presented in the balance sheet when, and only when, the Company has a legally enforceable right to set off the amount and it intends, either to settle them on a net basis or to realise the asset and settle the liability simultaneously.



## **PI Health Sciences Limited**

### **Notes to Standalone Financial Statements for the year ended March 31, 2025**

#### **f. Revenue Recognition**

##### **i) Sale of goods**

The Company manufactures and sells a range of products to various customers. Revenue is recognised over the period of time for contracts wherein the Company's performance does not create an asset with alternative use to the Company and the entity has an enforceable right to payment for performance completed till date. Management has determined that it is highly probable that there will be no rescission of the contract and a significant reversal in the amount of revenue recognised will not occur. Accordingly, revenue is recognised for these contracts based on Input method wherein amount of revenue to be recognised is determined based on the actual cost incurred till date and the estimated margin on the contract because there is a direct relationship between the Company's effort (i.e., based on the material consumed and labour hours incurred) and the enforceable right to payment for performance completed till date. For remaining contracts, Revenue is recognised when control of the products has transferred, being when the products are delivered to the customer, the customer has full discretion over the channel and price to sell the products, and there is no unfulfilled obligation that could affect the customer's acceptance of the products.

Revenue towards satisfaction of a performance obligation is measured at the amount of transaction price (net of variable consideration) allocated to that performance obligation. Accumulated experience is used to estimate and provide for the discounts and returns using the expected value method and revenue is recognized only to the extent that it is highly probable that a significant reversal will not occur. The validity of this assumption and the estimated amount of returns are reassessed at each reporting date. A refund liability (included in other current liabilities) and a right to recover the returned goods (included in other current assets) are recognised for the products expected to be returned. Liability (included in other financial liabilities) is recognised for expected volume discounts payable to customers in relation to sales made until the end of the reporting period.

Contract assets are recognised when there is excess of revenue earned over billings on contracts.

Amounts disclosed as revenue are net of returns, discounts, volume rebates and net of goods and service tax.

The Company does not have any contracts where the period between the transfer of the promised goods or services to the customer and payment by the customer exceeds one year. As a consequence, the Company does not adjust any of the transaction prices for the time value of money.



## **PI Health Sciences Limited**

### **Notes to Standalone Financial Statements for the year ended March 31, 2025**

#### **ii) Sale of services**

Revenue from sale of services is recognised over the period of time as per the terms of the contract with customers based on the stage of completion when the outcome of the transactions involving rendering of services can be estimated reliably.

#### **iii) Export Incentives**

Incentives on exports are recognised in books after due consideration of certainty of utilisation/ receipt of such incentives.

### **3.2 Other Accounting Policies**

#### **a. Foreign currency transactions**

##### **Initial recognition**

Transactions in foreign currencies are translated into the Company's functional currency at the exchange rates at the dates of the transactions.

##### **Conversion**

Monetary assets and liabilities denominated in foreign currencies are translated into the functional currency at the exchange rate at the reporting date. Non-monetary assets and liabilities that are measured at fair value in a foreign currency are translated into the functional currency at the exchange rate when the fair value was determined. Non-monetary assets and liabilities that are measured based on historical cost in a foreign currency are translated at the exchange rate at the date of the transaction.

##### **Exchange difference**

Exchange differences on settlement of foreign currency transactions and translation of foreign currency monetary assets and liabilities are recognised in statement of profit and loss, except exchange differences arising from the translation of the following items which are recognised in OCI:

- equity investments designated at fair value through OCI (FVTOCI); and
- qualifying cash flow hedges to the extent that the hedges are effective

#### **b. Derecognition of property, plant and equipment and Intangible assets**

An item of property, plant and equipment and intangible assets is derecognised when no future economic benefit benefits are expected to arise from the continued use of the asset or upon disposal. Any gain or loss on disposal is recognised in the statement of profit and loss.



## **PI Health Sciences Limited**

### **Notes to Standalone Financial Statements for the year ended March 31, 2025**

#### **c. Lease**

At inception of a contract, the Company assesses whether a contract is, or contains, a lease. A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange of consideration.

##### **As a lessee**

The company leases various offices, warehouses, IT equipment and vehicles.

The lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date, discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, the Company's incremental borrowing rate. Generally, the Company uses its incremental borrowing rate as the discount rate, being the rate that the Company would have to pay to borrow the funds necessary to obtain an asset of similar value to the right-of-use asset in a similar economic environment with similar terms, security and conditions.

##### **Short-term lease and leases of low value assets**

Short-term leases are leases with a lease term of 12 months or less. Low-value assets comprise IT equipment and small items of office furniture. The Company has elected not to recognise right-of-use assets and lease liabilities for short-term leased and leases of low value assets. The payments associated with short-term leases of equipment and vehicles and all leases of low-value assets are recognised on a straight-line basis in statement of profit and loss.

#### **d. Borrowing costs**

Borrowing costs are interest and other costs (including exchange differences relating to foreign currency borrowings to the extent that they are regarded as an adjustment to interest costs) incurred in connection with the borrowing of funds. Borrowing costs directly attributable to acquisition or construction of an asset which necessarily take a substantial period of time to get ready for their intended use are capitalised as part of the cost of that asset. Other borrowing costs are recognised as an expense in the period in which they are incurred using effective interest method. Investment income earned on the temporary investment of specific borrowings pending their expenditure on qualifying assets is deducted from the borrowing costs eligible for capitalisation.



## **PI Health Sciences Limited**

### **Notes to Standalone Financial Statements for the year ended March 31, 2025**

**e. Cash and cash equivalents**

Cash and cash equivalents comprise cash at bank and on hand and short-term deposits with original maturities of three months or less that are readily convertible to known amounts of cash and which are subject to an insignificant risk of changes in value.

**Cash flow statement**

Cash flow statements are prepared in accordance with "Indirect Method" as explained in the Indian Accounting Standard on Statement of Cash Flows (Ind AS - 7). The cash flows from regular revenue generating, financing and investing activity of the Company are segregated.

**f. Inventories**

Cost of Raw Materials, Packing Materials, Stores and Spares, Stock in Trade and other products are determined on weighted average basis and are net of Goods and service tax credit.

Cost of Work in progress and Finished Goods is determined on weighted average basis considering direct material cost and appropriate portion of manufacturing overheads based on normal operating capacity.

The Company recognises provision against obsolete/ slow and non-moving inventory items which are identified as no longer suitable for sale or use. Obsolete and slow-moving items are valued at cost or estimated net realisable value, whichever is lower. Any write-down of inventory is recognised as an expense during the year.

**g. Provisions, Contingent Liabilities and Contingent Assets**

A provision is recognised if, as a result of a past event, the Company has a present legal or constructive obligation that can be estimated reliably, and it is probable that an outflow of economic resources will be required to settle the obligation. If the effect of the time value of money is material, provisions are determined by discounting the expected future cash flows at a pre-tax rate that reflects current market assessments of the time value of money and the risks specific to the liability. Where discounting is used, the increase in the provision due to the passage of time is recognised as a finance cost.

Contingent liability is not recognised but disclosed in notes to the financial statements when there is a possible obligation arising from past events, the existence of which will be confirmed only by the occurrence or non-occurrence of one or more uncertain future events not wholly within the control of the Company or a present obligation that arises from past events where it is either not probable that an outflow of resources will be required to settle the obligation or a reliable estimate of the amount cannot be made. Contingent Liability is disclosed after careful evaluation of facts,





## **PI Health Sciences Limited**

### **Notes to Standalone Financial Statements for the year ended March 31, 2025**

uncertainties and possibility of reimbursement, unless the possibility of an outflow of resources embodying economic benefits is remote.

A contingent asset is not recognised unless it becomes virtually certain that an inflow of economic benefits will arise. When an inflow of economic benefits is probable, contingent asset are disclosed in the standalone financial statements.

#### **h. Other Income**

##### **Interest Income**

Interest income is accrued on a time basis, by reference to the principal outstanding and at the effective interest rate applicable, which is the rate that exactly discounts estimated future cash receipts through the expected life of the financial asset to the asset's net carrying amount on initial recognition.

Interest income is included in other income in the statement of profit and loss.

#### **i. Employee Benefits**

##### **i) Defined contribution plans**

Employees benefits in the form of the Company's contribution to Provident Fund, Pension scheme, Superannuation Fund and Employees State Insurance are defined contribution schemes. Under a defined contribution plan, the Company's sole obligation is to pay a fixed amount with no obligation to pay further contributions if the fund does not hold sufficient assets to pay all employee benefits. The related actuarial and investment risks are borne by the employee. The Company recognises contribution payable to these schemes as an expense, when employees provide services.

##### **ii) Defined benefit plans**

Retirement benefits in the form of gratuity are considered as defined benefit plans. Under a defined benefit plan, it is the Company's obligation to provide agreed benefits to the employees. The related actuarial and investment risks are borne by the Company. The Company's net obligation in respect of defined benefit plans is calculated by present value of the defined benefit obligation at the end of the reporting period less the fair value of plan assets.

The company provides for its gratuity liability based on actuarial valuation of the gratuity liability as at the Balance Sheet date, based on Projected Unit Credit Method, carried out by an actuary. The Company contributes to the gratuity fund, which are recognised as plan assets. The defined benefit obligation as reduced by fair value of plan assets is recognised in the Balance Sheet.



## **PI Health Sciences Limited**

### **Notes to Standalone Financial Statements for the year ended March 31, 2025**

The present value of the defined benefit obligation denominated in INR is determined by discounting the estimated future cash outflows by reference to market yields at the end of the reporting period on government bonds that have terms approximating to the terms of the related obligation.

Re-measurement of the net defined benefit liability, which comprise actuarial gains and losses, the return on plan assets (excluding interest) and the effect of the asset ceiling (if any, excluding interest), are recognised in the period in which they occur, directly in other comprehensive income. Net interest expense (income) on the net defined liability (assets) is computed by applying the discount rate, used to measure the net defined liability (asset), to the net defined liability (asset) at the start of the financial year after taking into account any changes as a result of contribution and benefit payments during the year. Net interest expense and other expenses related to defined benefit plans are recognised in statement of profit and loss under employee benefit expense.

When the benefits of a plan are changed or when a plan is curtailed, the resulting change in benefit that relates to past service or the gain or loss on curtailment is recognised immediately in statement of profit and loss. The Company recognises gains and losses on the settlement of a defined benefit plan when the settlement occurs.

#### **iii) Compensated absence**

The Company provides for accumulation of compensated absences, employees can carry forward a portion of the unutilised compensated absences and utilise them in future periods or receive cash in lieu thereof as per the Company's policy. The Company records a liability for compensated absences in the period in which the employee renders the services.

#### **j. Share-based payment transaction**

The grant date fair value of equity settled share-based payment awards granted to employees is recognised as an employee benefit expense, with a corresponding increase in equity. The total expense is recognised over the vesting period, which is the period over which all of the specified vesting conditions are to be satisfied and is adjusted to reflect the actual number of share options that vest.

The total amount to be expensed is determined by reference to the fair value of the options granted including any market performance conditions and the impact of any non-vesting conditions and excluding the impact of any service and non-market performance vesting conditions.



## **PI Health Sciences Limited**

### **Notes to Standalone Financial Statements for the year ended March 31, 2025**

#### **k. Income tax**

Income tax expense comprises current and deferred tax. It is recognised in profit or loss except to the extent that it relates to items recognised directly in equity or in Other Comprehensive Income.

##### **Current tax**

Current tax comprises the expected tax payable or receivable on the taxable income or loss for the year after taking credit of the benefits available under the Income Tax Act and any adjustment to the tax payable or receivable in respect of previous years. It is measured using tax rates enacted or substantively enacted at the reporting date.

##### **Deferred tax**

Deferred tax is recognized in respect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the corresponding tax bases used for taxation purposes.

Company also considers decisions of appropriate authorities and legal advice for recognising taxes.

#### **l. Segment Reporting**

An operating segment is defined as a component of the entity that represents business activities from which it earns revenues and incurs expenses and for which discrete financial information is available. The operating segments are based on the Company's internal reporting structure and the manner in which operating results are reviewed by the Chief Operating Decision Maker (CODM).

The Management Advisory Committee of the Company has been identified as the CODM by the Company.

#### **m. Earnings per share**

Basic earnings per share is calculated by dividing the net profit or loss for the period attributable to Equity Shareholders by the weighted average number of equity shares outstanding during the period.

For the purpose of calculating diluted Earnings per Share, the net profit or loss for the period attributable to Equity Shareholders and the weighted average number of shares outstanding during the period are adjusted for the effects of all dilutive potential equity shares.



## **PI Health Sciences Limited**

### **Notes to Standalone Financial Statements for the year ended March 31, 2025**

#### **n. Business Combination**

Acquisition of subsidiaries and businesses are accounted for using the acquisition method.

The acquiree's identifiable assets, liabilities and contingent liabilities that meet the conditions for recognition are recognised at their fair value at the acquisition date, except certain assets and liabilities that are required to be measured as per the applicable standard. Acquisition related costs are recognised in statement of profit and loss as incurred.

The cost of an acquisition also includes the fair value of any contingent consideration measured as at the date of acquisition, measured as present value of the expected outflow. Any subsequent changes to the fair value of contingent consideration classified as liabilities, other than measurement period adjustments, are recognised in the statement of profit and loss along with the unwinding of discount.

Purchase consideration in excess of the Company's interest in the acquiree's net fair value of identifiable assets, liabilities and contingent liabilities is recognised as goodwill.

Excess of the Company's interest in the net fair value of the acquiree's identifiable assets, liabilities and contingent liabilities over the purchase consideration is recognised, after reassessment of fair value of net assets acquired, in the capital reserve.



**PI HEALTH SCIENCES LIMITED**
**Notes to the Standalone Financial Statements for the year ended March 31, 2025**
**(All amounts in ₹ million, unless otherwise stated)**
**4 PROPERTY, PLANT AND EQUIPMENT**

	Freehold land	Buildings	Leasehold land	Furniture and fixtures	Office equipments	Plant and Machinery	Vehicles	Computer	Total
<b>Gross carrying amount</b>									
As at beginning of April 01, 2023	5.45	-	-	1.21	0.72	119.44	11.62	0.15	138.60
Additions	-	-	-	42.91	9.51	728.16	-	22.39	802.97
Additions through business combination*	-	134.38	191.80	3.59	1.64	191.48	0.92	1.42	525.23
Disposals	-	-	-	-	-	-	-	-	-
As at March 31, 2024	5.45	134.38	191.80	47.71	11.87	1,039.08	12.54	23.97	1,466.80
Additions	-	16.49	-	11.23	18.36	470.79	-	14.18	531.05
Disposals	-	-	-	(0.02)	(0.05)	(0.43)	(0.04)	(0.01)	(0.55)
As at March 31, 2025	5.45	150.87	191.80	58.92	30.18	1,509.44	12.50	38.14	1,997.30
<b>Accumulated depreciation</b>									
As at beginning of April 01, 2023	-	-	-	0.09	0.04	2.39	0.51	0.03	3.06
Depreciation charge during the year	-	4.77	2.06	1.59	0.68	51.30	1.54	0.97	62.91
Disposals	-	-	-	-	-	-	-	-	-
As at March 31, 2024	-	4.77	2.06	1.68	0.72	53.69	2.05	1.00	65.97
Depreciation charge during the year	-	5.79	2.94	5.29	3.67	129.80	1.56	5.17	154.21
Disposals	-	-	-	(0.01)	-	(0.35)	(0.01)	-	(0.37)
As at March 31, 2025	-	10.56	5.00	6.96	4.39	183.14	3.60	6.17	219.81
<b>Net carrying amount</b>									
As at March 31, 2024	5.45	129.61	189.74	46.03	11.15	985.39	10.49	22.97	1,400.83
As at March 31, 2025	5.45	140.31	186.80	51.96	25.79	1,326.30	8.90	31.97	1,777.48

\* Addition in leasehold land in the previous year represents land which has been acquired on acquisition of "Therachem Research Medilab (India) Private Limited (TRM)" and "Solis Pharmachem Private Limited" amounting to ₹ 160.80 and ₹ 31.00 respectively. Out of the above assets asset acquired of ₹ 160.80 are pending for registration in the name of the Company as on March 31, 2025.

Relevant line items in the Balance sheet	Description of item of property	Gross Carrying Value	Title deeds held in name of	Whether title deed holder is a promoter, director or relative of promoter/ director or employee of promoter or director	Property held since which date	Reason for not being held in the name of the company
Property, Plant and Equipment	Leasehold Land	160.8	TRM	N.A.	02-06-2023	Registration of leasehold land in the name of Company is under process

Refer note 40 for disclosure of contractual commitments for the acquisition of property, plant and equipment.

Refer note 46 for acquisition of property, plant and equipment through business combination.

Refer note 6 for operating expenses capitalized during the year

Note: No revaluation has been undertaken during the current year as well in the previous year.





**PI HEALTH SCIENCES LIMITED**
**Notes to the Standalone Financial Statements for the year ended March 31, 2025**
**(All amounts in ₹ million, unless otherwise stated)**
**5 RIGHT OF USE ASSETS**

	Land	Building	Office Equipment	Total
<b>Gross carrying amount</b>				
As at beginning of April 01, 2023	157.03	354.86	-	511.89
Additions	-	55.69	-	55.69
Additions through business combination*	-	3.36	-	3.36
Disposals	-	-	-	-
<b>As at March 31, 2024</b>	<b>157.03</b>	<b>413.91</b>	<b>-</b>	<b>570.94</b>
Additions	-	-	6.52	6.52
Disposals	-	(3.36)	-	(3.36)
<b>As at March 31, 2025</b>	<b>157.03</b>	<b>410.55</b>	<b>6.52</b>	<b>574.10</b>
*Refer Note 46				
<b>Accumulated amortisation</b>				
As at beginning of April 01, 2023	2.22	1.14	-	3.36
Amortisation charge during the year	3.09	17.73	-	20.82
Disposals	-	-	-	-
<b>As at March 31, 2024</b>	<b>5.31</b>	<b>18.87</b>	<b>-</b>	<b>24.18</b>
Amortisation charge during the year	7.10	16.89	1.84	25.83
Disposals	-	(3.36)	-	(3.36)
<b>As at March 31, 2025</b>	<b>12.41</b>	<b>32.40</b>	<b>1.84</b>	<b>46.65</b>
<b>Net Carrying Amount</b>				
As at March 31, 2024	151.72	395.05	-	546.76
As at March 31, 2025	144.62	378.15	4.68	527.44

**6 CAPITAL WORK-IN-PROGRESS**

(a)	Cost	Amount
	As at beginning of April 01, 2023	16.24
	Additions	881.94
	Disposal	-
	Amount transferred from CWIP	(802.97)
	<b>As at March 31, 2024</b>	<b>95.21</b>
	Additions	541.22
	Disposal	-
	Amount transferred from CWIP	(524.80)
	<b>As at March 31, 2025</b>	<b>111.63</b>

\* In current year, the additions in CWIP include capitalization of employee benefit expenses ₹13.37, finance cost ₹ 15.22 and other expense ₹ 3.87. (In previous year, additions in CWIP include capitalization of employee benefit expense ₹ 93.14, finance cost ₹ 26.31 and other expense ₹ 52.49).



**PI HEALTH SCIENCES LIMITED**

Notes to the Standalone Financial Statements for the year ended March 31, 2025

(All amounts in ₹ million, unless otherwise stated)

## (b) Ageing of capital work-in progress

Particulars	Amount in capital work-in progress for a period of				
	Less than 1 year	1-2 years	2-3 years	More than 3 years	Total
<b>As at March 31, 2025</b>					
Projects in progress	111.63	-	-	-	111.63
Projects temporarily suspended	-	-	-	-	-
<b>As at March 31, 2024</b>					
Projects in progress	95.21	-	-	-	95.21
Projects temporarily suspended	-	-	-	-	-

## (c) Completion schedule for capital work in progress whose completion is overdue or has exceeded its cost compared to its original plan

Particulars	To be completed in				
	Less than 1 year	1-2 years	2-3 years	More than 3 years	Total
<b>As at March 31, 2025</b>					
Projects in progress	-	-	-	-	-
Projects temporarily suspended	-	-	-	-	-
<b>Total</b>	-	-	-	-	-
<b>As at March 31, 2024</b>					
Projects in progress	95.21	-	-	-	95.21
Projects temporarily suspended	-	-	-	-	-
<b>Total</b>	95.21	-	-	-	95.21

Note: There are no project as on March 31, 2025 and March 31, 2024 where the project timeline is overdue.



**PI HEALTH SCIENCES LIMITED****Notes to the Standalone Financial Statements for the year ended March 31, 2025****(All amounts in ₹ million, unless otherwise stated)****7 GOODWILL**

<b>Cost</b>	<b>Amount</b>
<b>As at beginning of April 01, 2023</b>	-
Additions	-
Additions through business combination	871.61
<b>As at March 31, 2024</b>	<b>871.61</b>
Additions	-
<b>As at March 31, 2025</b>	<b>871.61</b>

Goodwill of ₹ 871.61 generated on account of business combination( Refer Note 46)

Goodwill is tested for impairment annually and when circumstances indicate that the carrying value may be impaired. For the purpose of impairment testing, goodwill acquired in a business combination is allocated to the cash generating units (CGU) or group of CGUs, which are benefited from the synergies of the acquisition. Goodwill is reviewed for any impairment at the operating segment, which is represented through group of CGUs, being lowest level at which goodwill is monitored for internal management purposes. When the recoverable amount of the CGU is less than its carrying amount, an impairment loss is recognised.

The recoverable amount of CGU has been determined from a value in use calculation which require the use of assumptions. The value in use calculation uses cash flow forecasts based on the most recently approved financial budgets and business projections by the management, which cover a period of five years. Key assumptions underlying the value in use calculation are those regarding expected revenues, a post-tax discount rate of 11% per annum. Sales growth projections considers managements' expectation of market development, current industry trends and post-tax discount rate based on the relevant risks. 5% growth rate has been used to extrapolate the cash flow projections beyond the five-year period of the approved financial budgets. The management believes that any reasonably possible change in the key assumptions would not cause the carrying amount to exceed the recoverable amount of the cash generating unit.

**8 OTHER INTANGIBLE ASSETS**

<b>Gross carrying amount</b>	<b>Customer contracts</b>	<b>Software</b>	<b>Total</b>
<b>As at beginning of April 01, 2023</b>	-	-	-
Additions	-	-	-
Additions through business combination	1,661.00	-	1,661.00
Disposals	-	-	-
<b>As at March 31, 2024</b>	<b>1,661.00</b>	<b>-</b>	<b>1,661.00</b>
Additions	-	14.62	14.62
Disposals	-	-	-
<b>As at March 31, 2025</b>	<b>1,661.00</b>	<b>14.62</b>	<b>1,675.62</b>
<b>Accumulated amortisation</b>			
<b>As at beginning of April 01, 2023</b>	-	-	-
Amortisation charge during the year	68.98	-	68.98
Disposals	-	-	-
<b>As at March 31, 2024</b>	<b>68.98</b>	<b>-</b>	<b>68.98</b>
Amortisation charge during the year	83.07	0.56	83.63
Disposals	-	-	-
<b>As at March 31, 2025</b>	<b>152.05</b>	<b>0.56</b>	<b>152.61</b>
<b>Net Carrying Amount</b>			
<b>As at March 31, 2024</b>	<b>1,592.02</b>	<b>-</b>	<b>1,592.02</b>
<b>As at March 31, 2025</b>	<b>1,508.95</b>	<b>14.06</b>	<b>1,523.01</b>

Note: Other intangible assets pertains to customer contracts and relations identified on acquisition of Therachem Research Medilab ( India ) Private Limited during FY 24.(Refer Note 46)



**9 INVESTMENTS**

	As at March 31, 2025	As at March 31, 2024
<b>Investment in equity instruments (fully paid up)</b>		
<b>Unquoted shares</b>		
<b>Investment in equity instruments of wholly-owned subsidiary company at cost</b>		
PI Health Sciences Netherlands B.V.	5,793.77	2,063.53
54,928,092 (March 31, 2024: 22,935,780) equity shares of ₹ 1 each fully paid		
<b>TOTAL</b>	<b>5,793.77</b>	<b>2,063.53</b>
<b>Aggregate amount of unquoted investment</b>	<b>5,793.77</b>	<b>2,063.53</b>
<b>Aggregate amount of impairment in value of investment</b>	-	-
Refer Note 42 for related party transactions.		

**10 LOANS**

	As at March 31, 2025	As at March 31, 2024
<b>Unsecured, considered good</b>		
Loans to related parties (Refer Note 42)	21.37	2,188.89
<b>TOTAL</b>	<b>21.37</b>	<b>2,188.89</b>

**11 DEFERRED TAX (ASSETS)/LIABILITIES**

	As at March 31, 2025	As at March 31, 2024
<b>The balance comprises temporary differences attributable to:</b>		
<b>(a) Deferred tax liabilities</b>		
Plant, property and equipment	165.66	68.87
Deferred purchase consideration	0.00	3.26
- Impact on deemed equity on OFCD	223.62	163.97
<b>Sub- Total (a)</b>	<b>389.28</b>	<b>236.10</b>
<b>(b) Deferred tax assets</b>		
Provision for employee benefits	10.86	5.99
Other provisions	1.00	0.48
Lease assets	(113.50)	(116.49)
OFCDs	154.55	22.41
Unabsorbed depreciation and losses	472.38	177.75
Unabsorbed loss on account of acquisition	0.69	0.71
<b>Other comprehensive items</b>		
- Remeasurement of defined benefit plans	(1.26)	0.15
Others	14.02	1.42
<b>Sub- Total (b)</b>	<b>538.74</b>	<b>92.42</b>
<b>Net deferred tax (assets)/liabilities (a)-(b)</b>	<b>-149.46</b>	<b>143.68</b>



**PI HEALTH SCIENCES LIMITED**
**Notes to the Standalone Financial Statements for the year ended March 31, 2025**
**(All amounts in ₹ million, unless otherwise stated)**

	As at March 31, 2024	Recognised in P&L	Recognised in OCI	As at March 31, 2025
<b>Movement in deferred tax:</b>				
(c) <b>Deferred tax liabilities</b>				
Plant, property and equipment	68.87	96.79	-	165.66
Deferred purchase consideration	3.26	(3.26)	-	-
<b>Sub- Total (c)</b>	<b>72.13</b>	<b>93.53</b>	<b>-</b>	<b>165.66</b>
(d) <b>Deferred tax assets</b>				
Provision for employee benefits	5.99	(4.87)	-	10.86
Other provisions	0.48	(0.51)	-	1.00
Lease assets	(116.49)	(2.99)	-	(113.50)
Optionally Fully Convertible Debentures	22.41	(132.14)	-	154.55
Unabsorbed depreciation and losses	177.75	(294.63)	-	472.38
Unabsorbed loss on account of acquisition	0.71	0.03	-	0.69
Other comprehensive items				
- Remeasurement of defined benefit plans	0.15	-	1.41	(1.26)
Others	1.42	(12.61)	-	14.02
<b>Sub- Total (d)</b>	<b>92.42</b>	<b>(447.72)</b>	<b>1.41</b>	<b>538.74</b>
(e) <b>Net deferred tax (assets)/liabilities (a)-(b)</b>	<b>-20.29</b>	<b>-354.19</b>	<b>1.41</b>	<b>-373.08</b>
(f) Other adjustments:				
- Impact on deemed equity on OFCD	163.97	-	59.65	223.62
<b>Net deferred tax (assets)/liabilities (e)-(f)</b>	<b>143.68</b>	<b>(354.19)</b>	<b>61.06</b>	<b>(149.46)</b>

	As at March 31, 2023	Recognised in P&L	Recognised in OCI	As at March 31, 2024
<b>Movement in deferred tax:</b>				
(c) <b>Deferred tax liabilities</b>				
Plant, property and equipment	1.75	67.12	-	68.87
Deferred purchase consideration	-	3.26	-	3.26
<b>Sub- Total (c)</b>	<b>1.75</b>	<b>70.38</b>	<b>-</b>	<b>72.13</b>
(d) <b>Deferred tax assets</b>				
Provision for employee benefits	-	(5.99)	-	5.99
Other provisions	-	(0.48)	-	0.48
Lease assets	1.06	117.55	-	(116.49)
Optionally fully convertible debenture (OFCD)	-	(22.41)	-	22.41
Unabsorbed depreciation and losses	25.62	(152.13)	-	177.75
Unabsorbed loss on account of acquisition	-	(0.71)	-	0.71
Other comprehensive items				
- Remeasurement of defined benefit plans	-	-	(0.15)	0.15
Others	-	(1.42)	-	1.42
<b>Sub- Total (d)</b>	<b>26.68</b>	<b>(65.59)</b>	<b>(0.15)</b>	<b>92.42</b>
(e) <b>Net deferred tax (assets)/liabilities (a)-(b)</b>	<b>(24.93)</b>	<b>4.79</b>	<b>(0.15)</b>	<b>(20.29)</b>
(f) Other adjustments:				
- Impact on OFCD equity portion, netted off from other equity	-	-	-	163.97
- Impact on business combination*	-	(593.84)	-	-
<b>Net deferred tax (assets)/liabilities (e)-(f)</b>	<b>(24.93)</b>	<b>(589.05)</b>	<b>(0.15)</b>	<b>143.68</b>
*Acquired through business acquisition				

**12 OTHER NON-CURRENT FINANCIAL ASSETS**

	As at March 31, 2025	As at March 31, 2024
<i>Unsecured, considered good unless stated otherwise</i>		
Security deposits	11.09	9.06
<b>TOTAL</b>	<b>11.09</b>	<b>9.06</b>





**PI HEALTH SCIENCES LIMITED**
**Notes to the Standalone Financial Statements for the year ended March 31, 2025**
**(All amounts in ₹ million, unless otherwise stated)**
**13 OTHER ASSETS**

	Non- Current		Current	
	As at March 31, 2025	As at March 31, 2024	As at March 31, 2025	As at March 31, 2024
<i>Unsecured unless stated otherwise</i>				
Capital advances				
- Considered good	6.35	17.93	-	-
- Doubtful	-	-	-	-
- Less: Allowance for doubtful advances	-	-	-	-
SUB-TOTAL	6.35	17.93	-	-
Advances to vendors - considered good				
- Considered good	-	-	7.35	31.21
- Doubtful	-	-	-	-
- Less: Allowance for doubtful advances	-	-	3.72	-
SUB-TOTAL	-	-	11.07	31.21
Prepayments	0.51	1.85	14.34	12.88
Balance with government authorities	-	-	366.25	275.11
Export incentives	-	-	3.99	4.14
Other receivable	-	-	0.17	0.14
<b>TOTAL</b>	<b>6.86</b>	<b>19.78</b>	<b>395.82</b>	<b>323.48</b>

**14 INVENTORIES**

	As at March 31, 2025	As at March 31, 2024
Raw materials	72.67	102.73
Semi-finished goods	0.14	18.19
Finished goods	9.17	1.73
Stores & spares	18.28	11.50
<b>TOTAL</b>	<b>100.26</b>	<b>134.15</b>

Note : Valuation of inventories is stated in note 3.2(f) of other accounting policies.

**15 CASH AND CASH EQUIVALENTS**

	As at March 31, 2025	As at March 31, 2024
Cash on hand	0.08	0.08
Balance with banks		
-Balances in current account	249.25	141.66
-Balances in EEFC account	17.07	-
-Deposits with original maturity of less than 3 months	32.06	235.00
<b>TOTAL</b>	<b>298.46</b>	<b>376.74</b>

**16 BANK BALANCES OTHER THAN CASH AND CASH EQUIVALENTS**

	As at March 31, 2025	As at March 31, 2024
Fixed deposits with bank	11.48	11.56
<b>TOTAL</b>	<b>11.48</b>	<b>11.56</b>

**17 OTHER CURRENT FINANCIAL ASSETS**

	As at March 31, 2025	As at March 31, 2024
Receivable from related parties (Refer Note 42)	0.61	21.77
Management fees receivable from related parties (Refer Note 42)	-	107.90
Interest accrued but not due	0.36	3.51
Other receivables*	3.48	11.39
<b>TOTAL</b>	<b>4.45</b>	<b>144.57</b>

\*Other receivables includes amount receivable from related party ₹2.35 million ( Refer Note 42)

**18 CURRENT TAX ASSETS**

	As at March 31, 2025	As at March 31, 2024
TDS receivable/Advance tax	2.94	98.05
<b>TOTAL</b>	<b>2.94</b>	<b>98.05</b>



**19 TRADE RECEIVABLES**

	As at March 31, 2025	As at March 31, 2024
Trade receivables	62.87	91.31
Receivable from related parties (refer note 42)	10.20	15.85
Less: Allowance for credit losses	-	(0.61)
<b>TOTAL</b>	<b>73.07</b>	<b>106.55</b>

**Break up of security details**

Trade receivables considered good, secured	-	-
Trade receivables considered good, unsecured	73.07	107.16
Trade receivables which have significant increase in credit risk	-	-
Trade receivables - credit impaired	-	-
Less: Allowance for credit losses	-	(0.61)
<b>TOTAL</b>	<b>73.07</b>	<b>106.55</b>

**Ageing of trade receivables as at March 31, 2025:**

	Outstanding for following periods from due date							
	Unbilled	Not Due	Less than 6 months	6 months -1 years	1-2 years	2-3 years	More than 3 years	Total
<b>Undisputed trade receivable</b>								
Considered good	-	-	73.07	-	-	-	-	73.07
Which have significant increase in credit risk	-	-	-	-	-	-	-	-
Credit impaired	-	-	-	-	-	-	-	-
<b>Disputed trade receivable</b>								
Considered good	-	-	-	-	-	-	-	-
Which have significant increase in credit risk	-	-	-	-	-	-	-	-
Credit impaired	-	-	-	-	-	-	-	-
<b>Sub-total</b>	-	-	73.07	-	-	-	-	73.07
<b>Less allowance for credit losses</b>								
<b>TOTAL</b>	-	-	73.07	-	-	-	-	73.07

**Ageing of trade receivables as at March 31, 2024:**

	Outstanding for following periods from due date							
	Unbilled	Not Due	Less than 6 months	6 months -1 years	1-2 years	2-3 years	More than 3 years	Total
<b>Undisputed trade receivable</b>								
Considered good	16.69	69.78	20.69	-	-	-	-	107.16
Which have significant increase in credit risk	-	-	-	-	-	-	-	-
Credit impaired	-	-	-	-	-	-	-	-
<b>Disputed trade receivable</b>								
Considered good	-	-	-	-	-	-	-	-
Which have significant increase in credit risk	-	-	-	-	-	-	-	-
Credit impaired	-	-	-	-	-	-	-	-
<b>Sub-total</b>	16.69	69.78	20.69	-	-	-	-	107.16
<b>Less allowance for credit losses</b>	-	-	-	-	-	-	-	(0.61)
<b>TOTAL</b>	16.69	69.78	20.69	-	-	-	-	106.55

**20 CONTRACT ASSETS**

	As at March 31, 2025	As at March 31, 2024
Contract assets	122.62	316.21
<b>TOTAL</b>	<b>122.62</b>	<b>316.21</b>

Note: Recoverable from customer under contract for supply of goods manufactured exclusively for customers



**PI HEALTH SCIENCES LIMITED**

Notes to the Standalone Financial Statements for the year ended March 31, 2025

(All amounts in ₹ Million, unless otherwise stated)

**21 EQUITY****(i) Equity share capital**

	As at March 31, 2025	As at March 31, 2024
<b>Authorised shares:</b>		
625,550,000 (March 31, 2024: 625,550,000 ) Equity Shares of ₹10 each	6,255.50	6,255.50
<b>Issued shares:</b>		
440,999,946 (March 31, 2024: 440,999,946) Equity Shares of ₹10 each	4,410.00	4,410.00
<b>Subscribed and fully paid up shares:</b>		
440,999,946 (March 31, 2024: 440,999,946) Equity Shares of ₹10 each	4,410.00	4,410.00

**(a) Terms / rights attached to equity shares**

The Company has only one class of equity shares having par value of ₹10 per share (March 31, 2024 - ₹10 per share). Each holder of equity shares is entitled to one vote per share. The equity shareholders are entitled to receive dividend as declared from time to time. In the event of liquidation of the Company, the holders of equity shares will be entitled to receive remaining assets of the Company, after distribution of all preferential amounts. The distribution will be in proportion to the number of equity shares held by the shareholders.

**(b) Reconciliation of equity shares outstanding at the beginning and at the end of the reporting year**

Particulars	As at March 31, 2025		As at March 31, 2024	
	Number	Amount	Number	Amount
Opening balance at the beginning of the year	44,09,99,946	4,410.00	2,44,99,997	245.00
Issued during the year	-	-	41,64,99,949	4,165.00
Outstanding at the end of the year	44,09,99,946	4,410.00	44,09,99,946	4,410.00

**(c) Details of shareholders holding more than 5% shares in the Company**

	As at March 31, 2025		As at March 31, 2024	
	Number	% holding	Number	% holding
PI Industries Limited and its nominees	44,09,99,946	100%	44,09,99,946	100%

**(d) Details of equity shares held by promoter : PI Industries Limited along with its nominees**

	As at March 31, 2025	As at March 31, 2024
Number of shares at the beginning of the year	44,09,99,946	2,44,99,997
Change during the year	-	41,64,99,949
Number of shares at the end of the year	<b>44,09,99,946</b>	<b>44,09,99,946</b>
% of total shares	100%	100%
% change during the year	0%	1700%

**(e) Approval of ESOP**

During the financial year ended March 31, 2025, Members of the Company approved an Employee Stock Option Plan (ESOP) viz. PI Health Sciences Employee Stock Option Plan 2025, in accordance with provisions of the Companies Act, 2013 read with rule made thereunder and other applicable laws and regulations, in Extra-ordinary General meeting held on dated January, 29 2025. As at March 31, 2025, no stock options have been granted under the approved scheme. Accordingly, no expense or liability has been recognised in the financial statements for the year under Ind AS 102 – Share-based Payment.

The Company intends to initiate the grant of options in accordance with the approved scheme in subsequent financial periods.



# Notes to the Standalone Financial Statements for the year ended March 31, 2025

(All amounts in ₹ Million, unless otherwise stated)

## (ii) Other equity

Particulars	As at March 31, 2025	As at March 31, 2024
Retained earnings (a)	(1,129.42)	(261.63)
Equity component of compound financial instrument (b)	664.76	487.39

### (a) Retained earnings

	Amount
<b>As at April 01, 2023</b>	(102.80)
Net loss for the year	(158.38)
-Items of other comprehensive income recognised directly in retained earnings	
Remeasurements gains/(losses) on defined benefit plans	(0.45)
<b>As at March 31, 2024</b>	<b>(261.63)</b>
Net profit/(loss) for the year	(871.99)
-Items of other comprehensive income recognised directly in retained earnings	
Remeasurements gains/(losses) on defined benefit plans	4.21
<b>As at March 31, 2025</b>	<b>(1,129.42)</b>

### Nature and Purpose of the reserve

Retained earnings are the profits that the Company has earned till end of reporting date, less any transfers to general reserve if any, dividend or other distributions paid to shareholders. Further, it also includes the impact of remeasurements of the defined benefit obligations, net of tax.

### (b) Equity component of compound financial instrument

During the year company has issued 200 million (Previous year 550 million) unlisted unsecured Optionally Fully Convertible Debentures ("OFCDs"), having a face value of Rs. 10 each, aggregating to INR 2,000 million (Previous year 5500 million), at an interest of 0.50% on a non-cumulative basis per annum to PI Industries Limited (PI), holding company through private placement on a preferential basis.

OFCDs shall be repaid for a maximum of 10 years, repayable on demand by PI with a moratorium of 5 years. The company has Conversion rights: PI shall have the right to convert, in whole or in part, the OFCDs into fully paid-up equity shares of INR 10 each of the Company, at PI's sole discretion, at the fair value on the date of issue, which shall be determined by the valuation report obtained by a registered valuer acceptable to the parties.

Redemption: PI shall be entitled to exercise the option for redemption of the OFCDs, during the term of the OFCDs. At maturity, or earlier if PI exercises its redemption option, OFCDs to be redeemed at a premium calculated as the average interest on Government Securities of an equivalent term for the period from the date of issuance of the OFCDs until the date of redemption, subject to an overall cap of 9% per annum.

Premium payable on exercise of redemption option has been estimated at 7.15%

Until conversion, OFCDs will rank higher than the Equity Shares for repayment of the principal amount and interest accrued there, and rank pari passu with other unsecured creditors.

OFCDs issued by the Company are classified as compound financial instruments. These OFCDs are separated into liability and equity components based on the terms of the contract. The liability component has been measured based on the present value of contractual obligation to pay cash as the Company doesn't have the discretionary right to avoid these obligation. The difference between the fair value of OFCDs on the date of issue and liability component measured has been presented as equity component. Interest on liability component is recognised as finance cost using the effective interest method.



**PI HEALTH SCIENCES LIMITED**

Notes to the Standalone Financial Statements for the year ended March 31, 2025  
(All amounts in ₹ million, unless otherwise stated)

**22 BORROWINGS**

	Non- Current		Current	
	As at March 31, 2025	As at March 31, 2024	As at March 31, 2025	As at March 31, 2024
<b>Unsecured</b>				
Liability component of OFCDs	7,225.69	4,937.69	-	-
<b>TOTAL</b>	<b>7,225.69</b>	<b>4,937.69</b>	<b>-</b>	<b>-</b>

**Changes in liabilities arising from financing activities - Borrowings**

Particulars	For the year ended	
	March 31, 2025	March 31, 2024
Opening balance	4,937.69	690.00
Add: New loan received during the year	2,000.00	9,410.00
Less: Transaction cost	-	(1.06)
Add: Interest cost (includes interest cost capitalized)	557.89	375.81
Less: Interest /accrued paid during the year	(32.86)	(285.56)
Less: Principal repayment during the year	-	(4,600.00)
Less: Equity component of OFCDs transferred to reserves	(237.02)	(651.50)
Closing balance	7,225.69	4,937.69

**Terms and Conditions**

- a) Kindly refer other equity note for terms of OFCDs.(note no 21)  
b) As on the Balance sheet date, there is no default in repayment of loans and interest.

**23 LEASE LIABILITIES**

	Non- Current		Current	
	As at March 31, 2025	As at March 31, 2024	As at March 31, 2025	As at March 31, 2024
Lease liabilities	63.88	71.45	12.59	12.44
<b>TOTAL</b>	<b>63.88</b>	<b>71.45</b>	<b>12.59</b>	<b>12.44</b>

**Changes in liabilities arising from financing activities - Lease liabilities**

	For the year ended	
	As at March 31, 2025	As at March 31, 2024
Opening balance	83.89	32.83
Add: New leases entered during the year	6.52	55.67
Add: Leases acquired on account of business combination	-	3.72
Add: Interest cost on leases	6.73	6.48
Less: lease termination	(2.40)	-
Less: Payment during the year	(18.27)	(14.81)
Closing balance	<b>76.47</b>	<b>83.89</b>

The Company incurred ₹ 5.42 million for the years ended March 31, 2025 (for the year ended March 31, 2024: ₹ 3.49) towards expenses relating to short term and low value leases.





**PI HEALTH SCIENCES LIMITED**
**Notes to the Standalone Financial Statements for the year ended March 31, 2025**
**(All amounts in ₹ million, unless otherwise stated)**
**24 OTHER FINANCIAL LIABILITIES**

	Non-Current		Current	
	As at March 31, 2025	As at March 31, 2024	As at March 31, 2025	As at March 31, 2024
Employee payables	-	-	34.08	17.04
Interest accrued but not due on borrowings	-	-	-	4.54
Creditors for capital purchases	-	-	83.68	33.46
Security deposits	-	2.20	2.60	-
Other payables*	-	-	263.84	328.44
<b>TOTAL</b>	<b>-</b>	<b>2.20</b>	<b>384.20</b>	<b>383.48</b>

\* Other payables include amounts payable to related party ₹ 94.05 million (Refer Note 42). For previous year other payable includes deferred purchase consideration of "Therachem Research Medilab (India) Private Limited" ₹ 254.36

**25 PROVISIONS**

	Non-Current		Current	
	As at March 31, 2025	As at March 31, 2024	As at March 31, 2025	As at March 31, 2024
<b>Provision for employee benefits</b>				
Gratuity (Refer note 39)	21.26	6.20	2.06	0.05
Compensated absences	13.52	16.70	1.27	1.44
<b>TOTAL</b>	<b>34.78</b>	<b>22.90</b>	<b>3.33</b>	<b>1.49</b>

**26 OTHER CURRENT LIABILITIES**

	As at March 31, 2025	As at March 31, 2024
Statutory dues payable	8.39	14.96
Advance from customers	49.67	20.17
Provision for CSR (Refer Note 36)	-	3.49
<b>TOTAL</b>	<b>58.06</b>	<b>38.62</b>



**PI HEALTH SCIENCES LIMITED**
**Notes to the Standalone Financial Statements for the year ended March 31, 2025**

(All amounts in ₹ million, unless otherwise stated)

**27 TRADE PAYABLES**

	As at March 31, 2025	As at March 31, 2024
Trade payables		
-Due to micro and small enterprises	7.26	7.62
-Others*	67.68	41.67
<b>TOTAL</b>	<b>74.94</b>	<b>49.29</b>

\* Other trade payables includes amount due to related parties amounting to ₹ 1.60 (March 31, 2024 ₹ 2.65 )

**(a) Trade payable ageing as at March 31, 2025:**

Particulars	Outstanding for following periods from due date						Total
	Unbilled dues	Not Due	Less than 1 year	1-2 years	2-3 years	More than 3 years	
<b>Undisputed trade payable</b>							
Micro and small enterprises	-	6.00	1.26	-	-	-	7.26
Others	-	33.86	33.54	0.28	-	-	67.68
<b>Disputed trade payable</b>							
Micro and small enterprises	-	-	-	-	-	-	-
Others	-	-	-	-	-	-	-
<b>Total</b>	-	<b>39.86</b>	<b>34.80</b>	<b>0.28</b>	-	-	<b>74.94</b>

**Trade payable ageing as at March 31, 2024**

Particulars	Outstanding for following periods from due date						Total
	Unbilled dues	Not Due	Less than 1 year	1-2 years	2-3 years	More than 3 years	
<b>Undisputed trade payable</b>							
Micro and small enterprises	-	7.62	-	-	-	-	7.62
Others	-	9.31	26.86	-	5.50	-	41.67
<b>Disputed trade payable</b>							
Micro and small enterprises	-	-	-	-	-	-	-
Others	-	-	-	-	-	-	-
<b>Total</b>	-	<b>16.93</b>	<b>26.86</b>	-	<b>5.50</b>	-	<b>49.29</b>

**(b) Disclosure required under the Micro, Small and Medium Enterprises Development Act, 2006, (MSMED Act):**

Particular	As at March 31, 2025	As at March 31, 2024
Principal amount due to supplier registered under the MSMED Act and remaining unpaid at the year end*	1.26	-
Interest due to suppliers registered under the MSMED Act and remaining unpaid as at year end	-	-
Principal amount paid to supplier registered under the MSMED Act, beyond the appointed day during the year	12.85	15.05
Interest paid, under section 16 of MSMED Act, to suppliers registered under the MSMED Act, beyond the appointed day during the year	0.16	0.06
Interest paid, other than under Section 16 of MSMED Act, to suppliers registered under the MSMED Act, beyond the appointed day during the year	-	-
Amount of interest due and payable for the period of delay in making payment (which has been paid but beyond the appointed day during the year) but without adding the interest specified under the MSMED Act.	-	-
Interest accrued and remaining unpaid at the end of the year	0.03	0.03
Amount of further interest remaining due and payable in succeeding years, until such date when the interest dues as above are actually paid to the small enterprise for the purpose of disallowance as a deductible expenditure under Section 23 of MSMED Act.	-	-

\* Does not include principal amount outstanding but not due of ₹ 6.00 Mn (March 31, 2024: ₹ 7.62) as the balance is not dues as on the reporting date.



**PI HEALTH SCIENCES LIMITED**

Notes to the Standalone Financial Statements for the year ended March 31, 2025  
(All amounts in ₹ million, unless otherwise stated)

**28 REVENUE FROM OPERATIONS**

	For the year ended March 31, 2025	For the year ended March 31, 2024
Revenue from operations includes		
a) Sale of products	136.67	244.78
b) Sale of services*	201.09	16.63
c) Other operating revenues:		
Scrap sales	9.64	2.21
Export incentives	8.21	13.37
<b>Revenue from operations (Net)</b>	<b>355.61</b>	<b>276.99</b>

\*Includes sale of Services of ₹ 18.57 to related party, previous year Nil (Refer Note 42)

(i) The Company has exclusive long-term contract manufacturing agreements with its customers which provides the Company an enforceable right to payment for performance completed to date and performance on these contracts does not create an asset with an alternative use to the Company. These contractual understanding with customers leads to satisfaction of performance obligations over a period of time and revenue is recognised based on percentage of completion of each performance obligation till date in line with Ind AS 115 - "Revenue from contract with customers".

(ii) The Company disaggregates revenue from contract with customer by geography as follows:

	For the year ended March 31, 2025	For the year ended March 31, 2024
USA	284.77	221.37
Europe	35.56	15.85
India	35.28	7.56
<b>Total</b>	<b>355.61</b>	<b>244.78</b>

(iii) Reconciliation of revenue recognised with the contract price is as follows:

	For the year ended March 31, 2025	For the year ended March 31, 2024
<b>Contract Price</b>	355.61	244.78
Adjustments for:		
Refund liabilities	-	-
Discount/Incentives	-	-
<b>Revenue recognised</b>	<b>355.61</b>	<b>244.78</b>

(iv) Changes in contract assets are as follows:

	For the year ended March 31, 2025	For the year ended March 31, 2024
<b>Opening balance</b>	316.21	825.79
Add: Increase due to revenue recognised during the year, excluding amounts billed during the year	133.70	55.08
Less: Invoices raised related to exclusive customer contracts	(327.29)	(564.66)
<b>Closing balance</b>	<b>122.62</b>	<b>316.22</b>

**29 OTHER INCOME**

	For the year ended March 31, 2025	For the year ended March 31, 2024
Interest income from financial assets at amortized cost	111.94	117.01
- Fixed deposits	11.76	12.11
- Others*	100.18	104.90
Interest income on unwinding of security deposits	0.04	0.14
Net foreign exchange differences (net of loss)	5.99	-
Miscellaneous income**	280.01	127.87
<b>TOTAL</b>	<b>397.98</b>	<b>245.01</b>

\* Others includes interest income from related party amounting to ₹ 94.58 (March 31, 2024- ₹ 104.49) (Refer Note 42)

\*\* In current year miscellaneous income includes deferred consideration payable written back ₹ 261.67(Refer Note 24)



**PI HEALTH SCIENCES LIMITED**
**Notes to the Standalone Financial Statements for the year ended March 31, 2025**
**(All amounts in ₹ million, unless otherwise stated)**
**30 COST OF MATERIAL CONSUMED**

	For the year ended March 31, 2025	For the year ended March 31, 2024
Opening stock of raw material	114.23	-
Add: Acquired on business combination	-	144.24
Add: Purchases	106.31	150.41
Less: Closing stock of raw material	90.95	114.23
<b>TOTAL</b>	<b>129.59</b>	<b>180.42</b>

**31 CHANGES IN INVENTORIES OF FINISHED GOODS, WORK IN PROGRESS AND STOCK IN TRADE**

	For the year ended March 31, 2025	For the year ended March 31, 2024
<b>Closing balance</b>		
Finished Goods	9.17	1.73
Work in Progress	0.14	18.19
<b>A</b>	<b>9.31</b>	<b>19.92</b>
<b>Opening balance</b>		
Finished Goods	1.73	-
Work in Progress	18.19	-
<b>B</b>	<b>19.92</b>	<b>-</b>
<b>Total changes in inventories of work-in-progress, stock-in-trade and finished goods</b>	<b>TOTAL (A-B)</b>	<b>(19.92)</b>

**32 EMPLOYEE BENEFIT EXPENSE**

	For the year ended March 31, 2025	For the year ended March 31, 2024
Salaries, wages and bonus	353.72	206.78
Contribution to provident and other funds (refer note 39)	17.08	12.88
Gratuity and long term compensated absences	20.33	12.35
Employees welfare expenses	6.57	7.44
<b>TOTAL</b>	<b>397.70</b>	<b>239.45</b>

**33 FINANCE COST**

	For the year ended March 31, 2025	For the year ended March 31, 2024
Interest on loan	9.78	270.35
Interest on OFCD	542.67	95.30
Interest on lease liabilities	6.73	6.48
<b>TOTAL</b>	<b>559.18</b>	<b>372.13</b>

**34 DEPRECIATION & AMORTISATION**

	For the year ended March 31, 2025	For the year ended March 31, 2024
Depreciation of property, plant and equipment (refer note - 4)	154.21	62.91
Amortization of intangible assets (refer note - 8)	83.63	68.98
Amortisation- right of use (refer note - 5)	25.83	20.82
<b>TOTAL</b>	<b>263.66</b>	<b>152.71</b>



**PI HEALTH SCIENCES LIMITED**
**Notes to the Standalone Financial Statements for the year ended March 31, 2025**
**(All amounts in ₹ million, unless otherwise stated)**
**35 OTHER EXPENSES**

	For the year ended March 31, 2025	For the year ended March 31, 2024
Power, fuel & water	10.77	8.42
Consumption of stores & spares	24.56	2.98
Repairs & maintenance		
- Buildings	2.63	1.36
- Plant and machinery	8.73	11.45
- Others	13.31	8.35
Environment & pollution control expenses	3.94	0.49
Laboratory & testing charges	59.90	17.74
Freight & cartage	8.05	0.11
Travelling and conveyance	43.06	26.24
Rental charges	5.42	3.49
Rates and taxes	166.11	5.98
Insurance	7.82	5.21
Advertisement & sales promotion	10.23	13.20
Payment to auditors	2.97	3.64
Telephone and communication charges	13.80	10.47
Foreign exchange loss (net of gain)	-	11.63
Provision for bad and doubtful debts & advances	2.66	1.61
Director sitting fees and commission	0.39	0.45
Legal & professional fees*	194.99	171.94
Bank charges	1.83	0.93
Corporate social responsibility expenditure (Refer Note 37)	-	3.49
Miscellaneous expenses	63.30	35.46
<b>TOTAL</b>	<b>644.65</b>	<b>344.64</b>
<b>a. Auditor's remuneration</b>		
As auditor:		
- Audit fee	0.95	2.11
- Limited review	0.90	1.10
- Tax audit	0.15	
In other capacity:		
- Certificates & Other matters	0.26	0.19
- Reimbursement of expenses	0.71	0.25
	<b>2.97</b>	<b>3.65</b>

\* Includes cross charge ₹ 66.54 from related parties ( Refer Note 42)





**PI HEALTH SCIENCES LIMITED**
**Notes to the Standalone Financial Statements for the year ended March 31, 2025**
**(All amounts in ₹ million, unless otherwise stated)**
**36 INCOME TAX EXPENSE**

a) Income tax expense recognized in statement of profit and loss	For the year ended March 31, 2025	For the year ended March 31, 2024
<b>Current tax expense</b>		
Current tax on profits for the year	-	-
Adjustment of current tax for prior year	(25.61)	-
<b>Total current tax expense</b>	<b>(25.61)</b>	<b>-</b>
<b>Deferred tax expense</b>		
(Decrease) / increase in deferred tax liability	93.53	70.38
Decrease / (increase) in deferred tax assets	(447.72)	(65.59)
Impact of business combination	-	(593.84)
<b>Net deferred tax expense</b>	<b>(354.19)</b>	<b>(589.05)</b>
<b>Total Income tax expense</b>	<b>(379.80)</b>	<b>(589.05)</b>
<b>b) Deferred tax related to items recognised in Other comprehensive income during the year</b>		
	<b>For the year ended March 31, 2025</b>	<b>For the year ended March 31, 2024</b>
Remeasurement of defined benefit plans	1.41	(0.15)
<b>Income tax charged to Other comprehensive income</b>	<b>1.41</b>	<b>(0.15)</b>
<b>c) Reconciliation of tax expense and the accounting profit multiplied by India's tax rate</b>		
	<b>For the year ended March 31, 2025</b>	<b>For the year ended March 31, 2024</b>
Accounting profit before tax	(1,251.80)	(747.43)
Tax at India's statutory income tax rate @ 25.168% (previous year @25.168%)	(315.05)	(188.11)
<b>Adjustments:</b>		
- Utilisation/credit of unrecognised tax losses, unabsorbed depreciation	3.54	(14.89)
- Effect of Ind AS adjustments in financial statements	(0.01)	149.31
- Effect of non-deductible expenses	22.59	(2.55)
- Effect of different tax treatment on upfront payment of premises	-	60.88
- Impact of business combination	-	(593.84)
- Adjustment of current tax for prior year	(25.61)	-
- Effect of liability no longer payable	(66.95)	-
- Others	1.67	-
- Transfer to OCI	-	0.15
<b>Income Tax Expense</b>	<b>(379.81)</b>	<b>(589.05)</b>

\*The Company has chosen to exercise the option of lower tax rate of 25.168% (inclusive of surcharge and tax) under section 115BAA of the Income Tax Act, 1961 effective April 01, 2019. Accordingly Company has taken the Impact on current tax liability and deferred tax.



**PI HEALTH SCIENCES LIMITED**
**Notes to the Standalone Financial Statements for the year ended March 31, 2025**
**(All amounts in ₹ million, unless otherwise stated)**
**37 CORPORATE SOCIAL RESPONSIBILITY EXPENDITURE**

	For the year ended March 31, 2025	For the year ended March 31, 2024
Amount required to be spent during the year*	-	3.49
Amount of expenditure incurred	-	-
Amount of shortfall for the year	-	3.49
Amount of cumulative shortfall at the end of the year	-	3.49

\*Although the company is in losses total CSR liability pertains to acquisition of Therachem Research Medilab (India) Private Limited ( 31 March 24-₹3.49 Mn)

**Disclosures in relation to corporate social responsibility expenditure**

	For the year ended March 31, 2025	For the year ended March 31, 2024
Contribution to PI foundation *	4.11	-
Accrual towards unspent obligations in relation to:		
On going projects	-	-
Other than ongoing projects	-	-

\* The Company acquired unspent CSR liability on acquisition of Therachem Research Medilab (India) Private Limited amounting to ₹ 9.37 Mn out of which 4.11 Mn remained unspent as on 31.03.2024 which has been paid to PI Foundation during FY 2024-25.

**Details of CSR expenditure U/S 135(5) of the act in respect of other than ongoing projects**

	For the year ended March 31, 2025	For the year ended March 31, 2024
Balance unspent as at the start of the year	3.49	-
CSR liability accrued on account of business combination	-	-
Amount deposited in Specified fund of Schedule VII of the act within 6 month	3.49	-
Amount required to be spent during the year	-	3.49
Amount spent during the year	-	-
Balance unspent as at the end of the year	-	3.49

**Details of excess CSR expenditure under section 135(5) of the act**

	For the year ended March 31, 2025	For the year ended March 31, 2024
Balance excess spent as at the start of the year	-	-
Amount required to be spent during the year	-	-
Amount spent during the year	-	-
Balance excess spent as at the end of the year	-	-



**PI HEALTH SCIENCES LIMITED****Notes to the Standalone Financial Statements for the year ended March 31, 2025**

(All amounts in ₹ million, unless otherwise stated)

**38 CAPITAL MANAGEMENT**

The Company's policy is to maintain a strong capital base so as to maintain investor, creditor and market confidence and to sustain future development of the business. The primary objective of the Company's Capital management is to maximise shareholder's value. The Company manages its capital and makes adjustment to it in light of the changes in economic and market conditions.

The Company monitors capital using a gearing ratio, which is net debt divided by total capital plus net debt. The Company includes within net debt, interest bearing loans and borrowings, less cash and cash equivalents.

Particulars	As at March 31, 2025	As at March 31, 2024
Borrowings	7,225.69	4,937.69
Less: Cash and cash equivalent and other bank balances	309.94	388.30
Net Debt	6,915.75	4,549.39
Total Equity	3,945.35	4,635.76
Equity Capital and Net Debt	10,861.10	9,185.15
Gearing Ratio	64%	50%

No changes were made in the objectives, policies or processes for managing capital of the Company during the current or previous year.

**39 EMPLOYEE BENEFITS**

The Company participates in defined contribution and benefit schemes, the assets of which are not funded in separately administered funds for defined benefit scheme. For defined contribution schemes the amount charged to the statements of profit or loss is the total of contributions payable in the year.

**Provident Fund**

In accordance with the Employees' Provident Fund and Miscellaneous Provisions Act, 1952 (EPF and MP Act), employees are entitled to receive benefits under the Provident Fund. Employers and employees both contribute @12% of wages in contribution accounts. Further, the employers also contribute towards administration of the benefits under the EPF and MP Act. All employees have an option to make additional voluntary contributions as permissible under the Act. These contributions are made to the fund administered and managed by the Employee Provident Fund organization. The Company has no further obligations under the fund managed by the Employee Provident Fund Organization (EPFO) beyond its monthly contributions which are charged to the statements of profit or loss in the period they are incurred. The benefits are paid to employees on their retirement or resignation from the EPFO.

**Gratuity Plan**

In accordance with the Payment of Gratuity Act of 1972, The company has established a defined benefit scheme. The Gratuity scheme provides a lump sum payment to the employees at the time of retirement or resignation (after 5 years of continued services of employment), being an amount based on the respective employee's last drawn salary and the number of years of employment with the Company. Based on actuarial valuations conducted as at year end, a provision is recognised in full for the benefit obligation. Remeasurements as a result of experience adjustments and changes in actuarial assumptions are recognised in other comprehensive income.

**Long term compensated absences**

The liabilities for compensated absence namely earned and sick leave are not expected to be settled wholly within 12 months after the end of the period in which the employees render the related service. They are therefore measured as the present value of expected future payments to be made in respect of services provided by employees up to the end of the reporting period using the projected unit credit method. Remeasurements as a result of experience adjustments and changes in actuarial assumptions are recognised in profit and loss.

**a) Defined Contribution Plans: -**

The Company has recognised an expense of ₹ 17.08 (previous year ₹ 12.88) towards the defined contribution plan.



**PI HEALTH SCIENCES LIMITED**
**Notes to the Standalone Financial Statements for the year ended March 31, 2025**
**(All amounts in ₹ million, unless otherwise stated)**
**b) Defined benefits plans - as per actuarial valuation**

	<b>Gratuity Non Funded</b>	
	<b>For the year ended</b>	
	<b>March 31, 2025</b>	<b>March 31, 2024</b>
<b>I Change in present value of obligation during the year</b>		
Present value of obligation at the beginning of the year	6.25	1.18
Total amount included in profit and loss:		
- Current Service Cost	6.77	4.39
- Interest Cost	0.45	0.09
- Past Service Cost	16.67	-
<b>Total amount recognised in profit or loss (refer note below)</b>	<b>23.90</b>	<b>4.48</b>
Total amount included in OCI:		
Actuarial losses/(gains) arising from:		
- Demographic	-	(0.68)
- Financial assumption	0.35	0.70
- Experience	(5.97)	0.58
<b>Total amount recognised in OCI</b>	<b>(5.62)</b>	<b>0.60</b>
Benefits Paid	(1.21)	-
<b>Present Value of obligation as at year-end</b>	<b>23.32</b>	<b>6.25</b>

**Note: Net amount recognised in statement of profit and loss on account of defined benefit obligations**

<b>II Change in Fair Value of Plan Assets during the year</b>	<b>For the year ended</b>	
	<b>March 31, 2025</b>	<b>March 31, 2024</b>
Plan assets at the beginning of the year	-	-
Included in profit and loss:		
Expected return on plan assets	-	-
Included in OCI:		
Actuarial Gain/(Loss) on plan assets	-	-
Others:		
Employer's contribution	-	-
Benefits paid	-	-
Claim received during the year from fund manager	-	-
Pending claim with fund manager	-	-
Plan assets at the end of the year	-	-

<b>III Reconciliation of present value of defined benefit obligation and fair value of plan assets</b>	<b>For the year ended</b>	
	<b>March 31, 2025</b>	<b>March 31, 2024</b>
Present Value of obligation as at year-end	23.32	6.25
Fair value of plan assets at yearend	-	-
<b>Net Asset/(Liability)</b>	<b>(23.32)</b>	<b>(6.25)</b>



**PI HEALTH SCIENCES LIMITED**
**Notes to the Standalone Financial Statements for the year ended March 31, 2025**
**(All amounts in ₹ million, unless otherwise stated)**

IV	Bifurcation of present value of obligation at the end of the year	For the year ended	
		March 31, 2025	March 31, 2024
	Current Liability	2.06	0.05
	Non-Current Liability	21.26	6.20

V	Actuarial Assumptions	For the year ended	
		March 31, 2025	March 31, 2024
	Discount Rate	6.99%	7.22%
	Expected rate of return on plan assets	N.A.	N.A.
	Mortality Table	100% of IALM (2012-14)	100% of IALM (2012-14)
	Salary Escalation	10%	10%

VI	Sensitivity Analysis @ 0.5% change	Year ended March 31, 2025		Year ended March 31, 2024	
		Increase	Decrease	Increase	Increase
	Discount rate	(0.77)	0.82	(0.17)	0.18
	Future salary growth	0.80	(0.76)	0.18	0.17

**VII Maturity profile of defined benefit obligation**

	For the year ended	
	March 31, 2025	March 31, 2024
Within the next 12 months	2.06	0.05
Between 1-5 years	9.47	2.68
Beyond 5 years	11.79	3.53

**40 CAPITAL & OTHER COMMITMENT**

a.	Estimated Amount of Contracts remaining to be executed on capital account and not provided for {Net of advances ₹ 6.35 Mn (March 31, 2024: ₹ 17.93 Mn )}	24.50	155.63
----	--	-------	--------

**41 CONTINGENT LIABILITIES**

	March 31, 2025	March 31, 2024
Claims against the company not acknowledged as debt		
-Income tax	1.92	-
-Customs	-	-
-Goods and service tax	-	-
Other matters, claims relating to customers, labours and third parties etc.	-	-
<b>Total</b>	<b>1.92</b>	<b>-</b>

The Company has reviewed all its pending litigations and proceedings and has adequately provided for where provisions are required and disclosed as contingent liabilities where applicable, in its financial statements. The Company does not expect the outcome of these proceedings to have a materially adverse effect on its financial position.



**PI HEALTH SCIENCES LIMITED**

Notes to the Standalone Financial Statements for the year ended March 31, 2025

(All amounts in ₹ million, unless otherwise stated)

**42 RELATED PARTY DISCLOSURES**

Related party disclosure, as required by Indian Accounting Standard-24, is as below:

**List of Related Parties:-****I. Enterprises which control the entity**

- (a) PI Industries Limited

**II. ENTERPRISES WHERE CONTROL EXISTS****Subsidiaries and their subsidiaries**

- (a) PI Health Sciences Netherlands B.V

- (b) PI Health Sciences USA LLC

- (c) Archimica S.P.A

**III. Fellow Subsidiaries**

- (a) PILL Finance and Investment Limited

- (b) PI Life Science Research Limited

- (c) PI Japan Co. Limited

- (d) Jivagro Limited

- (e) PI Fermachem Private Limited

- (f) PI Bioferma Private Limited

- (g) PI Industries Management Consultancies LLC

- (h) Plant Health Care limited

- (i) Plant Health Care, Inc., Nevada

- (j) Plant Health Care (Espana) S.A, Spain

- (k) Plant Health Care (UK) Limited

- (l) Plant Health Care de Mexico S. de R.L. de C.V, Mexico

- (m) Plant Health Care Insurnos Agricolas Ltd, Brazil

**IV. Key Managerial Personnel :-**

a) Mr. Narayan Keelveedhi Seshadri	Chairperson (Director)
b) Mr. Arunabha Raychaudhuri	Whole Time Director (w.e.f. July 05, 2024)
c) Mr. Mayank Singhal	Director
d) Mr. Rajnish Sarna	Director
e) Dr. Tanjore Soundararajan Balganes	Director
f) Dr. Atul Kumar Gupta	Director (w.e.f. August 03, 2024)
g) Ms. Suman Gopalan	Director (w.e.f. August 03, 2024)
h) Mr. Anil Kumar Jain	Managing Director upto July 05, 2024
i) Mr. Ankit Nayyar	Chief financial officer
j) Mrs. Ruchi Sheth	Company Secretary

**IV. Entities controlled by KMP with whom transactions have taken place:**

- a) PI Foundation

**V. The following transactions were carried out with related parties in the ordinary course of business:**

Nature of Transaction	For the year ended March 31, 2025		For the year March 31, 2024	
	Transaction during the year	Balance outstanding Dr / (Cr)	Transaction during the year	Balance outstanding Dr / (Cr)
<b><u>Compensation to KMP</u></b>				
- Short term employee benefits	23.63	-	61.76	-
- Post employment benefits*	1.80	-	7.98	-
- Director sitting fees	0.39	-	0.45	-
- Reimbursement on account of expenses incurred	2.97	-	9.27	(1.36)
- Salary and other perquisites	17.91	-	6.28	-
<b><u>Transactions with PI Industries Limited</u></b>				
- Issue of share capital	0.00	-	4165.00	-
- Issue of OFCD*	2,000.00	(7,500.00)	5500.00	(5,500.00)
- Loans received	0.00	-	3910.00	-
- Loans repaid	0.00	-	4600.00	-
- Interest paid on OFCD	32.86	(27.51)	5.05	(4.54)
- Interest paid on loan	0.00	-	281.02	-
- Rent paid	0.71	-	0.68	(0.06)
- Purchases	3.77	(1.60)	0.08	-
- Cross charge	4.92	-	2.40	(2.59)
- Reimbursement on account of expenses incurred	0.12	-	0.00	-
- Purchase of Capital Asset	0.22	(0.03)	0.00	-
- Sale of services	18.57	10.20	0.00	-
- Rent received	1.99	2.35	0.00	-

\*As per IND AS closing balance of OFCS is ₹7225.69 ( March 31, 2024 ₹ 4937.69)





**PI HEALTH SCIENCES LIMITED**
**Notes to the Standalone Financial Statements for the year ended March 31, 2025**
**(All amounts in ₹ million, unless otherwise stated)**

Nature of Transaction	For the year ended March 31, 2025		For the year March 31, 2024	
	Transaction during the year	Balance outstanding Dr / (Cr)	Transaction during the year	Balance outstanding Dr / (Cr)
<b>Transactions with PI Foundation</b>				
Contribution towards CSR Activities	0.00	-	9.37	-
<b>Transactions with PI Health Sciences Netherlands B.V</b>				
- Investments	657.64	-	2,063.53	-
- Investments (Loan & interest conversion)	3,072.60	-	-	-
- Loan given (Refer Note 10)	814.70	21.10	2,185.00	2,188.89
- Interest received on loan	94.58	0.61	104.49	21.27
- Management fees charged	-	-	110.39	107.90
<b>Transactions with Archimica S.P.A</b>				
- Sale of goods	-	-	15.85	15.85
-Business support services cross charge	5.99	(5.99)	-	-
<b>Transactions with PIHS USA LLC</b>				
-Business support services cross charge	60.55	(60.55)	-	-

**Terms and conditions of transactions with related parties**

The sales and purchases / services rendered to and from related parties are made on terms equivalent to those that prevail in arm's length transactions. Outstanding balances at the year-end are unsecured and interest free and settlement occurs in cash. There have been no guarantees provided or received for any related party receivables or payables. For the year ended March 31, 2025, the Company has not recorded any impairment of receivables relating to amounts owed by related parties (March 31, 2024: nil). This assessment is undertaken each financial year through examining the financial position of the related party and the market in which the related party operates.

**43 FINANCIAL INSTRUMENTS**
**Financial instruments – Fair values and risk management**
**A. Financial instruments by category**

	As at March 31, 2025			As at March 31, 2024		
	FVTPL	FVTOCI	Amortised Cost	FVTPL	FVTOCI	Amortised Cost
<b>Financial assets</b>						
<b>Non-current assets*</b>						
Loan	-	-	21.37	-	-	2,188.89
Other financial assets	-	-	11.09	-	-	9.06
<b>Current assets</b>						
Trade receivables	-	-	73.07	-	-	106.55
Cash and cash equivalents	-	-	298.46	-	-	376.74
Bank balance other than cash and cash equivalents	-	-	11.48	-	-	11.56
Other financial assets	-	-	4.45	-	-	144.57
<b>TOTAL</b>	-	-	<b>419.92</b>	-	-	<b>2,837.37</b>
<b>Financial liabilities</b>						
<b>Non-current liabilities**</b>						
Borrowings	-	-	7,225.69	-	-	4,937.69
Other financial liabilities	-	-	-	-	-	2.20
<b>Current liabilities**</b>						
Trade payables	-	-	74.94	-	-	49.29
Other financial liabilities	-	-	384.20	-	-	383.48
<b>TOTAL</b>	-	-	<b>7,684.83</b>	-	-	<b>5,372.67</b>

\* Excluding Investment in subsidiaries measured at cost in accordance with Ind AS 27

\*\* Excluding lease liabilities measured in accordance with Ind AS 116



**PI HEALTH SCIENCES LIMITED****Notes to the Standalone Financial Statements for the year ended March 31, 2025****(All amounts in ₹ million, unless otherwise stated)****B. Fair value hierarchy**

This section explains the judgements and estimates made in determining the fair values of the financial instruments that are

(a) recognised and measured at fair value and

(b) measured at amortised cost and for which fair values are disclosed in the financial statements.

To provide an indication about the reliability of the inputs used in determining fair value, the company has classified its financial instruments into the three levels prescribed under the accounting standard. An explanation of each level follows underneath the table.

**Assets and liabilities which are measured at amortised cost for which fair values are disclosed**

	As at March 31, 2025			As at March 31, 2024		
	Level 1	Level 2	Level 3	Level 1	Level 2	Level 3
<b>Financial assets</b>						
Security deposits	-	-	11.09	-	-	9.09
<b>Financial liabilities</b>						
Deferred purchase consideration	-	-	-	-	-	254.97
<b>TOTAL</b>	-	-	<b>11.09</b>	-	-	<b>264.06</b>

The fair value of cash and cash equivalents, bank balances other than Cash and cash equivalents, trade receivables, contract assets, current financial assets, trade payables and current financial liabilities approximate their carrying amount, largely due to the short-term nature of these instruments. Optionally fully convertible debentures has been recently floated to parent which resonates to its fair value as on reporting date. Fair value for security deposits (other than perpetual security deposits) and lease liabilities has been presented in the above table.

**Fair value hierarchy**

The table shown above analyses financial instruments carried at fair value, by valuation method. The different levels have been defined below:

**Level 1** - This includes financial instruments measured using quoted prices.

**Level 2** - The fair value of financial instruments that are not traded in an active market is determined using valuation techniques which maximise the use of observable market data and rely as little as possible on entity-specific estimates. If all significant inputs required to fair value an instrument are observable, the instrument is included in level 2. Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices).

**Level 3** - If one or more of the significant inputs is not based on observable market data, the instrument is included in level 3.

**Valuation technique used to determine fair value:**

Specific valuation techniques used to value financial instruments includes:

- the use of quoted market prices
- the fair value of forward foreign exchange contracts is determined using forward exchange rates at the balance sheet date
- the fair value of the remaining financial instruments is determined using discounted cash flow analysis.

The fair values for security deposits and deferred purchase consideration were calculated based on present values of cash flows and the discount rates used were adjusted for counterparty or own credit risk. They are classified as level 3 fair values in the fair value hierarchy due to the inclusion of unobservable inputs including counterparty credit.



**44 FINANCIAL RISK MANAGEMENT****Risk management framework**

The Company's activities expose it to a variety of financial risks - credit risk, market risk and liquidity risk. The Company's board of directors has the overall responsibility for the management of these risks

This note explains the sources of risk which the entity is exposed to and how the entity manages the risk.

As at the reporting date, the Management is of the opinion that the Company is not exposed to any substantial credit risk, liquidity risk and market risk.

**i. Credit risk**

Credit risk is the risk of financial loss to the Company if a customer or counterparty to a financial instrument fails to meet its contractual obligation, and arises from the operating activities primarily (trade receivables) and from its financing activities including cash and cash equivalents, deposits with banks and other financial instruments. The carrying amount of financial assets represents the maximum credit exposure and is as follows

**(i) Trade receivables and contract assets**

The Company's exposure to credit risk is influenced mainly by the individual characteristics of each customer and the concentration of risk from the top few customers. Exposure to customers is undiversified and all customers contribute more than 10% of outstanding trade receivables and contract assets. However, management also considers the factors that may influence the credit risk of its customer base, including the default risk of the industry and country in which customers operate including the past trends on recoverability.

The Company has established a credit policy under which each customer is analysed individually for creditworthiness before the Company's credit terms are offered. Credit risk is managed through credit approvals, establishing credit limits and continuously monitoring the creditworthiness of customers to which the Company grants credit terms in the normal course of business. Credit limits are established for each customer and reviewed periodically.

**Credit risk exposure**

To measure the expected credit losses, trade receivables and contract assets have been grouped based on shared risk characteristics and the days past due. The contract assets relates to unbilled work in progress and have substantially the same risk characteristics as trade receivables for the same type of contracts.

The allowance for lifetime expected credit loss on customer balances recognized for the years ended March 31, 2025- "nil" and March 31, 2024 is ₹ 0.61 .

**Particulars****Year ended March 31,**

	<b>2025</b>	<b>2024</b>
Balance at the beginning	0.61	-
Change in loss allowance	(0.61)	0.61
Amounts written off	-	-
Balance at the end	-	<b>0.61</b>

The exposure to credit risk and expected credit loss on contract assets as at 31 March 2025 is Nil.

**Cash and cash equivalents, deposits with banks:**

Credit risk from balances with banks and other financial instruments is managed by Company in accordance with its policy. Investments of surplus funds are made only with approved counterparties and within credit limits assigned to each counterparty. Counterparty credit limits are reviewed by the management and may be updated throughout the year.

Impairment on cash and cash equivalents, deposits and other financial instruments has been measured on the 12-month expected credit loss basis and reflects the short maturities of the exposures. For financial assets which are long term in nature, the expected credit loss is insignificant.

Accordingly, based on the assessment there is no material allowance in the above financial assets.

**Exposure to credit risk:**

The gross carrying amount of financial assets, net of impairment losses (if any) recognized represent the maximum credit exposure.



**PI HEALTH SCIENCES LIMITED**
**Notes to the Standalone Financial Statements for the year ended March 31, 2025**

(All amounts in ₹ million, unless otherwise stated)

**ii. Liquidity risk**

Liquidity risk is the risk that the Company will encounter difficulty in meeting the obligations associated with its financial liabilities that are settled by delivering cash or another financial asset. The Company's approach to managing liquidity is to ensure, as far as possible, that it will have sufficient liquidity to meet its liabilities when they are due, under both normal and stressed conditions, without incurring unacceptable losses or risking damage to the Company's reputation.

Management monitors rolling forecast of Company's liquidity position and cash and cash equivalents on the basis of expected cash flows. In addition, the company's liquidity management policy involves projecting cash flows in major currencies and considering the level of liquid assets necessary to meet these and monitoring balance sheet liquidity ratios against internal and external regulatory requirements.

**(a) Maturities of financial liabilities**

The following are the remaining contractual maturities of financial liabilities at the reporting date.

As at March 31, 2025	Contractual cash flows					
	Total	3 months or less	3-12 months	1-2 years	2-5 years	More than 5 years
<b>Financial liabilities</b>						
Borrowing	10,369.00	-	37.50	37.50	10,294.00	-
Lease liabilities	184.28	3.59	14.70	18.79	24.88	122.32
Trade payables	74.94	74.94	-	-	-	-
Other financial liabilities	384.20	384.20	-	-	-	-
<b>Total</b>	<b>11,012.42</b>	<b>462.73</b>	<b>52.20</b>	<b>56.29</b>	<b>10,318.88</b>	<b>122.32</b>

As at March 31, 2024	Contractual cash flows					
	Total	3 months or less	3-12 months	1-2 years	2-5 years	More than 5 years
<b>Financial liabilities</b>						
Borrowings	7,604.00	-	27.50	27.50	7,549.00	-
Lease liabilities	197.33	3.43	13.07	17.21	38.74	124.88
Trade payables	49.29	49.29	-	-	-	-
Other financial liabilities	399.86	131.66	266.00	2.20	-	-
<b>Total</b>	<b>8,250.48</b>	<b>184.38</b>	<b>306.57</b>	<b>46.91</b>	<b>7,587.74</b>	<b>124.88</b>

**iii. Market risk**

Market risk is the risk that changes in market prices - such as foreign exchange rates, interest rates and equity prices - will affect the Company's income or the value of its holdings of financial instruments. The objective of market risk management is to manage and control market risk exposures within acceptable parameters while optimising the return.

The Company is exposed to market risk primarily related to foreign exchange rate risk (currency risk) and interest rate risk. Thus, the Company's exposure to market risk is a function of investing and borrowing activities and revenue generating and operating activities in foreign currencies.

**Foreign Currency risk**

The company is exposed to foreign exchange risk arising from foreign currency transactions, primarily with respect to the US\$ and Euro. Foreign exchange risk arises from future commercial transactions and recognised assets and liabilities denominated in a currency that is not the Company's functional currency (₹).

**Foreign currency risk exposure -**

The currency profile of financial assets and financial liabilities as at March 31, 2025 and March 31, 2024 expressed in Indian Rupees (₹) are as below:

	As at March 31, 2025			As at March 31, 2024		
	USD	EURO	Others	USD	EURO	Others
<b>Financial assets</b>						
Trade receivables	62.87	-	10.20	106.55	-	-
Loans	21.37	-	-	417.03	1,771.86	-
Cash and cash equivalent (EEFC account)	17.07	-	-	16.27	-	-
Interest receivable on loan to subsidiaries	0.61	-	-	-	21.27	-
Management fees from related party	-	-	-	107.90	-	-
	<b>101.92</b>	<b>-</b>	<b>10.20</b>	<b>647.75</b>	<b>1,793.13</b>	<b>-</b>



**PI HEALTH SCIENCES LIMITED**
**Notes to the Standalone Financial Statements for the year ended March 31, 2025**
**(All amounts in ₹ million, unless otherwise stated)**

	As at March 31, 2025			As at March 31, 2024		
	USD	EURO	Others	USD	EURO	Others
<b>Financial liabilities</b>						
Trade payables	16.49	-	-	20.21	-	3.79
Creditors for capital purchases	1.59	-	-	17.71	0.07	3.79
	<b>18.08</b>	-	-	<b>37.92</b>	<b>0.07</b>	<b>7.58</b>
Spot exchange rate on reporting date	85.48	92.09	-	83.41	89.88	-

**Sensitivity analysis**

A reasonably possible strengthening (weakening) of the foreign currency at March 31 would have affected the measurement of financial instruments denominated in foreign currencies and affected equity and profit or loss by the amounts shown below. This analysis assumes that all other variables, interest rates, remain constant and ignores any impact of forecast sales and purchases. 1% increase or decrease is used when reporting foreign currency risk internally to key management personnel and represents management's assessment of the reasonably possible change in foreign currency rate.

Effect in INR	Profit or loss, net of tax		Impact on other components of equity, net of tax	
	Strengthening	Weakening	Strengthening	Weakening
<b>March 31, 2025</b>				
<b>1% movement</b>				
USD	0.63	(0.63)	-	-
EURO	-	-	-	-
Others	-	-	-	-
<b>March 31, 2024</b>				
<b>1% movement</b>				
USD	9.26	(9.26)	-	-
EURO	17.93	(17.93)	-	-
Others	-	-	-	-

**Interest rate risk**

The Company's has taken loan from holding Company carrying a fixed interest rate, hence there is no interest rate risk at the reporting date.

**Exposure to interest rate risk**

The interest rate profile of the Company's interest-bearing financial instruments as reported to the management of the Company is as follows.

Particular	As at March 31, 2025	As at March 31, 2024
<b>Fixed-rate instruments</b>		
Financial liabilities	7,225.69	4,937.69
<b>Total</b>	<b>7,225.69</b>	<b>4,937.69</b>

**Fair value sensitivity analysis for fixed-rate instruments**

The Company does not account for any fixed-rate financial assets or financial liabilities at fair value through profit or loss. Therefore, a change in interest rates at the reporting date would not affect profit or loss.

**Price risk**

The Company is not exposed to any price risk as at the reporting date.



**PI HEALTH SCIENCES LIMITED**

Notes to the Standalone Financial Statements for the year ended March 31, 2025

(All amounts in ₹ million, unless otherwise stated)

**45 RATIO ANALYSIS**

S.No.	Ratio	Numerator	Denominator	March 31, 2025	March 31, 2024	% Variance	Reason
1	Current ratio	Current asset	Current Liabilities	1.89	3.11	(39.2%)	Due to liquidation of trade receivable, resulted into these variance.
2	Debt-Equity ratio	Borrowing	Total Equity	1.83	1.07	71.9%	New funding through OFCD in the current year leading to higher debt equity ratio
3	Debt Service Coverage ratio	Earnings before interest, taxes, depreciation & amortization	Debt Service = Interest and Principal payments including lease payments	(1.50)	(1.28)	17.0%	Further subscription of OFCD's resulted in this variance
4	Return on Equity ratio	Profit after tax	Average Equity	(20.3%)	(3.4%)	494.9%	Losses have increased due to recognition of post acquisition one off expenses
5	Inventory Turnover ratio	Cost of Goods sold	Average Inventory	2.80	2.39	16.9%	Not required
6	Receivables Turnover ratio	Sales	Average Receivable	3.63	1.31	177.4%	Due to liquidation of dues
7	Payables Turnover ratio	Cost of Goods sold	Average Payable	2.26	6.51	-65.3%	Due to better negotiation in credit terms
8	Net Capital Turnover ratio	Sales	Working Capital	0.75	0.27	176.7%	due to better working capital management
9	Net Profit ratio	Profit after tax	Sales	-245%	-57.2%	328.8%	Losses have increased due to recognition of post acquisition one off expenses
10	Return on Capital Employed	Earnings before interest and taxes	Total Equity + Borrowings	(9.9%)	(6.4%)	55.0%	Losses have increased due to recognition of post acquisition one off expenses
11	Return on Investment	Earnings before interest and taxes	Total Assets	(0.09)	(0.06)	53.4%	Losses have increased due to recognition of post acquisition one off expenses





**46 BUSINESS COMBINATION**

During the current year there is no scheme of arrangement. However, in the previous year, the Company has acquired the following businesses:-

**(a) Acquisition of Therachem Research Medilab (India) Private Limited ("TRM India")**

PI Health Sciences Limited has entered into a share purchase agreement dated 27th April 2023 for the acquisition of 100% shareholding of "Therachem Research Medilab (India) Private Limited" which is now merged with the Company.

On 2nd June 2023, PI Health Sciences Limited acquired 53,800 equity shares of face value ₹ 100 each for total purchase consideration ₹ 3,595.11 million.

The acquisition will enable the Company's plans of growth and expansion in pharmaceutical sector.

TRM India was engaged in the business of research, development and manufacturing of chemical compounds which are ultimately used for manufacturing of API (active pharmaceutical ingredients) and other pharmaceutical products.

**(b) Acquisition of Solis Pharmachem Private Limited ("Solis India")**

PI Health Sciences Limited has entered into a share purchase agreement dated 27th April 2023 for the acquisition of 100% shareholding of "Solis Pharmachem Private Limited" which is now merged with the Company.

On 2nd June 2023, PI Health Sciences Limited acquired 24,757,900 equity shares of face value ₹ 10 each for total purchase consideration ₹ 248 million.

The acquisition will enable the Company's plans of growth and expansion in pharmaceutical sector.

Solis Pharmachem is engaged in the business of research, development and manufacturing of chemical compounds which are ultimately used for manufacturing of API (active pharmaceutical ingredients) and other pharmaceutical products.

**Assets acquired and liabilities assumed**

The fair values of the identifiable assets and liabilities as at the date of acquisition were:

	TRM India	Solis India
<b>Assets</b>		
Property, plant and equipment	288.50	236.75
Capital work in progress	0.20	-
Trade receivables	6.13	22.95
Contract Asset	825.79	-
Cash and cash equivalents	566.95	2.23
Other bank balances	19.65	-
Other financial assets	13.66	4.58
Inventories	144.34	0.26
Current tax assets	97.29	-
Deferred tax assets	9.57	-
Other assets	54.11	12.38
<b>Total Assets (I)</b>	<b>2,026.18</b>	<b>279.14</b>
<b>Liabilities</b>		
Trade payables	30.77	8.57
Lease liabilities	3.72	-
Provisions	9.84	0.23
Deferred tax liabilities	-	1.22
Other current liabilities	334.53	4.18
<b>Total Liabilities (II)</b>	<b>378.86</b>	<b>14.20</b>
Identifiable net assets at fair value (I-II)	1,647.32	264.95
Fair value of intangible asset identified on acquisition		
Customer contracts	1,661.00	-
<b>Total net assets assumed</b>	<b>3,308.32</b>	<b>264.95</b>

**Purchase consideration**

Cash paid on business combination	2,732.80	248.00
Deferred purchase consideration on account of working capital acquired as per share purchase agreement	624.53	-
Additional deferred purchase consideration*	237.78	-

Contingent consideration of 15% of material margin earned for the date of acquisition till March 31, 2029\*\*

<b>Total purchase consideration</b>	<b>3,595.11</b>	<b>248.00</b>
-------------------------------------	-----------------	---------------

\* Additional deferred purchase consideration shall be paid after a period of 18 months from the date of acquisition, thereby, has been measured at fair value.

\*\* Contingent consideration is an additional amount payable by PIHS LLC to TRM US equivalent to fifteen percent (15%) of the sum of the material margin (revenue minus raw material cost) from the date of acquisition till 31 March 2029 on respective payment dates as per APA subject to maximum amount of \$25 Mn.

To determine the contingent consideration, PIHS LLC has estimated its obligation on respective payment dates and discounted it at 14% weighted average cost of capital with 100% probability.



**PI HEALTH SCIENCES LIMITED**
**Notes to the Consolidated financial statements for the year ended March 31, 2025**
**(All amounts in ₹ million, unless otherwise stated)**

<b>Calculation of goodwill</b>	<b>TRM India</b>	<b>Solis India</b>
Purchase consideration	3,595.11	248.00
Less: Net assets assumed	3,308.32	264.95
Add: Deferred tax liability created on		
Fair value surplus on property, plant and equipment	39.00	2.49
Intangible asset identified on acquisition	418.04	-
Contract assets created on business combination	142.25	-
Exchange gain/(loss)	-	-
<b>Total goodwill</b>	<b>886.07</b>	<b>(14.46)</b>

TRM India and Solis India has been acquired as a part of single share purchase agreement having same parent and promoters, hence, capital reserve created on acquisition of Solis India has been netted off against the goodwill generated on acquisition of TRM India.

Goodwill is not tax deductible but is deductible for US tax purposes for PIHS LLC

Goodwill majorly includes the value expected from increase in revenues from various new streams of business, addition of new customers, and estimated synergies which does not qualify as an intangible asset.

<b>Acquired receivables</b>	<b>TRM India</b>	<b>Solis India</b>
Fair value of trade receivables	6.13	22.95
Fair value of contract assets	825.79	-
Total fair value of acquired receivable	831.92	22.95
Gross contractual amount of receivable	831.92	22.95
Contractual cash flows not expected to be collected	-	-

<b>Details of operational profit/loss</b>	<b>TRM India</b>	<b>Solis India</b>
<b>Had acquisition occurred at the start of the year</b>		
Revenue	326.83	34.63
Profit/(loss) before tax	(153.84)	(62.03)
<b>From the actual date of acquisition</b>		
Revenue	276.00	0.45
Profit/(loss) before tax	(123.62)	(24.80)

**(c) Merger of TRM India and Solis India with PI Health Sciences Limited**

PI Health Sciences Limited had filed a Scheme of Amalgamation for the purpose of amalgamation of TRM India and Solis India businesses together with all the related assets, liabilities, and employees with PI Health Sciences.

The said Scheme of Amalgamation has been approved by Hon'ble Regional Director, Ahmedabad, Ministry of Corporate Affairs vide its order dated 27th September 2023 under Section 233 read with rule 25 (5) of Companies Act, 2013 from effective date June 02, 2023.

**47 OPERATING SEGMENT**

An operating segment is defined as a component of the entity that represents business activities from which it may earn revenues and incur expenses and for which discrete financial information is available. The operating segments are based on the group's internal reporting structure and manner in which operating results are reviewed by Chief Operating Decision Maker (CODM). The Company has evaluated the applicability of segment reporting and has concluded that since the principal activities of the group are Manufacturing and/or trading, research and development of all kinds of Pharmaceuticals products, Pharma intermediates and related products accordingly the Company has one reportable business segment viz. Pharma Products.

**Geographical Areas**

The group is domiciled in India. The amount of its revenue from external customers broken down by location of the customers is shown in the table below:

<b>Particulars</b>	<b>For the year ended</b>	
	<b>March 31, 2025</b>	<b>March 31, 2024</b>
Europe	35.56	15.85
USA	284.77	221.37
India	35.28	7.56
Total	355.61	244.78

4 customers of the company has more than 10% of revenue during the year



**PI HEALTH SCIENCES LIMITED**
**Notes to the Standalone Financial Statements for the year ended March 31, 2025**
**(All amounts in ₹ million, unless otherwise stated)**
**48 EARNING PER SHARE (EPS)**

		<b>For the year ended</b>	
		<b>March 31, 2025</b>	<b>March 31, 2024</b>
(i)	<b>Net Loss for Basic EPS</b>	(871.99)	(158.38)
	Add: Finance cost on OFCDs	542.67	95.30
	<b>Net Loss for Diluted EPS</b>	(329.32)	(63.08)
(ii)	Number of Equity Shares at the beginning of the year	44,09,99,946	2,44,99,997
	Add: Number of shares issued during the year	-	41,64,99,949
	Total number of Shares outstanding during the year	44,09,99,946	44,09,99,946
	<b>Weighted average number of equity shares outstanding during the year - basic</b>	44,09,99,946	43,07,58,194
	Add: Weighted average number of equity shares to be issued on conversion of OFCDs	37,56,55,577	5,75,33,177
	<b>Weighted average number of equity shares outstanding during the year - diluted</b>	81,66,55,523	48,82,91,371
	Earning per share - Basic (₹)	(1.98)	(0.37)
	Earning per share - Diluted (₹)	(1.98)	(0.37)
	Face value per share (₹)	10.00	10.00
Note: OFCDs are anti-dilutive in nature during the year ended March 31, 2024 and March 31, 2025			

**49 Leases - Company as lessor**
Operating lease

The lease rentals recognized as income in these statements as per the rentals stated in the respective agreements:

**Particulars**

		<b>For the year ended</b>	
		<b>March 31, 2025</b>	<b>March 31, 2024</b>
	Lease rentals recognized as income during the year		
	- Variable lease rentals	-	-
	- Others	15.29	11.15

These assets relate to building subleased on account of idle space utilisation by subleasing it to respective customers.

Undiscounted Lease Payments to be received after the reporting date is ₹ 108.91 Million.



**50 OTHER STATUTORY INFORMATION**

- (i) The Company does not have any transactions and balances with companies struck off.
- (ii) The Company does not have any Benami property, where any proceeding has been initiated or pending against the Group for holding any Benami property.
- (iii) The Company does not have any charges or satisfaction which is yet to be registered with ROC beyond the statutory period.
- (iv) The Company has not traded or invested in Crypto currency or Virtual Currency during the financial year.
- (v) The Company has advanced or loaned or invested funds to following entities, including foreign entities (Intermediaries) with the understanding that the Intermediary shall:
- (a) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company (ultimate beneficiaries) or
- (b) provide any guarantee, security or the like to or on behalf of the ultimate beneficiaries
- The details are as follows:

Name of the intermediary to which the funds are loaned or invested	Type	Date of transaction	Amount	Ultimate beneficiaries
PI Health Sciences Netherland B.V.	Loan	April 05, 2024	90.48	Archimica s.p.a and PI Health Sciences USA, LLC
	Loan	June 05, 2024	90.70	
	Loan	June 28, 2024	89.25	
	Loan	July 31, 2024	135.82	
	Loan	August 12, 2024	91.71	
	Loan	September 10, 2024	20.16	
	Loan	September 26, 2024	107.22	
	Loan	October 30, 2024	168.26	
	Conversion of loan into Equity	October 31, 2024	(2,620.23)	
		October 31, 2024	(452.37)	
	Loan	November 13, 2024	21.10	
	Investment	December 05, 2024	89.17	
	Investment	December 23, 2024	353.56	
	Investment	January 30, 2025	180.60	
	Investment	March 25, 2025	34.31	

Name of the ultimate beneficiary to which the funds are further loaned or invested by intermediary disclosed above	Type	Date of transaction	Amount
Archimica s.p.a	Investment	April 09, 2024	€ 10,00,000
	Investment	June 05, 2024	€ 10,00,000
	Investment	June 28, 2024	€ 10,00,000
	Investment	August 02, 2024	€ 15,00,000
	Investment	August 19, 2024	€ 10,00,000
	Investment	September 27, 2024	€ 11,50,000
	Investment	October 30, 2024	€ 18,00,000
	Conversion of loan into Equity	October 31, 2024	€ 1,64,15,000
	Investment	December 06, 2024	€ 10,00,000
	Investment	December 24, 2024	€ 32,50,000
	Investment	January 30, 2025	€ 10,00,000
	Investment	February 17, 2025	€ 10,00,000
PI Health Sciences USA, LLC	Loan repaid	April 05, 2024	\$ (50,000)
	Loan repaid	June 12, 2024	\$ (2,30,000)
	Loan	September 12, 2024	\$ 2,00,000
	Loan	September 12, 2024	\$ 2,00,000
	Loan	October 28, 2024	\$ 35,000
	Loan	November 14, 2024	\$ 2,50,000
	Conversion of loan into Equity	November 30, 2024	\$ (26,23,015)
	Investment	December 31, 2024	\$ 5,50,000
	Loan repaid	February 11, 2025	\$ (2,50,000)
	Investment	February 05, 2025	\$ 2,50,000
	Investment	February 28, 2025	\$ 1,00,000
	Investment	March 19, 2025	\$ 40,000
	Investment	March 26, 2025	\$ 1,00,000



**PI HEALTH SCIENCES LIMITED**
**Notes to the Standalone Financial Statements for the year ended March 31, 2025**
**(All amounts in ₹ million, unless otherwise stated)**
**For the year ending March 31, 2024**

Name of the intermediary to which the funds are loaned or invested	Type	Date of transaction	Amount	Ultimate beneficiaries
PI Health Sciences Netherland B.V.	Investment	April 21, 2023	2,063.53	Archimica s.p.a and PI Health Sciences USA, LLC
	Loan	April 21, 2023	1,175.39	
	Loan	May 18, 2023	134.38	
	Loan	May 31, 2023	413.69	
	Loan	October 18, 2023	61.64	
	Loan	February 26, 2024	129.92	
	Loan	March 05, 2024	179.99	
	Loan	March 26, 2024	90.00	

Name of the ultimate beneficiary to which the funds are further loaned or invested by intermediary disclosed above	Type	Date of transaction	Amount
Archimica s.p.a	Investment	April 26, 2023	€ 3,42,00,000
	Loan	May 10, 2023	€ 10,00,000
	Loan	June 05, 2023	€ 10,00,000
	Loan	October 11, 2023	€ 4,40,000
	Loan	October 11, 2023	€ 3,75,000
	Loan	October 19, 2023	€ 7,00,000
	Loan	February 06, 2024	€ 14,50,000
	Loan	March 05, 2024	€ 20,00,000
	Loan	March 26, 2024	€ 10,00,000
PI Health Sciences USA, LLC	Investment	April 26, 2023	\$ 15,00,000
	Loan	June 02, 2023	\$ 35,00,000
	Loan	June 02, 2023	\$ 10,000
	Loan	August 23, 2023	\$ 4,00,000
	Loan repaid	October 10, 2023	\$ (4,00,000)
	Loan repaid	March 21, 2024	\$ (8,41,985)

- (vi) The Company has received fund from following entity (Funding Party) with the understanding (whether recorded in writing or otherwise) that the (a) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the funding party (ultimate beneficiaries) or (b) provide any guarantee, security or the like on behalf of the ultimate beneficiaries

The details are as follows: for the year March 31, 2025

Name of the funding party	Type	Date of transaction	Amount	Intermediate beneficiaries
PI Industries Limited	OFCDs	July 23, 2024	250.00	PI Health Sciences Netherland B.V.
	OFCDs	July 24, 2024	500.00	
	OFCDs	July 25, 2024	250.00	
	OFCDs	November 11, 2024	1,000.00	

**For the period ending March 31, 2024**

Name of the funding party	Type	Date of transaction	Amount	Intermediate beneficiaries
PI Industries Limited	Equity	April 10, 2023	4,165.00	PI Health Sciences Netherland B.V.
	Loan	May 31, 2023	2,986.00	

- (vii) The Company has no such transaction which is not recorded in the books of accounts that has been surrendered or disclosed as income during the year in the tax assessments under the Income Tax Act, 1961 (such as, search or survey or any other relevant provisions of the Income Tax Act, 1961).
- (viii) The Company has complied with the number of layers prescribed under clause (87) of section 2 of the Companies Act, 2013 read with the Companies (Restriction on number of Layers) Rules, 2017.
- (ix) The Company is maintaining its books of account in electronic mode and these books of account are accessible in India at all times and the back-up of books of account has been kept in servers physically located in India on a daily basis from the applicability date of the Companies (Accounts) Rules,
- (x) The Company has used accounting software for maintaining its books of account which has a feature of recording audit trail (edit log) facility and that has operated throughout the year for all relevant transactions recorded in the software, except that (a) the audit log at the application level, will not get generated in case of modification, if any performed by the users with certain specific privileged access; and (b) the audit trail feature at database level contains only the modified values to record any direct changes at the database level. During the course of performing our procedures, in respect of the audit trail feature enabled, we did not notice any instance of the audit trail feature being tampered with.



**PI HEALTH SCIENCES LIMITED**

**Notes to the Standalone Financial Statements for the year ended March 31, 2025**

**(All amounts in ₹ million, unless otherwise stated)**

**51 EVENTS OCCURRING AFTER THE BALANCE SHEET DATE**

No adjusting or significant non-adjusting events have occurred between the reporting date and date of authorization of these financial statements.

**As per our report of even date**

**For S S Kothari Mehta & Co LLP**  
**Chartered Accountants**  
Firm Reg. No. 000756/N/20500441

**AMIT GOEL**  
Partner  
Membership Number: 500607

Place: New Delhi  
Date: May 12, 2025



**For and on behalf of the Board of Directors**  
**PI Health Sciences Limited**

**Arunabha Raychaudhuri**  
Director  
DIN: 10685547

**Rajnish Sarna**  
Director  
DIN: 06429469

**Ankit Nayyar**  
Chief Financial Officer

Place: Mumbai  
Date: May 12, 2025

**Ruchi Jayesh Sheth**  
Company Secretary



## **Independent Auditors' Report**

**To the Members of  
PI Health Sciences Limited**

### **Report on the Audit of Consolidated Financial Statements**

#### **Opinion**

We have audited the accompanying consolidated financial statements of **PI Health Sciences Limited** (hereinafter referred to as the "Company" or "Holding Company") and its subsidiaries including step down subsidiaries (Holding Company and its subsidiaries/step down subsidiaries together referred to as "the Group"), which comprise the consolidated balance sheet as at March 31, 2025, and the consolidated statement of profit and loss (including other comprehensive income), consolidated statement of changes in equity and consolidated statement of cash flows for the year then ended, and notes to the consolidated financial statements, including a summary of the material accounting policies and other explanatory information (hereinafter referred to as "the consolidated financial statements").

In our opinion and to the best of our information and according to the explanations given to us and based on the consideration of reports of the other auditors on separate financial statements/ other financial information of the subsidiaries including step down subsidiaries, referred to in the other matters section below, the aforesaid consolidated financial statements give the information required by the Companies Act, 2013 (the "Act") in the manner so required and give a true and fair view in conformity with Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Act read with the Companies (Indian Accounting Standards) Rules, 2015, as amended and other accounting principles generally accepted in India, of the consolidated state of affairs of the Group, as at March 31, 2025, its consolidated loss including other comprehensive income, consolidated changes in equity and its consolidated cash flows for the year ended on that date.

#### **Basis for Opinion**

We conducted our audit of the consolidated financial statements in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Act. Our responsibilities under those SAs are further described in the Auditor's Responsibilities for the Audit of the consolidated financial statements section of our report. We are independent of the Group in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India (ICAI) together with the independence requirements that are relevant to our audit of the consolidated financial statements under the provisions of the Act and the Rules made thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and Code of Ethics. We believe that the audit evidence we have obtained, and the audit evidence obtained by the other auditors in terms of their reports referred to in 'Other Matters' paragraph below is sufficient and appropriate to provide a basis for our audit opinion on the consolidated financial statements.



### **Information other than the Consolidated Financial Statements and Auditors' Report thereon**

The Holding Company's Board of Directors is responsible for the other information. The other information comprises the information included in the Director's report but does not include the consolidated financial statements and our auditor's report thereon. Our opinion on the consolidated financial statements does not cover the other information and we do not express any form of assurance conclusions thereon.

In connection with our audit of the consolidated financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the consolidated financial statements, or our knowledge obtained in the audit or otherwise appears to be materially misstated. If, based on the work we have performed and based on the audit reports of other auditors, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

### **Management's Responsibility for the Consolidated Financial Statements**

The Holding Company's Board of Directors is responsible for the matters stated in section 134(5) of the Act with respect to preparation of these consolidated financial statements that give a true and fair view of the consolidated financial position, consolidated financial performance, consolidated total comprehensive income, consolidated changes in equity and consolidated cash flows of the Group in accordance with the Ind AS and other accounting principles generally accepted in India, including the Indian Accounting Standards (Ind AS) specified under section 133 of the Act read with the Companies (Indian Accounting Standards) Rules, 2015, as amended. The respective Board of Directors of the companies included in the Group are responsible for maintenance of the adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Group and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the consolidated financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error which have been used for the purpose of preparation of the consolidated financial statements by the Directors of the Holding Company, as aforesaid.

In preparing the consolidated financial statements, the respective Board of Directors of the companies included in the Group are responsible for assessing the ability of Group to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the Companies included in the Group are responsible for overseeing the financial reporting process of the Group.

### **Auditor's Responsibilities for the Audit of the Consolidated Financial Statements**

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial statements.



As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the Holding Company has adequate internal financial controls system in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures in the consolidated financial statements made by the Management.
- Conclude on the appropriateness of the Management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the consolidated financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the consolidated financial statements, including the disclosures, and whether the consolidated financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial statements of the entities or business activities within the Group, to express an opinion on the consolidated financial statements. We are responsible for the direction, supervision and performance of the audit of financial statements of such entities included in the financial statements, of which we are the independent auditors. For the other entities included in the financial statements, which have been audited by the other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion.

We communicate with those charged with governance of the Company and such other entity included in the consolidated financial statements of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.



We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

**Other Matters**

- i. We did not audit the financial statements of one step-down subsidiary, whose Financial Statements reflect total assets of Rs.4,487.29 Million as at March 31, 2025, total revenue of Rs. 1,769.62 Million and total net loss after tax of Rs.1,197.37 Million, total comprehensive loss of Rs.1,208.78 Million for the year ended March 31, 2025, and net cash outflow of Rs.138.88 Million for the year ended March 31, 2025 as considered in the consolidated financial statements. These financial statements/financial information have been audited by other auditor whose report has been furnished to us by the Management, and our opinion on the consolidated financial statements in so far as it relates to the amounts and disclosures included in respect of this Step down subsidiary and our report in terms of sub-section (3) of Section 143 of the Act, in so far as it relates to the aforesaid step down subsidiary, is based solely on the report of the other auditor.
- ii. Above step-down subsidiary is located outside India whose financial statements and other financial information have been prepared in accordance with accounting principles generally accepted in their respective country and which have been audited by other auditors under generally accepted auditing standards applicable in their respective country. The Group's management has converted the financial statements/financial information of such step down subsidiary, located outside India from accounting principles generally accepted in their respective country to accounting principles generally accepted in India. We have audited these conversion adjustments made by the Group's management. Our opinion in so far as it relates to the balances and affairs of such step down subsidiary, located outside India is based on the reports of other auditor and the conversion adjustments prepared by the management of the Group and audited by us. Our opinion on the consolidated financial statements, and our report on Other Legal and Regulatory Requirements below, is not modified in respect of the above matters with respect to our reliance on the work done and the reports of the other auditor.
- iii. The Consolidated Financial Statement include the unaudited Financial statement of 2 step-down subsidiaries whose financial information reflect total assets of Rs. 7,396.48 Million as at March 31, 2025, total revenue of Rs. 25.74 Million and total net loss after tax of Rs. 360.95 Million, total comprehensive loss of Rs. 329.88 Million for the year ended March 31, 2025, and net cash inflow of Rs. 9.07 Million for the year ended March 31, 2025 as considered in consolidated financial statements have not been audited either by us or by other auditors. These unaudited financial statements/ financial information have been furnished to us by the Management and our opinion on the consolidated financial statements, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries (including step-down subsidiaries) and our report in terms of sub-section (3) of Section 143 of the Act in so far as it relates to the aforesaid subsidiaries (including step-down subsidiaries), is based solely on such unaudited financial statements / financial information certified by the management. In our opinion and according to the information and explanations given to us by the Management, these financial statements / financial information are not material to the Group. Our opinion on the consolidated financial statements, and our report on Other Legal and Regulatory Requirements below, is not modified in respect of this matter with respect to the financial statements/financial information certified by the Management.





**Report on Other Legal and Regulatory Requirements**

1. With respect to the matters specified in paragraphs 3(xxi) and 4 of the Companies (Auditor's Report) Order, 2020 (the "Order"/ "CARO") issued by the Central Government in terms of Section 143(11) of the Act, to be included in the Auditor's report, according to the information and explanations given to us, and based on the CARO reports issued by us for the Holding Company included in the consolidated financial statements of the Group, to which reporting under CARO is applicable, we report that there are no qualifications or adverse remarks in these CARO reports.
2. As required by Section 143(3) of the Act, based on our audit we report, to the extent applicable, that:
  - a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit of the aforesaid consolidated financial statements.
  - b) In our opinion, proper books of account as required by law have been kept by the Group so far as it appears from our examination of those books except for certain matters in respect of audit trail as stated in the paragraph 2(i)(vi) below on reporting under Rule 11(g) of the Companies (Audit and Auditors) Rules 2014 (as amended);
  - c) The consolidated balance sheet, the consolidated statement of profit and loss (including other comprehensive income), the consolidated statement of changes in equity and the consolidated statement of cash flows dealt with by this Report are in agreement with the books of account and records maintained for the purpose of preparation of the consolidated financial statements.
  - d) In our opinion, the aforesaid consolidated financial statements comply with the Ind AS specified under section 133 of the Act, read with relevant rules, as amended.
  - e) On the basis of the written representations received from the directors of the Holding Company and taken on record by the Board of Directors of the Holding Company, none of the directors of the Holding Company, incorporated in India, is disqualified as on March 31, 2025 from being appointed as a director in terms of Section 164 (2) of the Act;
  - f) With respect to the adequacy of the internal financial controls with reference to consolidated financial statements of the Group and the operating effectiveness of such controls, refer to our separate Report in "Annexure A" which is based on the auditor's report of the Holding Company incorporated in India. Our report expresses an unmodified opinion on the adequacy and operating effectiveness of internal financial controls with reference to Consolidated Financial Statements of those companies.
  - g) In our opinion the managerial remuneration for the year ended March 31, 2025, has been paid/provided by the Holding Company, to their directors in accordance with the provision of section 197 read with Schedule V to the Act;
  - h) The modifications relating to the maintenance of accounts and other matters connected therewith in respect of audit trail are as stated in the paragraph 2(b) above on reporting under Section 143(3)(b) of the Act and paragraph 2(i)(vi) below on reporting under Rule 11(g) of the Companies (Audit and Auditors) Rules, 2014 (as amended); and



- i) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, as amended in our opinion and to the best of our information and according to the explanations given to us and based on the considerations of the reports of the other auditors on separate financial statements;
- i. The Group does not have any pending litigation as at March 31, 2025 which would impact its financial position.
- ii. The Group, did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses;
- iii. There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Group.
- iv. a) The management of Holding Company has represented that, to the best of its knowledge and belief, except as disclosed in the note 48 to the consolidated financial statements, no funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the Group incorporated in India to or in any other person(s) or entity(ies), including foreign entities ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall, whether, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Group ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries;
- b) The management of the Holding Company has represented that, to the best of its knowledge and belief, except as disclosed in the note 48 to the consolidated financial statements, no funds have been received by the Group incorporated in India from any person(s) or entity(ies), including foreign entities ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the group shall, whether, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries; and
- c) Based on such audit procedures that were considered reasonable and appropriate in the circumstances, nothing has come to our notice that has caused us to believe that the representations under sub-clause (a) and (b) contain any material misstatement.
- v. No dividend has been declared or paid during the year by the Group.
- vi. Based on our examination, which included test checks, the Holding Company has used accounting software for maintaining its books of account which have a feature of recording audit trail (edit log) facility and that has operated throughout the year for all relevant transactions recorded in the software, except that the audit log is not maintained in case of modification, if any, by users with specific access rights; and was not enabled to capture any direct changes at the database level.





Further, during the course of our audit, we did not notice any instance of audit trail feature being tampered with.

Additionally, the audit trail has been preserved by the company as per the statutory requirements for record retention.

In case of the financial statements of one subsidiary and two step-down subsidiaries incorporated outside India, the reporting requirement under Rule 11 (g) of the Companies (Audit and Auditors) Rules, 2014 is not applicable. Hence, we have not commented on the same.

For **S.S. KOTHARI MEHTA & CO. LLP**  
Chartered Accountants  
Firm registration number: 000756N/N500441



**AMIT GOEL**  
Partner  
M.No: 500607

Place: New Delhi  
Dated: May 12, 2025  
UDIN : 25500607BMLATM6104

**Annexure A to the Independent Auditor's Report to the members of PI Health Sciences Limited dated May 12, 2025 on its consolidated financial statements.**

**Report on the internal financial controls with reference to the consolidated financial statements under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013.**

**Our reporting on the internal financial control with reference to consolidated financial statement is not applicable in respect of one subsidiary/two step down subsidiaries incorporated outside India.**

(Referred to in paragraph 2(A)(f) under 'Report on Other Legal and Regulatory Requirements' section of our report of even date)

In conjunction with our audit of the consolidated financial statements of the Company as of and for the year ended March 31, 2025, we have audited the internal financial controls with reference to financial statements of **PI Health Sciences Limited** (hereinafter referred to as "the Holding Company") as of that date.

#### **Management's Responsibility for Internal Financial Controls**

The Board of Directors of the Holding Company are responsible for establishing and maintaining internal financial controls based on internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting ("the Guidance Note") issued by the Institute of Chartered Accountants of India ("ICAI"). These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to the respective company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Act.

#### **Auditors' Responsibility**

Our responsibility is to express an opinion on the Company's internal financial controls with reference to financial statements based on our audit. We conducted our audit in accordance with the Guidance Note issued by the ICAI and the Standards on Auditing deemed to be prescribed under Section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls, both applicable to an audit of internal financial controls and both issued by the ICAI. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls with reference to financial statements was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system with reference to financial statements and their operating effectiveness. Our audit of internal financial controls with reference to financial statements included obtaining an understanding of internal financial controls with reference to financial statements, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error



We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Holding Company's internal financial controls system with reference to consolidated financial statements.

#### **Meaning of Internal Financial Controls over Financial Reporting**

A company's internal financial control with reference to financial statements is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control with reference to financial statements includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorisations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorised acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

#### **Inherent Limitations of Internal Financial Controls over Financial Reporting**

Because of the inherent limitations of internal financial controls with reference to financial statements, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls with reference to financial statements to future periods are subject to the risk that the internal financial control with reference to financial statements may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

#### **Opinion**

In our opinion, the Holding Company has, in all material respects, an adequate internal financial controls system with reference to financial statements and such internal financial controls with reference to financial statements were operating effectively as at March 31, 2025, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note..

For **S.S. KOTHARI MEHTA & CO. LLP**  
Chartered Accountants  
Firm registration number: 000756N/N500441



**AMIT GOEL**  
Partner  
M.No: 500607

Place: New Delhi  
Dated: May 12, 2025  
UDIN : 25500607BMLATM6104

**PI HEALTH SCIENCES LIMITED**  
**Consolidated Balance Sheet as at March 31, 2025**  
(All amounts in ₹ million, unless otherwise stated)

Particulars	Notes	As at March 31, 2025	As at March 31, 2024
<b>ASSETS</b>			
<b>Non-current assets</b>			
Property, plant and equipment	4	3,861.87	3,488.98
Right of use assets	5	527.44	546.76
Capital work-in-progress	6	1,018.93	561.13
Goodwill	7	2,830.53	2,783.17
Other Intangible assets	7	1,766.16	1,840.05
Financial assets			
(i) Investments	8	5.66	5.52
(ii) Other financial assets	9	21.70	31.18
Deferred tax assets (net)	23	143.14	-
Other non-current assets	10	6.86	19.78
<b>Total non-current assets</b>		<b>10,182.28</b>	<b>9,276.57</b>
<b>Current assets</b>			
Inventories	11	762.32	862.20
Financial assets			
(i) Trade receivables	12	933.22	1,285.39
(ii) Cash and cash equivalents	13	546.70	475.31
(iii) Bank balances other than (ii) above	14	11.48	11.56
(iv) Other financial assets	15	3.84	15.07
Contract assets	16	225.59	723.26
Current tax assets	17	26.69	137.85
Other current assets	10	646.17	500.07
<b>Total current assets</b>		<b>3,156.01</b>	<b>4,010.71</b>
<b>Total assets</b>		<b>13,338.30</b>	<b>13,287.28</b>
<b>EQUITY &amp; LIABILITIES</b>			
<b>Equity</b>			
Equity share capital	18	4,410.00	4,410.00
Other equity	19	(2,718.92)	(538.54)
<b>Total equity</b>		<b>1,691.08</b>	<b>3,871.46</b>
<b>Liabilities</b>			
<b>Non current liabilities</b>			
Financial liabilities			
(i) Borrowings	20	7,988.19	5,554.25
(ii) Lease liabilities	21	63.88	71.45
(iii) Other financial liabilities	22	1,501.49	1,347.85
Deferred tax liabilities (net)	23	4.07	365.12
Provisions	25	199.56	180.38
<b>Total non current liabilities</b>		<b>9,757.19</b>	<b>7,519.06</b>
<b>Current Liabilities</b>			
Financial liabilities			
(i) Borrowings	20	329.20	662.39
(ii) Lease liabilities	21	12.59	12.44
(iii) Trade payables			
a) total outstanding dues of micro enterprises and small enterprises	24	7.26	7.62
b) total outstanding dues of creditors other than micro enterprises and small enterprises	24	871.05	612.58
(iv) Other financial liabilities	22	592.94	551.96
Other current liabilities	26	58.94	38.64
Provisions	25	18.05	11.14
<b>Total current liabilities</b>		<b>1,890.03</b>	<b>1,896.77</b>
<b>Total liabilities</b>		<b>11,647.22</b>	<b>9,415.83</b>
<b>Total equity and liabilities</b>		<b>13,338.30</b>	<b>13,287.28</b>

**Notes to accounts**

1 to 49


The accompanying notes referred to above formed the integral part of these consolidated financial statement

As per our report of even date

For S S Kothari Mehta & Co. LLP


Chartered Accountants

Firm Reg. No. 000756N/N500441

  
**AMIT GOEL**  
Partner  
Membership Number: 500607



For and on behalf of the Board of Directors  
PI Health Sciences Limited

  
**Arunabha Raychaudhari**  
Director  
DIN: 10685547

  
**Rajnish Sarna**  
Director  
DIN: 06429468

  
**Ankit Nayyar**  
Chief Financial Officer

  
**Ruchi Jayesh Sheth**  
Company Secretary

Place: New Delhi  
Date: May 12, 2025

Place: Mumbai  
Date: May 12, 2025

**PI HEALTH SCIENCES LIMITED**
**Consolidated Statement of Profit & Loss for the year ended March 31, 2025**
**(All amounts in ₹ million, unless otherwise stated)**

Particulars	Notes	For the year ended March 31, 2025	For the year ended March 31, 2024
Revenue from operations	27	2,150.96	3,148.63
Other income	28	316.01	75.97
<b>Total income</b>		<b>2,466.97</b>	<b>3,224.60</b>
<b>Expenses:</b>			
Cost of materials consumed	29	908.25	1,069.48
Changes in inventories of finished goods, work in progress and stock in trade	30	124.09	218.51
Employee benefit expense	31	1,298.59	952.90
Finance cost	32	802.66	571.58
Depreciation and amortisation expense	33	609.48	578.41
Other expense	34	1,768.76	1,314.58
<b>Total expenses</b>		<b>5,511.83</b>	<b>4,705.46</b>
<b>Loss before tax for the year</b>		<b>(3,044.86)</b>	<b>(1,480.86)</b>
<b>Income tax expense</b>	35		
Current tax		-	-
Deferred tax		(564.13)	(588.91)
Income tax of earlier years		(25.61)	-
<b>Total tax expense</b>		<b>(589.74)</b>	<b>(588.91)</b>
<b>Loss after tax for the year</b>		<b>(2,455.12)</b>	<b>(891.95)</b>
<b>Other comprehensive income / (expense)</b>			
(i) Items that will not be reclassified to profit or loss			
Remeasurements gains/(losses) on defined benefit plans		5.62	(0.60)
Income tax relating to the above item		(1.41)	0.15
(ii) Items that will be reclassified to profit or loss			
Exchange difference on translation of foreign operations		104.57	(13.45)
Net gain on cash flow hedges		(14.96)	(21.68)
Income tax relating to the above item		3.55	4.40
<b>Total comprehensive expense for the year</b>		<b>(2,357.75)</b>	<b>(923.13)</b>
<b>Earnings per equity share</b>	37		
1) Basic (in ₹)		(5.57)	(2.07)
2) Diluted (in ₹)		(5.57)	(2.07)
<b>Face value per share (in ₹)</b>		<b>10.00</b>	<b>10.00</b>

**Notes to accounts**

1 to 49

The accompanying notes referred to above formed the integral part of these consolidated financial statement

**As per our report of even date**
**For S S Kothari Mehta & Co. LLP**
**Chartered Accountants**

Firm Reg. No. 000756/N/N500441



**AMIT GOEL**
**Partner**

Membership Number: 500607


**For and on behalf of the Board of Directors**
**PI Health Sciences Limited**

**Arunabha Raychaudhari**
**Director**

DIN: 10685547


**Rajnish Sarna**
**Director**

DIN: 06429468


**Ankit Nayyar**
**Chief Financial Officer**

**Ruchi Jayesh Sheth**
**Company Secretary**

Place: New Delhi

Date: May 12, 2025

Place: Mumbai

Date: May 12, 2025



**PI HEALTH SCIENCES LIMITED**
**Consolidated Statement of Cash Flows for the year ended March 31, 2025**
**(All amounts in ₹ million, unless otherwise stated)**

Particulars	For the year ended March 31, 2025	For the year ended March 31, 2024
<b>A Cash flows from operating activities</b>		
Loss before tax for the year	(3,044.86)	(1,480.86)
<b>Adjustments for :-</b>		
Depreciation and amortisation expense	609.48	578.41
Interest income on loan and bank deposits	(4.93)	(25.41)
Interest income on unwinding of security deposits	(0.04)	(0.14)
Liabilities written back	(264.09)	-
Loss on sale of property, plant and equipment	0.18	2.57
Provision for bad and doubtful debt	215.03	1.61
Finance cost	788.88	571.58
Unrealised exchange loss on foreign currency transactions (net)	2.72	38.41
Change in foreign currency translation reserve	(43.53)	(31.18)
Lease income	(15.29)	-
<b>Operating loss before working capital changes</b>	<b>(1,756.45)</b>	<b>(345.01)</b>
(Increase)/decrease in inventories	99.88	218.91
(Increase)/decrease in other assets	(129.56)	(58.97)
(Increase)/decrease in other financial assets	10.17	(40.18)
(Increase)/decrease in trade receivables and contract assets	634.80	51.76
Increase/(decrease) in provisions	43.82	(6.86)
Increase/(decrease) in other financial liabilities	284.57	283.19
Increase/(decrease) in trade payables	255.40	(255.89)
Increase/(decrease) in other liabilities	6.91	(453.26)
<b>Cash used in operations before tax</b>	<b>(550.46)</b>	<b>(606.31)</b>
Taxes (paid) / refund	136.77	(76.55)
<b>Net cash used in operating activities</b>	<b>(413.69)</b>	<b>(682.86)</b>
<b>B Cash flows from investing activities</b>		
Payments for purchase of property, plant & equipment including capital work in progress, intangible assets, capital advances and creditors	(1,286.59)	(1,408.25)
Acquisition of businesses net of cash and bank balances	-	(6,336.93)
Investment in bank deposits	0.08	(11.56)
Rent received	25.74	-
Interest received	1.77	21.90
<b>Net cash used in investing activities</b>	<b>(1,259.00)</b>	<b>(7,734.84)</b>
<b>C Cash flows from financing activities</b>		
Proceeds from issue of equity share capital	-	4,165.00
Issue of optionally fully convertible debentures	2,000.00	-
Proceeds from long term borrowings	-	9,410.00
Loan issued / (repayment) (net)	(187.26)	247.63
Loan repayment to parent company	-	(4,600.00)
Payment of lease liabilities	(18.26)	(14.81)
Finance cost paid	(50.40)	(348.96)
<b>Net cash inflow from financing activities</b>	<b>1,744.08</b>	<b>8,858.86</b>
<b>D Net cash inflow from operating, investing &amp; financing activities (A+B+C)</b>	<b>71.39</b>	<b>441.16</b>
<b>Cash &amp; cash equivalents as on April 01, 2024</b>	<b>475.31</b>	<b>34.15</b>
<b>Closing balance of cash &amp; cash equivalents</b>	<b>546.70</b>	<b>475.31</b>





**Consolidated Statement of Cash Flows for the year ended March 31, 2025**  
(All amounts in ₹ million, unless otherwise stated)

Note: Cash and cash equivalents included in the cash flow statement comprise of the following :-

- i) **Cash on hand**  
ii) **Balance with banks :**  
-In current accounts  
-In fixed deposits with original maturity less than 3 months  
**Total**

As at Mar 31,2025	As at Mar 31, 2024
0.08	0.08
514.56	240.23
32.06	235.00
<b>546.70</b>	<b>475.31</b>

The above cash flow statement has been prepared under the Indirect method as set out in IND AS - 7 "Statement of Cash Flows".  
Figures in brackets indicate cash outflows.

The accompanying notes referred to above formed the integral part of these consolidated financial statement

**As per our report of even date**  
**For S S Kothari Mehta & Co. LLP**  
Chartered Accountants  
Firm Reg. No. 000756N/N500441

**For and on behalf of the Board of Directors**  
**PI Health Sciences Limited**




**AMIT GOEL**  
Partner  
Membership Number: 500607



Place: New Delhi  
Date: May 12, 2025



**Arunabha Raychaudhari**  
Director  
DIN: 10685547



**Rajnish Sarna**  
Director  
DIN: 06429468



**Ankit Nayyar**  
Chief Financial Officer



**Ruchi Jayesh Sheth**  
Company Secretary

Place: Mumbai  
Date: May 12, 2025

**PI HEALTH SCIENCES LIMITED**
**Consolidated Statement of Changes in Equity for the year ended March 31, 2025**

(All amounts in ₹ million, unless otherwise stated)

**a. Equity share capital**


Particulars	Note No.	As at March 31, 2025		As at March 31, 2024	
		No. of Shares	Amount	No. of Shares	Amount
Balance at the beginning of the year	18	44,09,99,946	4,410.00	2,44,99,997	245.00
Changes in equity share capital during the year		-	-	41,64,99,949	4,165.00
<b>Balance at the end of the year</b>		<b>44,09,99,946</b>	<b>4,410.00</b>	<b>44,09,99,946</b>	<b>4,410.00</b>

**b. Other equity**

Particulars	Reserves & Surplus		Other Reserves		Equity component of compound financial instruments	Total other equity
	Statement of profit and loss	Foreign Currency Translation Reserve	Cash Flow Hedge Reserve			
<b>Opening balance as on April 1, 2023</b>	<b>(102.80)</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>(102.80)</b>
Loss for the year	(891.95)	-	-	-	-	(891.95)
Other comprehensive expense	(0.45)	(13.45)	(17.28)	-	-	(31.18)
<b>Total comprehensive loss for the year</b>	<b>(892.40)</b>	<b>(13.45)</b>	<b>(17.28)</b>	<b>-</b>	<b>-</b>	<b>(923.13)</b>
<b>Transaction with owners in their capacity as owners:</b>						
Issue of optionally fully convertible debentures (OFCD)	-	-	-	651.50	651.50	651.50
Deferred tax created	-	-	-	(163.97)	(163.97)	(163.97)
Transaction cost	-	-	-	(0.14)	(0.14)	(0.14)
	-	-	-	487.39	487.39	487.39
<b>Balance at March 31, 2024</b>	<b>(995.20)</b>	<b>(13.45)</b>	<b>(17.28)</b>	<b>487.39</b>	<b>(538.54)</b>	<b>(538.54)</b>
Loss for the year	(2,455.12)	-	-	-	-	(2,455.12)
Other comprehensive expense	4.21	104.57	(11.41)	-	-	97.37
<b>Total comprehensive loss for the year</b>	<b>(2,450.91)</b>	<b>104.57</b>	<b>(11.41)</b>	<b>-</b>	<b>(2,357.75)</b>	<b>(2,357.75)</b>
<b>Transaction with owners in their capacity as owners:</b>						
Issue of optionally fully convertible debentures (OFCD)	-	-	-	237.02	237.02	237.02
Deferred tax created	-	-	-	(59.65)	(59.65)	(59.65)
Transaction cost	-	-	-	-	-	-
	-	-	-	177.37	177.37	177.37
<b>Balance at March 31, 2025</b>	<b>(3,446.11)</b>	<b>91.12</b>	<b>(28.69)</b>	<b>664.76</b>	<b>(2,718.92)</b>	<b>(2,718.92)</b>

**As per our report of even date**

For S S Kothari Mehta & Co. LLP  
Chartered Accountants  
Firm Reg. No. 000756NAN500441



**AMIT GOEL**  
Partner  
Membership Number: 500607



Place: New Delhi  
Date: May 12, 2025

For and on behalf of the Board of Directors  
PI Health Sciences Limited



**Arunabha Raychaudhari**  
Director  
DIN: 10685547



**Rajnish Sarma**  
Director  
DIN: 06429468



**Ankit Nayyar**  
Chief Financial Officer



**Ruchi Jayesh Sheth**  
Company Secretary

Place: Mumbai  
Date: May 12, 2025

## PI Health Sciences Limited

### Notes to Consolidated Financial Statements for the year ended March 31, 2025

#### 1. Corporate Information

The consolidated financial statements comprise financial statements of PI Health Sciences Limited ('the Company') and its subsidiaries (collectively, 'the Group') for the year ended 31 March, 2025. The company is a public limited company having corporate identification number: U24290RJ2021PLC076803 and has its registered office situated at Udaisagar Road, Udaipur, Rajasthan -313001. The principal activities of the Group are research, preparation, manufacture, distribution and sale of active pharmaceutical ingredients ("APIs") and intermediates.

#### 2. Basis of preparation

The Group has consistently applied the following accounting policies to all periods presented in the financial statements unless otherwise stated.

##### a. Statement of compliance

These financial statements have been prepared in all material aspects, in accordance with the recognition and measurement principles laid down in Indian Accounting Standard ('Ind AS') as per the Companies (Indian Accounting Standards) Rules, 2015 notified under Section 133 of the Companies Act, 2013 ('the Act') and other relevant provisions of the Act to the extent applicable. These financial statements were approved and adopted by the board of directors in their meeting dated May 12, 2025, and are subject to shareholder approval at the forthcoming Annual General Meeting of shareholders.

##### b. Basis of measurement

The financial statements have been prepared on an accrual basis and under the historical cost convention, except for the following:

- Certain financial assets and liabilities (including OFCD's and derivate instruments) and contingent considerations are measured at fair value;
- Net defined benefit plan assets/ (liability) are measured at fair value of plan assets less the present value of defined benefit obligations;
- Share-based payments measured at fair value

##### c. Functional and presentation currency

The financial statements of the Company are prepared in Indian National Rupee ('₹'), which is both the functional and presentation currency of the Company. In respect of foreign subsidiaries, the functional currency is the currency of the primary economic environment in which the respective subsidiary operates. Accordingly, the financial statements of foreign subsidiaries are prepared in their respective functional currencies.



## PI Health Sciences Limited

### Notes to Consolidated Financial Statements for the year ended March 31, 2025

3. For the purpose of consolidation, the assets and liabilities of foreign subsidiaries are translated into Indian Rupees at the exchange rate prevailing at the reporting date. Income and expenses are translated at average exchange rates for the year, unless exchange rates fluctuate significantly during the period, in which case the exchange rates at the date of the transactions are used. The resulting exchange differences arising on translation of the financial statements of foreign subsidiaries are recognised in Other Comprehensive Income and accumulated in the Foreign Currency Translation Reserve (FCTR) under equity.

#### Use of judgements and estimates

In preparing these financial statements, management has made judgements, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, the disclosures of contingent liabilities and contingent assets at the date of financial statements, income and expenses during the period. Actual results may differ from these estimates. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to estimates are recognized prospectively.

Application of accounting policies that require critical accounting estimates and assumption judgements having the most significant effect on the amounts recognized in the financial statements are:

(i) **Provision for expected credit losses (ECL) on trade receivables**

The Group uses a provision matrix to calculate ECL for trade receivables. The ECL provision matrix is based on the Group's historical observed default rates. The Group adjust the historical credit loss experience with forward-looking information. At every reporting date, the historical observed default rates are updated and changes in the forward-looking estimates are analysed. The amount of ECL is sensitive to changes in circumstances and accordingly Group's actual default in the future may be different.

(ii) **Recognition of deferred tax**

Deferred tax is recorded on temporary differences between the tax bases of assets and liabilities and their carrying amounts, at the rates that have been enacted or substantively enacted at the reporting date. The ultimate realisation of deferred tax assets is dependent upon the generation of future taxable profits during the periods in which those temporary differences and tax loss carry-forwards become deductible. The Group considers expected reversal of deferred tax liabilities and projected future taxable income in making this assessment. The amount of deferred tax assets considered realisable, however, could reduce in the near term if estimates of future taxable income during the carry-forward period are reduced.



## PI Health Sciences Limited

### Notes to Consolidated Financial Statements for the year ended March 31, 2025

(iii) **Impairment test of non-financial assets (goodwill and intangible assets)**

The Group assesses at each reporting date whether there is an indication that goodwill and intangible assets recognized on business combination may be impaired. If any indication exists, or when annual impairment testing for an asset is required, the Group estimates the asset's recoverable amount. An asset's recoverable amount is the higher of an asset's CGU'S fair value less cost of disposal and its value in use. Where the carrying amount of an asset or CGU exceeds its recoverable amount, the asset is considered impaired and is written down to its recoverable amount.

In assessing value in use, the estimated future cash flows are estimated based on past trend and discounted to their present value using a post-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset. In determining fair value less costs of disposal, recent market transactions are taken into account. If no such transactions can be identified, an appropriate valuation model is used. These calculations are corroborated by valuation multiples, or other fair value indicators.

#### 4. **Material Accounting Policies**

a. **Current versus non-current classification**

The Company presents assets and liabilities in the balance sheet based on current/non-current classification considering an operating cycle of 12 months being time elapsed between deployment of resources and the realization/ settlement in cash and cash equivalents thereagainst.

a. **Property, plant and equipment**

i) **Recognition and measurement**

Freehold land is carried at historical cost. All other items of property, plant and equipment are measured at cost, less accumulated depreciation and accumulated impairment losses, if any.

Capital work-in-progress are measured at cost less accumulated impairment losses, if any.

Such cost includes purchase price, borrowing cost and any cost directly attributable to bringing the assets to its working condition for its intended use

ii) **Depreciation**

Depreciation on property, plant and equipment is depreciated on straight-line method based on the useful life of assets estimated by the Management which coincide with the life specified under Schedule II of the Companies Act, 2013.

The Group has estimated the useful lives as prescribed in schedule II of Companies Act, 2013, as follows:

-Plant and machinery	4 - 15 years
-Computer	3 - 6 years
- Electrical installations and equipment	4 - 10 years



## PI Health Sciences Limited

### Notes to Consolidated Financial Statements for the year ended March 31, 2025

- Furniture and fixtures	10 years
- Office equipment	4 - 5 years
- Vehicles	8 - 10 years

Leasehold land is being amortised over the lease period and cost of improvement on leasehold building is being amortised over the lease period or useful life whichever is lower, unless the entity expects to use the assets beyond the lease term.

Based on assessment made by technical experts, the Management believes that the useful lives as given above best represent the period over which it expects to use these assets.

#### **b. Intangible assets**

##### **i) Recognition and measurement**

###### Goodwill

Goodwill is not amortised but it is tested for impairment annually, or more frequently if events or changes in circumstances indicate that it might be impaired, and is carried at cost less accumulated impairment losses, if any.

###### Intangible assets acquired separately

Intangible assets that are acquired by the Group on initial recognition are measured at cost. Subsequently, intangible assets are carried at cost; less accumulated amortization and accumulated impairment losses, if any.

###### Internally generated intangible assets - Research and development

Research costs are expensed as incurred. Development costs are capitalised only if the expenditure can be measured reliably, the product or process is technically and commercially feasible, future economic benefits are probable, and the Group intends to and has sufficient resources to complete development and to use or sell the asset. The expenditures to be capitalized include the cost of materials and other costs directly attributable to preparing the asset for its intended use. Other development expenditures are recognized in profit or loss as incurred.

##### **ii) Amortisation**

Amortization is recognized in the income statement on a straight-line basis over the estimated useful lives of intangible assets or on any other basis that reflects the pattern in which the asset's future economic benefits are expected to be consumed by the entity. Intangible assets that are not available for use are amortized from the date they are available for use.

The estimated useful life of customer contract is 20 years.





## **PI Health Sciences Limited**

### **Notes to Consolidated Financial Statements for the year ended March 31, 2025**

#### **c. Impairment of non-financial assets**

Goodwill and intangible assets that have an indefinite useful life are not subject to amortisation and are tested annually for impairment, or more frequently if events or changes in circumstances indicate that they might be impaired. Other assets are tested for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable.

#### **d. Financial instruments**

##### **i) Initial recognition**

The group recognises financial assets and financial liabilities when it becomes a party to the contractual provisions of the instrument. All financial assets and liabilities are recognised at fair value on initial recognition, except for trade receivables (which do not contain a significant financing component) which are initially measured at transaction price. Transaction costs that are directly attributable to the acquisition or issue of financial assets and financial liabilities that are not at fair value through profit or loss are added to the fair value on initial recognition.

##### **ii) Subsequent measurement**

###### **i) Financial assets carried at amortized cost**

A financial asset (which includes loans and advances, security deposits, deposits with banks and financial institutions, cash and cash equivalents, bank balance other than cash and cash equivalents, and trade receivables) is subsequently measured at amortised cost if it is held within a business model whose objective is to hold the asset in order to collect contractual cash flows and the contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding. When the financial asset is derecognised or impaired, the gain or loss is recognised in the statement of profit and loss.

###### **ii) Financial assets at fair value through other comprehensive income (FVOCI)**

A financial asset (which includes derivative financial instruments designated as cash flow hedge) is subsequently measured at fair value through other comprehensive income if it is held within a business model whose objective is achieved by both collecting contractual cash flows and selling financial assets and the contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding. Movements in the carrying amount are taken through OCI, except for the recognition of impairment gains or losses, interest revenue and foreign exchange gains and losses which are recognised in statement of profit and loss. When the financial asset is derecognised, the cumulative gain or loss previously recognised in OCI is reclassified from equity to statement of profit and loss and recognised in other income.



## **PI Health Sciences Limited**

### **Notes to Consolidated Financial Statements for the year ended March 31, 2025**

Equity instruments are subsequently measured at fair value. On initial recognition of an equity investment that is not held for trading, the Company may irrevocably elect to present subsequent changes in the investment's fair value in OCI (designated as FVOCI – equity investment). This election is made on an investment-by-investment basis. Fair value gains and losses recognised in OCI are not reclassified to profit and loss. However, dividend on such equity investments are recognised in statement of profit and loss when the Group's right to receive payment is established.

**iii) Financial assets at fair value through profit or loss**

A financial asset (which includes investments in mutual funds) which is not classified in any of the above categories are subsequently fair valued through profit or loss.

**iv) Financial liabilities**

Financial liabilities (which includes borrowings, trade payables and other financial liabilities (other than derivative financial instruments)) are subsequently carried at amortized cost using the effective interest method.

**v) Offsetting**

Financial Assets and Financial Liabilities are offset and the net amount is presented in the balance sheet when, and only when, the Company has a legally enforceable right to set off the amount and it intends, either to settle them on a net basis or to realise the asset and settle the liability simultaneously.

**vi) Derivative financial instruments**

The Group is exposed to exchange rate risk which arises from its foreign exchange revenues. The Group uses options contracts (derivative financial instruments), to hedge its interest rate risk.

Derivatives are initially measured at fair value. Subsequent to initial recognition, derivatives are measured at fair value and accounted as follows:

**Cash flow hedges**

Derivatives are held to hedge the foreign currency risk associated with highly probable forecasted transactions and are classified as being part of cash flow hedge relationships. For an effective hedge, gains and losses from changes in the fair value of derivatives are recognised in other comprehensive income. Any ineffective elements of the hedge is recognised in statement of profit and loss. The amount accumulated in other comprehensive income is subsequently taken to the statement of profit and loss at the same time as the related cash flow.



## **PI Health Sciences Limited**

### **Notes to Consolidated Financial Statements for the year ended March 31, 2025**

**e. Inventories**

Cost of Raw Materials, Packing Materials, Stores and Spares, Stock in Trade and other products are determined on a weighted average basis and are net of Goods and service tax credit.

Cost of Work in progress and Finished Goods is determined on a weighted average basis considering direct material cost and appropriate portion of manufacturing overheads based on normal operating capacity.

**f. Provisions, Contingent Liabilities and Contingent Assets**

A provision is recognized if, as a result of a past event, the Group has a present legal or constructive obligation that can be estimated reliably, and it is probable that an outflow of economic resources will be required to settle the obligation. If the effect of the time value of money is material, provisions are determined by discounting the expected future cash flows at a pre-tax rate that reflects current market assessments of the time value of money and the risks specific to the liability. Where discounting is used, the increase in the provision due to the passage of time is recognized as a finance cost.

Contingent Liability is disclosed after careful evaluation of facts, uncertainties and possibility of reimbursement, unless the possibility of an outflow of resources embodying economic benefits is remote. Contingent liabilities are not recognised but are disclosed in notes to the financial statements.

Contingent assets are not disclosed in the financial statements unless an inflow of economic benefits is probable.

**g. Revenue Recognition**

**i) Sale of goods**

The Group manufactures and sells a range of products to various customers. Revenue is recognised over the period of time for contracts wherein the Group's performance does not create an asset with alternative use to the Group and the entity has an enforceable right to payment for performance completed till date. Management has determined that it is highly probable that there will be no rescission of the contract and a significant reversal in the amount of revenue recognised will not occur. Accordingly, revenue is recognised for these contracts based on Input method wherein amount of revenue to be recognised is determined based on the actual cost incurred till date and the estimated margin on the contract because there is a direct relationship between the Group's effort (i.e., based on the material consumed and labour hours incurred) and the enforceable right to payment for performance completed till date. For remaining contracts, Revenue is recognised when control of the products has transferred, being when the products are delivered to the customer, the customer has full discretion over the channel and price to sell the products, and there is no unfulfilled obligation that could affect the customer's acceptance of the products.



## **PI Health Sciences Limited**

### **Notes to Consolidated Financial Statements for the year ended March 31, 2025**

Revenue towards satisfaction of a performance obligation is measured at the amount of transaction price (net of variable consideration) allocated to that performance obligation. Accumulated experience is used to estimate and provide for the discounts and returns using the expected value method and revenue is only recognized to the extent that it is highly probable that a significant reversal will not occur. The validity of this assumption and the estimated amount of returns are reassessed at each reporting date. A refund liability (included in other current liabilities) and a right to recover the returned goods (included in other current assets) are recognised for the products expected to be returned. Liability (included in other financial liabilities) is recognized for expected volume discounts payable to customers in relation to sales made until the end of the reporting period

Contract assets are recognised when there is excess of revenue earned over billing contracts.

Amounts disclosed as revenue are net of returns, discounts, volume rebates and net of goods and service tax.

The Group does not have any contracts where the period between the transfer of the promised goods or services to the customer and payment by the customer exceeds one year. As a consequence, the Group does not adjust any of the transaction prices for the time value of money.

#### **ii) Sale of services**

Revenue from sale of services is recognised over the period of time as per the terms of the contract with customers based on the stage of completion when the outcome of the transactions involving rendering of services can be estimated reliably.

#### **iii) Export Incentives**

Incentives on exports are recognised in books after due consideration of certainty of utilisation/ receipt of such incentives.

### **h. Employee Benefits**

#### **i) Defined contribution plans**

Employees benefits in the form of the Group's contribution to Provident Fund, Pension scheme, Superannuation Fund and Employees State Insurance are defined contribution schemes. Under a defined contribution plan, the Groups's sole obligation is to pay a fixed amount with no obligation to pay further contributions if the fund does not hold sufficient assets to pay all employee benefits. The related actuarial and investment risks are borne by the employee. The Group recognises contribution payable to these schemes as an expense, when employees provide services.



## **PI Health Sciences Limited**

### **Notes to Consolidated Financial Statements for the year ended March 31, 2025**

#### **ii) Defined benefit plans**

Retirement benefits in the form of gratuity are considered as defined benefit plans. Under a defined benefit plan, it is the Group's obligation to provide agreed benefits to the employees. The related actuarial and investment risks are borne by the Group. The Group's net obligation in respect of defined benefit plans is calculated by present value of the defined benefit obligation at the end of the reporting period less the fair value of plan assets.

The Group provides for its gratuity liability based on actuarial valuation of the gratuity liability as at the Balance Sheet date, based on Projected Unit Credit Method, carried out by an actuary. The Groups contributes to the gratuity fund, which are recognised as plan assets. The defined benefit obligation as reduced by fair value of plan assets is recognised in the Balance Sheet.

The present value of the defined benefit obligation denominated in INR is determined by discounting the estimated future cash outflows by reference to market yields at the end of the reporting period on government bonds that have terms approximating to the terms of the related obligation.

Re-measurement of the net defined benefit liability, which comprise actuarial gains and losses, the return on plan assets (excluding interest) and the effect of the asset ceiling (if any, excluding interest), are recognised in the period in which they occur, directly in other comprehensive income. Net interest expense (income) on the net defined liability (assets) is computed by applying the discount rate, used to measure the net defined liability (asset), to the net defined liability (asset) at the start of the financial year after taking into account any changes as a result of contribution and benefit payments during the year. Net interest expense and other expenses related to defined benefit plans are recognised in statement of profit and loss under employee benefit expense.

When the benefits of a plan are changed or when a plan is curtailed, the resulting change in benefit that relates to past service or the gain or loss on curtailment is recognised immediately in statement of profit and loss. The Group recognises gains and losses on the settlement of a defined benefit plan when the settlement occurs.

#### **i. Income tax**

Income tax expense comprises current and deferred tax. It is recognised in profit or loss except to the extent that it relates to items recognised directly in equity or in Other Comprehensive Income.





## **PI Health Sciences Limited**

### **Notes to Consolidated Financial Statements for the year ended March 31, 2025**

#### **i) Current tax**

Current tax comprises the expected tax payable or receivable on the taxable income or loss for the year after taking credit of the benefits available under the Income Tax Act and any adjustment to the tax payable or receivable in respect of previous years. It is measured using tax rates enacted or substantively enacted at the reporting date.

#### **ii) Deferred tax**

Deferred tax is recognized in respect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the corresponding tax bases used for taxation purposes.

Group also considers decisions of appropriate authorities and legal advice for recognizing taxes.

#### **j. Segment Reporting**

An operating segment is defined as a component of the entity that represents business activities from which it earns revenues and incurs expenses and for which discrete financial information is available. The operating segments are based on the Group's internal reporting structure and the manner in which operating results are reviewed by the Chief Operating Decision Maker (CODM). The Management Advisory Committee of the Group has been identified as the CODM by the Company.

#### **k. Lease**

At inception of a contract, the Group assesses whether a contract is, or contains, a lease. A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange of consideration.

##### **i) As a lessee**

The Group leases various offices, warehouses, IT equipment and vehicles.

The Group recognises a right-of-use asset and a lease liability at the lease commencement date.

The lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date, discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, the Group's incremental borrowing rate. Generally, the Group uses its incremental borrowing rate as the discount rate, being the rate that the Group would have to pay to borrow the funds necessary to obtain an asset of similar value to the right-of-use asset in a similar economic environment with similar terms, security and conditions.

Right-of-use assets are generally depreciated over the shorter of the asset's useful life and the lease term on a straight-line basis.





## **PI Health Sciences Limited**

### **Notes to Consolidated Financial Statements for the year ended March 31, 2025**

#### **Short-term lease and leases of low value assets**

Short-term leases are leases with a lease term of 12 months or less. Low-value assets comprise IT equipment and small items of office furniture. The Group has elected not to recognise right-of-use assets and lease liabilities for short-term leased and leases of low value assets. The payments associated with short-term leases of equipment and vehicles and all leases of low-value assets are recognised on a straight-line basis in statement of profit and loss.

#### **ii) As a lessor**

When the Group acts as a lessor, it determines at lease inception whether each lease is a finance lease or an operation lease.

If lease transfers substantially all of the risks and rewards incidental to ownership of underlying assets it is classified as finance lease or otherwise as an operating lease. Rental income from operating lease is recognised on a straight-line basis over the term of the relevant lease.

#### **Other Accounting Policies**

##### **I. Foreign currency transactions**

#### **Initial recognition**

Transactions in foreign currencies are translated into the Group's functional currency at the exchange rates at the dates of the transactions.

#### **Conversion**

Monetary assets and liabilities denominated in foreign currencies are translated into the functional currency at the exchange rate at the reporting date. Non-monetary assets and liabilities that are measured at fair value in a foreign currency are translated into the functional currency at the exchange rate when the fair value was determined. Non-monetary assets and liabilities that are measured based on historical cost in a foreign currency are translated at the exchange rate at the date of the transaction.

#### **Exchange difference**

Exchange differences are recognised in profit or loss, except exchange differences arising from the translation of the following items which are recognised in OCI

- equity investments at fair value through OCI (FVOCI);
- a financial liability designated as a hedge of the net investment in a foreign operation to the extent that the hedge is effective; and
- qualifying cash flow hedges to the extent that the hedges are effective



## **PI Health Sciences Limited**

### **Notes to Consolidated Financial Statements for the year ended March 31, 2025**

**m. Borrowing costs**

Borrowing costs are interest and other costs (including exchange differences relating to foreign currency borrowings to the extent that they are regarded as an adjustment to interest costs) incurred in connection with the borrowing of funds. Borrowing costs directly attributable to acquisition or construction of qualifying asset which necessarily take a substantial period of time to get ready for their intended use are capitalised as part of the cost of that asset. Other borrowing costs are recognised as an expense in the period in which they are incurred. Investment income earned on the temporary investment of specific borrowings pending their expenditure on qualifying assets is deducted from the borrowing costs eligible for capitalisation.

**n. Cash and cash equivalents**

Cash and cash equivalents comprise cash at bank and on hand and short-term deposits with original maturities of three months or less that are readily convertible to known amounts of cash and which are subject to an insignificant risk of changes in value.

**Cash flow statement**

Cash flow statements are prepared in accordance with "Indirect Method" as explained in the Indian Accounting Standard on Statement of Cash Flows (Ind AS - 7). The cash flows from regular revenue generating, financing and investing activity of the Group are segregated

**o. Earnings per share:**

Basic earnings per share is calculated by dividing the net profit or loss for the period attributable to Equity Shareholders by the weighted average number of equity shares outstanding during the period. For the purpose of calculating diluted Earnings per Share, the net profit or loss for the period attributable to Equity Shareholders and the weighted average number of shares outstanding during the period are adjusted for the effects of all dilutive potential equity shares.

**p. Share-based payment transaction:**

The grant date fair value of equity settled share-based payment awards granted to employees is recognised as an employee benefit expense, with a corresponding increase in equity. The total expense is recognised over the vesting period, which is the period over which all of the specified vesting conditions are to be satisfied and is adjusted to reflect the actual number of share options that vest.

The total amount to be expensed is determined by reference to the fair value of the options granted including any market performance conditions and the impact of any non-vesting conditions and excluding the impact of any service and non-market performance vesting conditions.

**q. Dividends**

Final dividends on shares are recorded as a liability on the date of approval by the shareholders and interim dividends are recorded as a liability on the date of declaration by the Company's Board of Directors.



## PI Health Sciences Limited

### Notes to Consolidated Financial Statements for the year ended March 31, 2025

#### r. Basis of consolidation

##### Subsidiaries

Subsidiaries are entities controlled by the Group. the Group controls an entity when it is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power over the entity. The financial statements of subsidiaries are included in the consolidated financial statements from the date on which control commences until the date on which control ceases.

The financial statements of the Group companies are consolidated on a line-by-line basis and all intra-Group balances, transactions, income and expenses are eliminated in full on consolidation.

The subsidiary companies considered in the consolidated financial statements are:

Name of the group	Country of Incorporation	% of voting power held as at March 31st, 2025
PI Health Sciences Netherlands B.V	Netherlands	100% (100%)
PI Health Sciences USA LLC	USA	100% (100%)
Archimica S.p.A	Italy	100% (100%)

#### s. Business Combination

Acquisitions of subsidiaries and businesses are accounted for using the acquisition method. The acquiree's identifiable assets, liabilities and contingent liabilities that meet the conditions for recognition are recognised at their fair value at the acquisition date, except certain assets and liabilities that are required to be measured as per the applicable standard. Acquisition related costs are recognised in statement of profit and loss as incurred. The cost of an acquisition also includes the fair value of any contingent consideration measured as at the date of acquisition, measured as present value of the expected outflow. Any subsequent changes to the fair value of contingent consideration classified as liabilities, other than measurement period adjustments, are recognised in the statement of profit and loss along with the unwinding of discount.

Purchase consideration in excess of the Company's interest in the acquiree's net fair value of identifiable assets, liabilities and contingent liabilities is recognised as goodwill.

Excess of the Company's interest in the net fair value of the acquiree's identifiable assets, liabilities and contingent liabilities over the purchase consideration is recognised, after reassessment of fair value of net assets acquired, in the capital reserve.



**PI HEALTH SCIENCES LIMITED**

Notes to the Consolidated financial statements for the year ended March 31, 2025

(All amounts in ₹ million, unless otherwise stated)

**4 PROPERTY, PLANT & EQUIPMENT**

	Leasehold Land	Freehold land	Buildings	Plant and Machinery	Furniture and fixtures	Office equipment	Vehicles	Computer	Total
<b>Gross carrying amount</b>									
As at beginning of April 01, 2023	-	5.45	-	119.44	1.21	0.72	11.62	0.16	138.60
Addition	-	-	12.37	882.16	42.91	9.51	0.01	22.39	969.35
Additions through business combination	191.80	72.88	445.90	2,369.83	9.73	2.83	6.48	5.22	3,104.67
Disposals	-	-	-	(1.01)	-	-	(0.45)	-	(1.46)
Changes due to fair valuation	-	-	-	(268.05)	-	-	-	-	(268.05)
Effect of foreign currency translation from functional currency to reporting currency	-	0.73	3.13	22.15	0.06	0.01	0.06	0.04	26.18
<b>As at March 31, 2024</b>	<b>191.80</b>	<b>79.06</b>	<b>461.40</b>	<b>3,124.52</b>	<b>53.91</b>	<b>13.07</b>	<b>17.72</b>	<b>27.81</b>	<b>3,969.29</b>
Addition	-	-	93.10	662.34	12.49	18.36	-	14.18	800.47
Disposals	-	-	-	(0.43)	(0.02)	(0.05)	(0.04)	(0.01)	(0.55)
Changes due to fair valuation	-	-	-	-	-	-	-	-	-
Effect of foreign currency translation from functional currency to reporting currency	-	1.81	7.92	64.84	0.16	0.03	0.13	0.09	74.98
<b>As at March 31, 2025</b>	<b>191.80</b>	<b>80.87</b>	<b>562.42</b>	<b>3,851.27</b>	<b>66.54</b>	<b>31.41</b>	<b>17.81</b>	<b>42.07</b>	<b>4,844.19</b>
<b>Accumulated Depreciation</b>									
As at beginning of April 01, 2023	-	-	-	2.39	0.09	0.04	0.51	0.03	3.06
Depreciation charged during the year	1.61	-	24.63	437.49	2.31	1.74	3.41	4.37	475.55
Disposals / Adjustments	-	-	-	-	-	-	(0.11)	-	(0.11)
Effect of foreign currency translation from functional currency to reporting currency	-	-	0.07	1.71	0.00	0.00	0.01	0.01	1.81
<b>As at March 31, 2024</b>	<b>1.61</b>	<b>-</b>	<b>24.70</b>	<b>441.59</b>	<b>2.40</b>	<b>1.78</b>	<b>3.82</b>	<b>4.41</b>	<b>480.31</b>
Depreciation charged during the year	2.94	-	25.75	440.94	6.14	3.74	3.26	5.39	488.16
Disposals / Adjustments	-	-	-	(0.35)	(0.01)	-	(0.01)	-	(0.37)
Effect of foreign currency translation from functional currency to reporting currency	-	-	0.81	13.17	0.03	0.03	0.07	0.10	14.21
<b>As at March 31, 2025</b>	<b>4.55</b>	<b>-</b>	<b>51.26</b>	<b>895.34</b>	<b>8.56</b>	<b>5.55</b>	<b>7.14</b>	<b>9.90</b>	<b>982.32</b>
<b>Net carrying amount</b>									
As at March 31, 2025	187.25	80.87	511.16	2,955.91	57.98	25.86	10.67	32.17	3,861.87
As at March 31, 2024	190.19	79.06	436.70	2,682.92	51.51	11.29	13.90	23.40	3,488.98

Notes:

- a. Addition in leasehold land in the previous year represents land which has been acquired on acquisition of "Therachem Research Medilab (India) Private Limited (TRM)" and "Solis Pharmachem Private Limited" amounting to ₹ 160.80 and ₹ 31.00 respectively. Out of the above assets acquired of ₹ 160.80 are pending for registration in the name of the Company as on March 31, 2025.



- b. Refer note 41 for disclosure of contractual commitments for the acquisition of property, plant and equipment.  
c. Refer note 46 for acquisition of property, plant and equipment through business combination.  
d. No revaluation has been undertaken during the current year as well in the previous year.

Relevant line items in the Balance sheet	Description of item of property	Gross Carrying Value	Title deeds held in name of	Whether title deed holder is a promoter, director or relative of promoter/ director or employee of promoter or director	Property held since which date	Reason for not being held in the name of the company
Property, Plant and Equipment	Leasehold Land	160.80	TRM	NA	02-06-2023	Registration of leasehold land in the name of Company is under process

**PI HEALTH SCIENCES LIMITED**
**Notes to the Consolidated financial statements for the year ended March 31, 2025**
**(All amounts in ₹ million, unless otherwise stated)**
**5 RIGHT OF USE ASSETS**
**Gross carrying amount**

	Land	Building	Office Equipment	Total
<b>As at beginning of April 01, 2023</b>	<b>157.03</b>	<b>354.86</b>	<b>-</b>	<b>511.89</b>
Addition	-	55.69	-	55.69
Additions through business combination*	-	3.36	-	3.36
Disposal / Transfer	-	-	-	-
Effect of foreign currency translation from functional currency to reporting currency	-	-	-	-
<b>As at March 31, 2024</b>	<b>157.03</b>	<b>413.91</b>	<b>-</b>	<b>570.94</b>
Addition	-	-	6.51	6.51
Disposal / Transfer	-	(3.36)	-	(3.36)
Effect of foreign currency translation from functional currency to reporting currency	-	-	-	-
<b>As at March 31, 2025</b>	<b>157.03</b>	<b>410.55</b>	<b>6.51</b>	<b>574.09</b>

\*Additions due to conversion of "Therachem Research Medilab (India) Private Limited" financials from Indian Generally Accepted Accounting Principles (IGAAP) to Indian Accounting Standard (Ind AS).

**Accumulated Depreciation**

	Land	Building	Office Equipment	Total
<b>As at beginning of April 01, 2023</b>	<b>2.22</b>	<b>1.14</b>	<b>-</b>	<b>3.36</b>
Depreciation charged during the year	3.09	17.73	-	20.82
Disposal / Transfer	-	-	-	-
Effect of foreign currency translation from functional currency to reporting currency	-	-	-	-
<b>As at March 31, 2024</b>	<b>5.31</b>	<b>18.87</b>	<b>-</b>	<b>24.18</b>
Depreciation charged during the year	-	23.99	1.84	25.83
Disposal / Transfer	-	(3.36)	-	(3.36)
Effect of foreign currency translation from functional currency to reporting currency	-	-	-	-
<b>As at March 31, 2025</b>	<b>5.31</b>	<b>39.50</b>	<b>1.84</b>	<b>46.65</b>

**Net carrying amount**

<b>As at March 31, 2025</b>	<b>151.72</b>	<b>371.05</b>	<b>4.67</b>	<b>527.44</b>
<b>As at March 31, 2024</b>	<b>151.72</b>	<b>395.04</b>	<b>-</b>	<b>546.76</b>

**6 CAPITAL WORK-IN-PROGRESS**

(a) Cost	Amount
<b>As at beginning of April 01, 2023</b>	<b>16.24</b>
Additions through business combination	215.35
Addition	1,205.77
Disposal / Transfer	(876.56)
Effect of foreign currency translation from functional currency to reporting currency	0.33
<b>As at March 31, 2024</b>	<b>561.13</b>
Addition*	1167.58
Disposal / Transfer	(728.01)
Effect of foreign currency translation from functional currency to reporting currency	18.23
<b>As at March 31, 2025</b>	<b>1018.93</b>

\* In current year, the additions in CWIP include capitalization of employee benefit expenses ₹33, finance cost ₹ 15 and other expense ₹ 49. (In previous year, additions in CWIP include capitalization of employee benefit expense ₹ 93, finance cost ₹ 26 and other expense ₹ 52).



**PI HEALTH SCIENCES LIMITED**

Notes to the Consolidated financial statements for the year ended March 31, 2025

(All amounts in ₹ million, unless otherwise stated)

**(b) Ageing of capital work-in progress**

Particulars	Amount in capital work-in progress for a period of				Total
	Less than 1 year	1-2 years	2-3 years	More than 3 years	
<b>As at March 31, 2025</b>					
Projects in progress	745.50	273.43	-	-	<b>1,018.93</b>
Projects temporarily suspended	-	-	-	-	-
<b>As at March 31, 2024</b>					
Projects in progress	475.52	85.61	-	-	<b>561.13</b>
Projects temporarily suspended	-	-	-	-	-

**(c) Completion schedule for capital work in progress whose completion is overdue or has exceeded its cost compared to its original plan**

Particulars	To be completed in				Total
	Less than 1 year	1-2 years	2-3 years	More than 3 years	
<b>As at March 31, 2025</b>					
Projects in progress	-	-	-	-	-
Projects temporarily suspended	-	-	-	-	-
<b>As at March 31, 2024</b>					
Projects in progress					
- R&D lab Hyderabad (Phase -III)	95.21	-	-	-	<b>95.21</b>
Projects temporarily suspended	-	-	-	-	-

Note: There are no project as on March 31, 2025 and March 31, 2024 where the project timeline is overdue.





**PI HEALTH SCIENCES LIMITED**
**Notes to the Consolidated financial statements for the year ended March 31, 2025**
**(All amounts in ₹ million, unless otherwise stated)**
**7 GOODWILL AND OTHER INTANGIBLE ASSET**

	Software	Technical know-how	Customer contracts and relationships	Total other than goodwill	Goodwill	Total
<b>Gross carrying amount</b>						
<b>As at beginning of April 01, 2023</b>	-	-	-	-	-	-
Addition	9.43	-	-	9.43	-	9.43
Additions through business combination	-	251.76	1,661.00	1,912.76	2,768.43	4,681.19
Disposal / Transfer	-	-	-	-	-	-
Effect of foreign currency translation from functional currency to reporting currency	(0.00)	(0.11)	-	(0.11)	14.74	14.63
<b>As at March 31, 2024</b>	<b>9.43</b>	<b>251.65</b>	<b>1,661.00</b>	<b>1,922.08</b>	<b>2,783.17</b>	<b>4,705.25</b>
Addition	15.68	-	-	15.68	-	15.68
Disposal / Transfer	-	-	-	-	-	-
Effect of foreign currency translation from functional currency to reporting currency	0.21	6.19	-	6.41	47.36	53.76
<b>As at March 31, 2025</b>	<b>25.32</b>	<b>257.84</b>	<b>1,661.00</b>	<b>1,944.17</b>	<b>2,830.53</b>	<b>4,774.69</b>
<b>Accumulated amortisation</b>						
<b>As at beginning of April 01, 2023</b>	-	-	-	-	-	-
Amortisation charged during the year	3.67	9.39	68.98	82.04	-	82.04
Disposal / Transfer	-	-	-	-	-	-
Effect of foreign currency translation from functional currency to reporting currency	0.00	(0.01)	-	(0.01)	-	(0.01)
<b>As at March 31, 2024</b>	<b>3.67</b>	<b>9.38</b>	<b>68.98</b>	<b>82.03</b>	-	<b>82.03</b>
Addition	2.27	10.17	83.06	95.50	-	95.50
Disposal / Transfer	-	-	-	-	-	-
Effect of foreign currency translation from functional currency to reporting currency	0.12	0.36	-	0.48	-	0.48
<b>As at March 31, 2025</b>	<b>6.06</b>	<b>19.91</b>	<b>152.04</b>	<b>178.01</b>	-	<b>178.01</b>
<b>Net carrying amount</b>						
<b>As at March 31, 2025</b>	<b>19.26</b>	<b>237.93</b>	<b>1508.96</b>	<b>1766.16</b>	<b>2830.53</b>	<b>4596.69</b>
<b>As at March 31, 2024</b>	<b>5.76</b>	<b>242.28</b>	<b>1592.02</b>	<b>1840.05</b>	<b>2783.17</b>	<b>4623.22</b>

**Note:**

- a. Goodwill of ₹ 2,831 generated on account of business combination ( Refer Note 46)

Goodwill is tested for impairment annually and when circumstances indicate that the carrying value may be impaired. For the purpose of impairment testing, goodwill acquired in a business combination is allocated to the cash generating units (CGU) or group of CGUs, which are benefited from the synergies of the acquisition. Goodwill is reviewed for any impairment at the operating segment, which is represented through group of CGUs, being lowest level at which goodwill is monitored for internal management purposes. When the recoverable amount of the CGU is less than its carrying amount, an impairment loss is recognised.

The recoverable amount of CGU has been determined from a value in use calculation which require the use of assumptions. The value in use calculation uses cash flow forecasts based on the most recently approved financial budgets and business projections by the management, which cover a period of five years. Key assumptions underlying the value in use calculation are those regarding expected revenues, a post-tax discount rate of 11% per annum. Sales growth projections considers managements' expectation of market development, current industry trends and post-tax discount rate based on the relevant risks. 5% growth rate has been used to extrapolate the cash flow projections beyond the five-year period of the approved financial budgets. The management believes that any reasonably possible change in the key assumptions would not cause the carrying amount to exceed the recoverable amount of the cash generating unit.

- b. Other intangible assets pertains to customer contracts and relationship identified on business combination (Refer note 46).



**PI HEALTH SCIENCES LIMITED**
**Notes to the Consolidated financial statements for the year ended March 31, 2025**
**(All amounts in ₹ million, unless otherwise stated)**
**8 NON CURRENT INVESTMENT**

	As at March 31, 2025	As at March 31, 2024
<b>Investment carried at cost</b>		
<b>Unquoted shares</b>		
<b>Investment in equity instruments</b>		
Shares in Soc Industria e Università Srl (4250 shares of EUR 1 each)	0.39	0.38
Shares in Ecolombardia 4 SpA (2200 shares of EUR 25.99 each)	5.27	5.14
<b>TOTAL</b>	<b>5.66</b>	<b>5.52</b>

**9 OTHER NON-CURRENT FINANCIAL ASSETS**

	As at March 31, 2025	As at March 31, 2024
<b>Unsecured, considered good unless stated otherwise:</b>		
Security deposits	17.42	12.45
Derivative financial instruments	4.28	18.73
<b>TOTAL</b>	<b>21.70</b>	<b>31.18</b>

**10 OTHER ASSETS**

	Non- Current		Current	
	As at March 31, 2025	As at March 31, 2024	As at March 31, 2025	As at March 31, 2024
<b>Capital advances</b>				
Considered good	6.35	17.93	-	-
Doubtful	-	-	-	-
Less: Allowance for doubtful advances	-	-	-	-
<b>Advances to Vendors</b>				
Considered good	-	-	11.07	31.21
Doubtful	-	-	-	-
Less: Allowance for doubtful advances	-	-	-	-
Prepayments	0.51	1.85	141.16	114.70
Balance with government authorities	-	-	489.78	349.88
Export incentive receivables	-	-	3.99	4.14
Other miscellaneous advances	-	-	0.17	0.14
<b>TOTAL</b>	<b>6.86</b>	<b>19.78</b>	<b>646.17</b>	<b>500.07</b>

**11 INVENTORIES**

	As at March 31, 2025	As at March 31, 2024
Raw materials	290.42	239.63
Semi- Finished goods	43.57	187.58
Finished goods	428.33	434.99
<b>TOTAL</b>	<b>762.32</b>	<b>862.20</b>

Note: Valuation of inventories is stated in note 3(e) of material accounting policies.

**13 CASH AND CASH EQUIVALENTS**

	As at March 31, 2025	As at March 31, 2024
<b>Cash &amp; Cash Equivalents</b>		
Balance with banks		
-Balances in current account	497.49	240.23
-Balances in EEFC account	17.07	-
Cash on hand	0.08	0.08
Deposits with original maturity of less than 3 months	32.06	235.00
<b>TOTAL</b>	<b>546.70</b>	<b>475.31</b>

**14 BANK BALANCES OTHER THAN CASH AND CASH EQUIVALENTS**

	As at March 31, 2025	As at March 31, 2024
Fixed deposits with bank	11.48	11.56
	<b>11.48</b>	<b>11.56</b>



**PI HEALTH SCIENCES LIMITED**
**Notes to the Consolidated financial statements for the year ended March 31, 2025**
**(All amounts in ₹ million, unless otherwise stated)**
**12 TRADE RECEIVABLES**

	As at March 31, 2025	As at March 31, 2024
Trade receivables	1,154.02	1,309.12
Receivable from related parties (refer note 41)	10.20	-
Less: Allowance for doubtful debts	(231.00)	(23.73)
<b>TOTAL</b>	<b>933.22</b>	<b>1,285.39</b>

**Break up of security details**

	As at March 31, 2025	As at March 31, 2024
Trade receivables considered good - secured	-	-
Trade receivables considered good - unsecured	1,164.22	1,309.12
Trade receivables which have significant increase in credit risk	-	-
Trade receivables - credit impaired	-	-
Less: Allowance for doubtful debts	(231.00)	(23.73)
<b>TOTAL</b>	<b>933.22</b>	<b>1,285.39</b>

**Trade Receivables ageing as at March 31, 2025**

Particulars	Outstanding for following periods from due date							Total
	Unbilled	Not Due	Less than 6 months	6 months -1 years	1-2 years	2-3 years	More than 3 years	
<b>Undisputed trade receivable</b>								
Considered good*	-	577.56	145.26	145.17	270.37	0.03	25.82	1,164.22
Which have significant increase in credit risk	-	-	-	-	-	-	-	-
Credit impaired	-	-	-	-	-	-	-	-
<b>Disputed trade receivable</b>								
Considered good	-	-	-	-	-	-	-	-
Which have significant increase in credit risk	-	-	-	-	-	-	-	-
Credit impaired	-	-	-	-	-	-	-	-
<b>Total</b>	-	577.56	145.26	145.17	270.37	0.03	25.82	1,164.22
Less: Allowance for doubtful debts								(231.00)
<b>Net Total</b>	-	577.56	145.26	145.17	270.37	0.03	25.82	933.22

**Trade Receivables ageing as at March 31, 2024**

Particulars	Outstanding for following periods from due date							Total
	Unbilled	Not Due	Less than 6 months	6 months -1 years	1-2 years	2-3 years	More than 3 years	
<b>Undisputed trade receivable</b>								
Considered good*	16.69	825.77	463.42	2.12	-	0.95	0.17	1,309.12
Which have significant increase in credit risk	-	-	-	-	-	-	-	-
Credit impaired	-	-	-	-	-	-	-	-
<b>Disputed trade receivable</b>								
Considered good	-	-	-	-	-	-	-	-
Which have significant increase in credit risk	-	-	-	-	-	-	-	-
Credit impaired	-	-	-	-	-	-	-	-
<b>Total</b>	16.69	825.77	463.42	2.12	-	0.95	0.17	1,309.12
Less: Allowance for doubtful debts								(23.73)
<b>Net Total</b>	16.69	825.77	463.42	2.12	-	0.95	0.17	1,285.39

\* Trade receivable outstanding for period more than 1 year are acquired through business combination during the year.



**15 OTHER FINANCIAL ASSETS**

	As at March 31, 2025	As at March 31, 2024
<b>Unsecured, considered good unless stated otherwise:</b>		
Interest accrued on fixed deposit	0.36	3.51
Other receivables*	3.48	11.56
	<b>3.84</b>	<b>15.07</b>

\*Other receivables includes amount receivable from related party ₹2.35 ( Refer note 43)

**16 CONTRACT ASSETS**

	As at March 31, 2025	As at March 31, 2024
Contract asset*	225.59	723.26
	<b>225.59</b>	<b>723.26</b>

\* Recoverable from customer under contract for supply of goods manufactured exclusively for customers

**17 CURRENT TAX ASSETS**

	As at March 31, 2025	As at March 31, 2024
TDS receivable / advance tax	26.69	137.85
<b>TOTAL</b>	<b>26.69</b>	<b>137.85</b>

**18 EQUITY SHARE CAPITAL**

	As at March 31, 2025	As at March 31, 2024
<b>Authorised Shares</b>		
62,55,50,000 Equity Shares of ₹ 10 each (62,55,50,000 Equity Shares March 31, 2024 : ₹ 10 each)	6,256	6,256
	<b>6,256</b>	<b>6,256</b>
<b>Issued Shares</b>		
44,09,99,946 Equity Shares of ₹ 10 each (44,09,99,946 Equity Shares March 31, 2024 : ₹ 10 each)	4,410	4,410
	<b>4,410</b>	<b>4,410</b>
<b>Subscribed &amp; Fully Paid up Shares</b>		
44,09,99,946 Equity Shares of ₹ 10 each (44,09,99,946 Equity Shares March 31, 2024 : ₹ 10 each)	4,410	4,410
<b>Total subscribed and fully paid up share capital</b>	<b>4,410</b>	<b>4,410</b>

**a. Terms/ rights attached to Equity Shares**

The Company has only one class of equity shares having par value of ₹10 per share. Each holder of equity shares is entitled to one vote per share. The equity shareholders are entitled to receive dividend as declared from time to time. In the event of liquidation of the Company, the holders of equity shares will be entitled to receive remaining assets of the Company, after distribution of all preferential amounts. The distribution will be in proportion to the number of equity shares held by the shareholders.

**b. Reconciliation of shares outstanding at the beginning and at the end of the reporting year**

Particulars	As at March 31, 2025		As at March 31, 2024	
	Number	Amount	Number	Amount
Opening balance at the beginning of the year	44,09,99,946	4,410.00	2,44,99,997	245.00
Shares issued during the year	-	-	41,64,99,949	4,165.00
Share outstanding at end of year	<b>44,09,99,946</b>	<b>4,410.00</b>	<b>44,09,99,946</b>	<b>4,410.00</b>

**c. Details of shareholders holding more than 5% shares in the Company**

	As at March 31, 2025		As at March 31, 2024	
	Number	% holding	Number	% holding
PI Industries Limited and its nominees	44,09,99,946	100.00%	44,09,99,946	100.00%

**d. Details of shareholding by promoters**

Promoter Name	As at March 31, 2025			As at March 31, 2024		
	Shares held on 31st March 2024	% of Total Share	% change during the year	Shares held on 31st March 2024	% of Total Share	% change during the year
PI Industries Limited and its nominees	44,09,99,946	100.00%	-	44,09,99,946	100.00%	1700.00%

**e. Approval of ESOP**

During the financial year ended March 31, 2025, Members of the Holding Company approved an Employee Stock Option Plan (ESOP) viz. PI Health Sciences Employee Stock Option Plan 2025, in accordance with provisions of the Companies Act, 2013 read with rule made thereunder and other applicable laws and regulations, in Extra-ordinary General meeting held on dated January, 29 2025.

As at March 31, 2025, no stock options have been granted under the approved scheme. Accordingly, no expense or liability has been recognised in the financial statements for the year under Ind AS 102 – Share-based Payment.

The Holding Company intends to initiate the grant of options in accordance with the approved scheme in subsequent financial periods.



**19 OTHER EQUITY**

	As at March 31, 2025	As at March 31, 2024
Retained earnings	(3,383.68)	(1,025.93)
Equity component of compound financial instrument	664.76	487.39
<b>TOTAL</b>	<b>(2,718.92)</b>	<b>(538.55)</b>

(a)	As at March 31, 2025	As at March 31, 2024
<b>Retained earnings</b>		
<b>Opening Balance</b>	(1,025.93)	(102.80)
Net loss for the year	(2,455.12)	(891.95)
-Items of other comprehensive income recognised directly in retained earnings		
Remeasurements gains/(losses) on defined benefit plans	4.21	(0.45)
Cash Flow Hedge Reserve	(11.41)	(17.28)
Exchange difference on translation of foreign operations	104.57	(13.45)
<b>Closing Balance</b>	<b>(3,383.68)</b>	<b>(1,025.93)</b>

**Nature and purpose of the reserve**

Retained earnings are the profits that the Company has earned till date, less any transfers to general reserve if any, dividend or other distributions paid to shareholders. Further, it also includes the impact of remeasurements of the defined benefit obligations, net of tax.

**(b) Equity component of compound financial instruments**

During the year company has issued 200 million unlisted unsecured Optionally Fully Convertible Debentures ("OFCDs"), having a face value of Rs. 10 each, aggregating to INR 2,000, at an interest of 0.50% on a non-cumulative basis per annum to PI Industries Limited (PI), holding company through private placement on a preferential basis.

OFCDs shall be repaid for a maximum of 10 years, repayable on demand by PI with a moratorium of 5 years. The company has issued OFCD cumulating to INR 7500 as on date.

Conversion rights: PI shall have the right to convert, in whole or in part, the OFCD into fully paid-up equity shares of INR 10 each of the Company, at PI's sole discretion, at the fair value on the date of issue, which shall be determined by the valuation report obtained by a registered valuer acceptable to the parties.

Redemption: PI shall be entitled to exercise the option for redemption of the OFCD, during the term of the OFCD. At maturity, or earlier if PI exercises its redemption option, OFCD to be redeemed at a premium calculated as the average interest on Government Securities of an equivalent term for the period from the date of issuance of the OFCD until the date of redemption, subject to an overall cap of 9% per annum.

Premium payable on exercise of redemption option has been estimated at 7.15% p.a.

Until conversion, OFCD will rank higher than the Equity Shares for repayment of the principal amount and interest accrued there, and rank pari passu with other unsecured creditors.

OFCD issued by the Company are classified as compound financial instruments. These OFCD are separated into liability and equity components based on the terms of the contract. The liability component has been measured based on the present value of contractual obligation to pay cash as the Company doesn't have the discretionary right to avoid these obligation. The difference between the fair value of OFCD on the date of issue and liability component measured has been presented as equity component. Interest on liability component is recognised as finance cost using the effective interest method.

**20 BORROWINGS**

	Non- Current		Current	
	As at March 31, 2025	As at March 31, 2024	As at March 31, 2025	As at March 31, 2025
<b>Unsecured</b>				
Loan from bank (refer note below)	762.49	616.56	329.20	662.39
Liability component of OFCD	7,225.69	4,937.69	-	-
<b>TOTAL</b>	<b>7,988.19</b>	<b>5,554.25</b>	<b>329.20</b>	<b>662.39</b>



**PI HEALTH SCIENCES LIMITED**
**Notes to the Consolidated financial statements for the year ended March 31, 2025**
**(All amounts in ₹ million, unless otherwise stated)**
**Changes in liabilities arising from financing activities - Borrowings**

Particulars	As at March 31, 2025	As at March 31, 2024
Opening balance	6,224.11	690.00
Add: New loan received during the year	2,363.13	10,276.42
Less: Transaction cost	0.03	(9.25)
Add: Borrowing acquired on account of business combination	-	1,043.88
Add: Impact of derivatives	-	35.67
Add: Interest cost	606.23	447.57
Less: Interest paid during the year	(81.20)	(352.22)
Less: Principal repayment during the year	(504.83)	(5,265.39)
Less: Equity component of OFCD transferred to reserves	(237.02)	(651.50)
Add: Effect of foreign currency translation from functional currency to reporting currency	(53.06)	8.93
Closing balance*	<b>8,317.38</b>	<b>6,224.11</b>

Closing balance as on March 31, 2024 includes ₹ 7.47 interest accrued but not due (₹ 4.54 payable to parent company) which has been disclosed under current financial liability.

**Terms and Conditions:**

- The group had taken loan in previous year from parent company carrying interest rate of 9.5% per annum which is repayable after five years in five equal instalment as mutually decided by both parties. This loan was repaid by the Company as on March 31, 2024.
- Term loan sanctioned to wholly owned subsidiary "Archimica S.p.A" in EURO bearing floating interest rate that are linked to EURIBOR 3 months spread ranging from 0.7% to 1.75%. Maturity ranging from July 2025 to September 2029.
- The Archimica S.p.A has availed a working capital facility from HSBC Bank with a sanctioned limit of EURO 10. As at March 31, 2025, an amount of EUR 4 has been drawn. The facility carries floating interest rate that are linked to EURIBOR 3 months spread of 1.75%. Maturity ranging from May 2027 to March 2032.
- Kindly refer other equity note for terms of OFCD.
- As on the Balance sheet date there is no default in repayment of loans and interest.

**21 LEASE LIABILITIES**

	Non- Current		Current	
	As at March 31, 2025	As at March 31, 2024	As at March 31, 2025	As at March 31, 2024
Lease liabilities	63.88	71.45	12.59	12.44
<b>TOTAL</b>	<b>63.88</b>	<b>71.45</b>	<b>12.59</b>	<b>12.44</b>

**Changes in liabilities arising from financing activities - Lease liabilities**

	As at March 31, 2025	As at March 31, 2024
Opening balance	83.89	32.83
Add: New leases entered during the year	6.51	55.68
Add: Leases acquired on account of business combination	-	3.72
Add: Interest cost on leases	6.73	6.48
Less: Lease Termination	(2.42)	-
Less: Payment during the year	(18.26)	(14.81)
Closing balance	<b>76.47</b>	<b>83.89</b>

The Company incurred ₹ 66.22 (March 31, 2024 ₹ 48.06) towards expenses relating to short term leases.

**22 OTHER FINANCIAL LIABILITIES**

	As at March 31, 2025	As at March 31, 2024	As at March 31, 2025	As at March 31, 2024
	Non- Current		Current	
Employee payables	-	-	183.84	176.60
Interest accrued and due on borrowings*	-	-	-	7.47
Creditors for capital purchases	-	-	83.68	33.46
Derivative financial instruments	-	-	4.88	4.56
Security Deposit	-	2.20	2.60	-
Other payable**	1501.49	1345.65	317.94	329.87
<b>TOTAL</b>	<b>1,501.49</b>	<b>1,347.85</b>	<b>592.94</b>	<b>551.96</b>

\* Includes due to related party amounting to ₹ 27.51 (March 31, 2024 ₹ 4.54).

\*\* It includes the following:

- Contingent consideration is an additional amount payable by PIHS LLC to TRM US equivalent to fifteen percent (15%) of the sum of the material margin (revenue minus raw material cost) from the date of acquisition till 31 March 2029 on respective payment dates as per APA subject to maximum amount of \$25.
- Deferred purchase consideration due to "Therachem Research Medilab (India) Private Limited" after 18 months from completion date has been waived by the seller amounting to ₹ 261.67 (March 31, 2024 ₹ 254.36 was payable to seller).





**23 DEFERRED TAX ASSET / LIABILITY**

The balance comprises temporary differences attributable to:

	As at March 31, 2025	As at March 31, 2024
<b>(a) Deferred tax liabilities</b>		
Property, plant and equipment	412.26	411.20
Deferred purchase consideration	-	3.26
<b>Sub- Total (a)</b>	<b>412.26</b>	<b>414.46</b>
<b>(b) Deferred tax assets</b>		
Provision for employee benefits	10.86	5.99
Other provisions	1.00	0.49
Lease assets	(113.50)	(116.49)
Optionally fully convertible debenture (OFCD)	154.55	22.41
Unabsorbed depreciation and losses	711.97	303.13
Unabsorbed loss on account of acquisition	0.69	0.71
<b>Other comprehensive items</b>		
- Remeasurements on defined benefit plans	(1.26)	(0.15)
- Effective portion on cash flow hedges	7.95	(4.40)
Others	(220.93)	(162.35)
<b>Sub- Total (b)</b>	<b>551.33</b>	<b>49.34</b>
<b>Net deferred tax (assets)/liabilities (a)-(b)</b>	<b>(139.07)</b>	<b>365.12</b>

Movement in deferred tax for FY 2024-25:

	As at April 01, 2024	Acquired on Business Combination	Recognised in P&L	Recognised in OCI	Other Adjustments*	As at March 31, 2025
<b>(c) Deferred tax liabilities</b>						
Property, plant and equipment	411.20	-	1.06	-	-	412.26
Deferred purchase consideration	3.26	-	(3.26)	-	-	-
<b>Sub- Total (c)</b>	<b>414.46</b>	<b>-</b>	<b>(2.20)</b>	<b>-</b>	<b>-</b>	<b>412.26</b>
<b>(d) Deferred tax assets</b>						
Provision for employee benefits	5.99	-	(4.87)	-	-	10.86
Other provisions	0.49	-	(0.51)	-	-	1.00
Lease assets	(116.49)	-	(2.99)	-	-	(113.50)
OFCD	22.41	-	(132.14)	-	-	154.55
Unabsorbed depreciation and business losses	303.13	-	(408.84)	-	-	711.97
Unabsorbed loss on account on acquisition	0.71	-	0.03	-	-	0.69
<b>Other comprehensive items</b>						
- Remeasurement of defined benefit plans	0.15	-	-	1.41	-	(1.26)
- Net gain on cash flow hedge	4.40	-	-	(3.55)	-	7.95
Others	(171.45)	-	(12.61)	-	(62.09)	(220.93)
<b>Sub- Total (d)</b>	<b>49.34</b>	<b>-</b>	<b>(561.93)</b>	<b>(2.14)</b>	<b>(62.09)</b>	<b>551.33</b>
<b>(e) Net deferred tax (assets)/liabilities (c)-(d)</b>	<b>365.12</b>	<b>-</b>	<b>(564.13)</b>	<b>(2.14)</b>	<b>62.09</b>	<b>(139.07)</b>

\*Deferred tax on OFCD equity portion netted off from other equity and others.

Movement in deferred tax for FY 2023-24:

	As at April 1, 2023	Acquired on Business Combination	Recognised in P&L	Recognised in OCI	Other Adjustments*	As at March 31, 2024
<b>Deferred tax liabilities</b>						
Property, plant and equipment	1.75	795.48	(386.03)	-	-	411.20
Deferred purchase consideration	-	-	3.26	-	-	3.26
<b>Sub- Total (a)</b>	<b>1.75</b>	<b>795.48</b>	<b>(382.77)</b>	<b>-</b>	<b>-</b>	<b>414.46</b>
<b>Deferred tax assets</b>						
Provision for employee benefits	3.55	-	(2.44)	-	-	5.99
Other provisions	21.38	50.87	71.76	-	-	0.49
Lease assets	-	-	116.49	-	-	(116.49)
OFCD	-	-	-22.41	-	-	22.41
Unabsorbed depreciation and business losses	1.74	49.01	(252.38)	-	-	303.13
Unabsorbed loss on account on acquisition	-	-	(0.71)	-	-	0.71
<b>Other comprehensive items</b>						
- Remeasurement of defined benefit plans	-	-	-	(0.15)	-	(0.15)
- Net gain on cash flow hedge	-	-	-	(4.40)	-	(4.40)
Others*	-	(100.71)	(116.45)	-	(178.09)	(162.35)
<b>Sub- Total (b)</b>	<b>26.67</b>	<b>(0.83)</b>	<b>(206.14)</b>	<b>(4.55)</b>	<b>(178.09)</b>	<b>49.34</b>
<b>Net deferred tax assets (a)-(b)</b>	<b>(24.92)</b>	<b>796.31</b>	<b>(588.91)</b>	<b>(4.55)</b>	<b>(178.09)</b>	<b>365.12</b>

\*Deferred tax on OFCD equity portion netted off from other equity and others.



**PI HEALTH SCIENCES LIMITED**

Notes to the Consolidated financial statements for the year ended March 31, 2025  
(All amounts in ₹ million, unless otherwise stated)

**24 TRADE PAYABLES**

	As at March 31, 2025	As at March 31, 2024
Trade payables		
-Due to micro and small enterprises	7.26	7.62
-Others*	871.05	612.58
<b>TOTAL</b>	<b>878.31</b>	<b>620.20</b>

\* Other trade payables includes amount due to related parties amounting to ₹ 1.60 (March 31, 2024 ₹ 2.65)

**Trade Payable ageing as at March 31, 2025**

Particulars	Outstanding for following periods from due date						Total
	Unbilled dues	Not Due	Less than 1 year	1-2 years	2-3 years	More than 3 years	
<b>Undisputed trade payable</b>							
Micro and small enterprises	-	6.00	1.26	-	-	-	7.26
Others*	327.41	472.70	67.16	3.78	-	-	871.05
<b>Disputed trade payable</b>							
Micro and small enterprises	-	-	-	-	-	-	-
Others	-	-	-	-	-	-	-
<b>Total</b>	<b>327.41</b>	<b>478.70</b>	<b>68.42</b>	<b>3.78</b>	<b>-</b>	<b>-</b>	<b>878.31</b>

**Trade Payable ageing as at March 31, 2024**

Particulars	Outstanding for following periods from due date						Total
	Unbilled	Not Due	6 months -1 years	1-2 years	2-3 years	More than 3 years	
<b>Undisputed trade payable</b>							
Micro and small enterprises	-	7.62	-	-	-	-	7.62
Others	312.98	186.44	93.64	13.66	5.50	0.36	612.58
<b>Disputed trade payable</b>							
Micro and small enterprises	-	-	-	-	-	-	-
Others	-	-	-	-	-	-	-
<b>Total</b>	<b>312.98</b>	<b>194.06</b>	<b>93.64</b>	<b>13.66</b>	<b>5.50</b>	<b>0.36</b>	<b>620.20</b>

\* Trade payable outstanding for period more than 1 year are acquired through business combination during the year.



**PI HEALTH SCIENCES LIMITED**

Notes to the Consolidated financial statements for the year ended March 31, 2025

(All amounts in ₹ million, unless otherwise stated)

**25 PROVISIONS**

	Non- Current		Current	
	As at March 31, 2025	As at March 31, 2024	As at March 31, 2025	As at March 31, 2024
Provision for employee benefits				
- Gratuity (refer note 38)	21.26	6.20	2.06	0.05
- Long term compensated absences	28.13	30.92	1.27	1.44
Provision for risk and charges*	150.17	143.26	14.72	9.65
<b>TOTAL</b>	<b>199.56</b>	<b>180.38</b>	<b>18.05</b>	<b>11.14</b>

\* It relates to provision created for other contingencies.

**26 OTHER CURRENT LIABILITIES**

	As at March 31, 2025	As at March 31, 2024
Advance from customers	49.67	20.19
Statutory dues payable	9.27	14.96
Corporate Social Responsibility (CSR)*	-	3.49
<b>TOTAL</b>	<b>58.94</b>	<b>38.64</b>

\* Although the Company is in losses total CSR liability pertains to previous year for liability acquired of "Therachem Research Medilab (India) Private Limited".



**PI HEALTH SCIENCES LIMITED****Notes to the Consolidated financial statements for the year ended March 31, 2025**

(All amounts in ₹ million, unless otherwise stated)

**27 REVENUE FROM OPERATIONS**

	For the year ended March 31, 2025	For the year ended March 31, 2024
<b>Revenue from operations includes</b>		
a) Sale of products	1,796.26	3,096.03
b) Sale of services*	336.85	37.02
c) Other operating revenues:		
Scrap sales	9.64	2.21
Export incentives	8.21	13.37
<b>TOTAL</b>	<b>2,150.96</b>	<b>3,148.63</b>

\*Includes sale of services of ₹ 18.57 (March 31, 2024 ₹ Nil) to related party (Refer Note 43)

(i) The Company has exclusive long-term contract manufacturing agreements with its customers which provides the Company an enforceable right to payment for performance completed to date and performance on these contracts does not create an asset with an alternative use to the Company. These contractual undersatnding with customers leads to satisfaction of performance obligations over a period of time and revenue is recognised based on percentage of completion of each performance obligation till date.

(ii) The Company disaggregates revenue from contract with customer by geography as follows:

	For the year ended March 31, 2025	For the year ended March 31, 2024
United States of America	503.83	1,400.29
Europe	1,123.48	1,246.96
Rest of the world	523.65	501.39
<b>Total</b>	<b>2,150.96</b>	<b>3,148.63</b>

(iii) Reconciliation of revenue recognised with the contract price is as follows:

	For the year ended March 31, 2025	For the year ended March 31, 2024
<b>Contract Price</b>	<b>2,150.96</b>	<b>3,148.63</b>
Adjustments for:		
Refund liabilities	-	-
Discount/Incentives	-	-
<b>Revenue recognised</b>	<b>2,150.96</b>	<b>3,148.63</b>

(iv) Changes in contract assets are as follows:

	For the year ended March 31, 2025	For the year ended March 31, 2024
<b>Opening balance</b>	<b>723.26</b>	<b>-</b>
Add: Effect of business combination	-	1,618.50
Less: Invoices raised related to exclusive customer contracts	(731.76)	(950.62)
Add: Increase due to revenue recognised during the year, excluding amounts billed during the year	228.54	51.99
Add: Exchange difference	5.55	3.39
<b>Closing balance</b>	<b>225.59</b>	<b>723.26</b>

**28 OTHER INCOME**

	For the year ended March 31, 2025	For the year ended March 31, 2024
Interest income	<b>25.03</b>	<b>49.53</b>
- Fixed Deposits	4.93	25.41
- Others	20.10	24.12
Interest income on unwinding of security deposits	0.04	0.14
Net foreign exchange differences	2.72	-
Miscellaneous income**	288.22	26.30
<b>TOTAL</b>	<b>316.01</b>	<b>75.97</b>

\*\* In current year miscellaneous income includes deferred consideration payable written back ₹ 261.67.



**PI HEALTH SCIENCES LIMITED****Notes to the Consolidated financial statements for the year ended March 31, 2025**

(All amounts in ₹ million, unless otherwise stated)

**29 COST OF MATERIAL CONSUMED**

	For the year ended March 31, 2025	For the year ended March 31, 2024
Opening Stock of raw material	239.63	-
Acquired on business combination	-	1,081.11
Add: Purchase	959.04	228.00
Less: Closing stock of raw material	290.42	239.63
<b>TOTAL</b>	<b>908.25</b>	<b>1,069.48</b>

**30 CHANGES IN INVENTORIES OF FINISHED GOODS, WORK IN PROGRESS AND STOCK IN TRADE**

	For the year ended March 31, 2025	For the year ended March 31, 2024
<b>Closing Balance</b>		
Finished Goods	428.33	434.99
Work in Progress	43.57	187.58
<b>A</b>	<b>471.90</b>	<b>622.57</b>
<b>Opening Balance</b>		
Finished Goods	434.99	-
Work in Progress	187.58	-
<b>B</b>	<b>622.57</b>	<b>-</b>
<b>Acquisition of inventory during business combination</b>		
Finished Goods	-	643.40
Work in Progress	-	201.62
<b>C</b>	<b>-</b>	<b>845.02</b>
<b>Forex impact on above changes</b>	<b>D</b>	
	(26.58)	(3.94)
<b>Total changes in inventories of work-in-progress, stock-in-trade and finished goods (B+C+D-A)</b>	<b>124.09</b>	<b>218.51</b>

**31 EMPLOYEE BENEFIT EXPENSE**

	For the year ended March 31, 2025	For the year ended March 31, 2024
Salaries, wages and bonus	1,076.06	759.53
Contribution to provident and other funds	189.88	168.50
Gratuity and long term compensated absences	20.33	12.35
Employees welfare expenses	12.32	12.52
<b>TOTAL</b>	<b>1,298.59</b>	<b>952.90</b>

**32 FINANCE COST**

	For the year ended March 31, 2025	For the year ended March 31, 2024
Interest on loan	62.12	330.18
Interest on OFCD (Refer note 43)	542.67	95.30
Interest on lease liability	6.73	6.48
Finance cost on financial liability measured at FVTPL	191.14	139.62
<b>TOTAL</b>	<b>802.66</b>	<b>571.58</b>



**PI HEALTH SCIENCES LIMITED****Notes to the Consolidated financial statements for the year ended March 31, 2025****(All amounts in ₹ million, unless otherwise stated)****33 DEPRECIATION AND AMORTISATION EXPENSE**

	<b>For the year ended March 31, 2025</b>	<b>For the year ended March 31, 2024</b>
Depreciation of property, plant and equipment (Refer note - 4)	488.15	475.55
Amortisation of Intangible Assets (Refer note - 7)	95.50	82.04
Amortisation- right of use (Refer note - 5)	25.83	20.82
<b>TOTAL</b>	<b>609.48</b>	<b>578.41</b>

**34 OTHER EXPENSES**

	<b>For the year ended March 31, 2025</b>	<b>For the year ended March 31, 2024</b>
Power, fuel & water	126.03	92.70
Consumption of stores & spares	43.69	25.60
Repairs & maintenance		
- Buildings	14.60	1.88
- Plant and machinery	246.61	281.90
- Others	25.55	22.79
Environment & pollution control expenses	3.94	0.77
Laboratory & testing charges	140.64	85.05
Freight & cartage	62.76	45.69
Travelling and conveyance	65.71	37.90
Rental charges	66.22	48.06
Rates and taxes	183.39	40.37
Insurance	36.28	39.90
Advertisement & sales promotion	11.06	14.68
Loss on sale of property, plant and equipment (net)	0.18	2.57
Telephone and communication charges	68.91	53.07
Foreign exchange loss (net of gain)	-	19.62
Provision for bad and doubtful debts & advances	215.03	1.61
Director sitting fees and commission	0.39	0.45
Legal & professional fees	347.97	398.23
Bank charges	12.49	20.30
Miscellaneous expenses	97.31	81.44
<b>TOTAL</b>	<b>1,768.76</b>	<b>1,314.58</b>





## PI HEALTH SCIENCES LIMITED

## Notes to the Consolidated financial statements for the year ended March 31, 2025

(All amounts in ₹ million, unless otherwise stated)

## 35 INCOME TAX EXPENSE

a) Income tax expense recognized in statement of Profit and Loss	For the year ended	For the year ended
	March 31, 2025	March 31, 2024
<b>Current tax expense</b>		
Current tax on profits for the year	-	-
Adjustment of current tax for prior year	(25.61)	-
<b>Total Current tax expense</b>	<b>(25.61)</b>	<b>-</b>
<b>Deferred tax expense</b>		
(Decrease) / Increase in Deferred tax liability	(2.20)	(382.77)
Decrease / (Increase) in Deferred tax assets	(561.93)	(206.14)
Impact of business combination	-	-
<b>Net Deferred tax expense</b>	<b>(564.13)</b>	<b>(588.91)</b>
<b>Total Income tax expense</b>	<b>(589.74)</b>	<b>(588.91)</b>
b) Deferred tax related to items recognised in Other comprehensive income during the year		
	For the year ended	For the year ended
	March 31, 2025	March 31, 2024
Remeasurement of defined benefit plans	1.41	(0.15)
Net gain on cash flow hedge	(3.55)	(4.40)
<b>Income tax charged to Other comprehensive income</b>	<b>(2.14)</b>	<b>(4.55)</b>
c) Reconciliation of tax expense and the accounting profit multiplied by India's tax rate		
	For the year ended	For the year ended
	March 31, 2025	March 31, 2024
Accounting profit before tax	(3,044.86)	(1,480.86)
Tax at India's statutory income tax rate @ 25.17% (previous year @25.17%)	<b>(766.33)</b>	<b>(372.70)</b>
Adjustment in respect of current income tax of previous years	-	-
- Utilisation/credit of unrecognised tax losses, unabsorbed depreciation	3.54	(91.16)
- Effect of Ind AS adjustments in financial statements	(0.01)	149.31
- Effect of non-deductible expenses	22.59	(2.55)
- Effect of different tax treatment on upfront payment of premises	-	60.87
- Impact of business combination	-	(593.84)
- Adjustment of current tax for prior year	(25.61)	-
- Effect of liability no longer payable	(66.95)	-
- Others	243.01	256.61
- Transfer to OCI	-	4.55
<b>Income Tax Expense</b>	<b>(589.74)</b>	<b>(588.91)</b>

## Note:

The Company has chosen to exercise the option of lower tax rate of 25.17% (inclusive of surcharge and tax) under section 115BAA of the Income Tax Act, 1961 effective April 01, 2019. Accordingly Company has taken the Impact on current tax liability and deferred tax.



# **PI HEALTH SCIENCES LIMITED**

**Notes to the Consolidated financial statements for the year ended March 31, 2025**  
(All amounts in ₹ million, unless otherwise stated)

## **36 CAPITAL MANAGEMENT**

The Group's policy is to maintain a strong capital base so as to maintain investor, creditor and market confidence and to sustain future development of the business. The primary objective of the Group's Capital management is to maximise shareholder's value. The Group manages its capital and makes adjustment to it in light of the changes in economic and market conditions.

The Group monitors capital using a gearing ratio, which is net debt divided by total capital plus net debt. The Group includes within net debt, interest bearing loans and borrowings, less cash and cash equivalents.

	As at March 31, 2025	As at March 31, 2024
Borrowings (Non-current) (Refer Note 20)	7,988.19	5,554.25
Borrowings (Current) (Refer Note 20)	329.20	662.39
Total Debt	8,317.39	6,216.64
Less: Cash and bank balance	(558.17)	(486.87)
<b>Net Debt</b>	<b>7,759.22</b>	<b>5,729.77</b>
Total Equity Capital	1,691.08	3,871.46
Equity Capital and Net Debt	9,450.29	9,601.23
Gearing Ratio	82.11%	59.68%

No changes were made in the objectives, policies or processes for managing capital of the Group during the current or previous year.

## **37 EARNING PER SHARE (EPS)**

	Year ended March 31, 2025	Year ended March 31, 2024
a Net Loss after tax for Basic EPS	(2,455.12)	(891.95)
Add: Finance cost on OFCD's	542.67	95.30
Net Loss after tax for Diluted EPS	(1,912.45)	(796.65)
b Number of Equity Shares at the beginning of the year	44,09,99,946	2,44,99,997
Add: Number of shares issued during the year	-	41,64,99,949
Total number of Shares outstanding during the year	44,09,99,946	44,09,99,946
Weighted average number of Equity shares outstanding during the year - Basic	44,09,99,946	43,07,58,194
Add: Weighted average number of Equity shares to be issued on conversion of Optionally Fully Convertible Debenture	37,56,55,577	5,75,33,177
Weighted average number of Equity shares outstanding during the year - Diluted	81,66,55,523	48,82,91,371
Earning per share - Basic (₹)	(5.57)	(2.07)
Earning per share - Diluted (₹)	(5.57)	(2.07)
Face value per share (₹)	10.00	10.00

### **Note:**

OFCD are anti-dilutive in nature for year ended March 31, 2025 and March 31, 2024.



**PI HEALTH SCIENCES LIMITED**

**Notes to the Consolidated financial statements for the year ended March 31, 2025**  
(All amounts in ₹ million, unless otherwise stated)

**38 EMPLOYEE BENEFITS**

In respect of entities incorporated in India, the Group participates in defined contribution and benefit schemes, the assets of which are not funded in separately administered funds for Defined Benefit scheme. For defined contribution schemes the amount charged to the statements of profit or loss is the total of contributions payable in the year.

**Provident Fund**

In accordance with the Employees' Provident Fund and Miscellaneous Provisions Act, 1952 (EPF and MP Act), employees are entitled to receive benefits under the Provident Fund. Employers and employees both contribute @12% of wages in contribution accounts. Further, the employers also contribute towards administration of the benefits under the EPF and MP Act. All employees have an option to make additional voluntary contributions as permissible under the Act. These contributions are made to the fund administered and managed by the Employee Provident Fund organization. The Company has no further obligations under the fund managed by the Employee Provident Fund Organization (EPFO) beyond its monthly contributions which are charged to the statements of profit or loss in the period they are incurred. The benefits are paid to employees on their retirement or resignation from the EPFO.

**Gratuity Plan**

In accordance with the Payment of Gratuity Act of 1972, PI Health Sciences Limited has established a defined benefit plan. The Gratuity scheme provides a lump sum payment to the employees at the time of retirement or resignation (after 5 years of continued services of employment), being an amount based on the respective employee's last drawn salary and the number of years of employment with the Group. Based on actuarial valuations conducted as at year end, a provision is recognised in full for the benefit obligation. Remeasurements as a result of experience adjustments and changes in actuarial assumptions are recognised in other comprehensive income.

**a) Defined Contribution Plans: -**

The Company has recognised an expense of ₹ 17.08 (March 31, 2024 ₹ 12.88) towards the defined contribution plan.

**b) Defined benefits plans - as per actuarial valuation**
**I Change in present value of obligation during the year**

	Year ended March 31, 2025	Year ended March 31, 2024
	Gratuity Unfunded	Gratuity Unfunded
Present value of obligation at the beginning of the year	6.25	1.18
Total amount included in profit and loss:		
- Current Service Cost	6.77	4.38
- Interest Cost	0.45	0.09
- Past Service Cost	16.67	-
Total amount recognised in profit or loss	23.90	4.47
Total amount included in OCI:		
Remeasurement related to gratuity:		
Actuarial losses/(gains) arising from:	(5.62)	0.60
- Demographic Assumption	-	(0.68)
- Financial assumption	0.35	0.70
- Experience Judgement	(5.97)	0.58
Others		
Benefits Paid	(1.21)	-
<b>Present Value of obligation as at year-end</b>	<b>23.32</b>	<b>6.25</b>

**Note:**
**Net amount recognised in statement of profit and loss account of defined benefit obligations**

Particulars	Year ended March 31, 2025	Year ended March 31, 2024
Amount as per actuarial	-	4.47
Reversal of gratuity liability	-	(9.17)
	-	(4.70)



**PI HEALTH SCIENCES LIMITED**

Notes to the Consolidated financial statements for the year ended March 31, 2025  
(All amounts in ₹ million, unless otherwise stated)

**II Change in Fair Value of Plan Assets during the year**

	Year ended March 31, 2025	Year ended March 31, 2024
Plan assets at the beginning of the year	-	-
<b>Included in profit and loss:</b>		
Expected return on plan assets	-	-
<b>Included in OCI:</b>		
Actuarial Gain/(Loss) on plan assets	-	-
<b>Others:</b>		
Employer's contribution	-	-
Benefits paid	-	-
Claim received during the year from fund manager	-	-
Pending claim with fund manager	-	-
<b>Plan assets at the end of the year</b>	-	-

**III Reconciliation of Present value of Defined Benefit Obligation and Fair Value of Plan Assets**

	Year ended March 31, 2025	Year ended March 31, 2024
	Gratuity Unfunded	Gratuity Unfunded
Present Value of obligation as at year-end	23.32	6.25
Fair value of plan assets at year end	-	-
Net Asset / (Liability)	(23.32)	(6.25)

**IV Bifurcation of Present value of obligation at the end of the year**

	Year ended March 31, 2025	Year ended March 31, 2024
Current liability	2.06	0.05
Non-current liability	21.26	6.20

**V Actuarial Assumptions**

	Year ended March 31, 2025	Year ended March 31, 2024
Discount rate	6.99%	7.22%
Expected rate of return on plan assets	N.A.	N.A.
Mortality table	100% of IALM (2012-14)	100% of IALM (2012-14)
Salary escalation	10%	10%

**VI Sensitivity Analysis**

	Year ended March 31, 2025		Year ended March 31, 2024	
	Increase	Decrease	Increase	Decrease
Discount rate (0.50 % movement)	(0.77)	0.82	(0.17)	0.18
Future salary growth (0.50 % movement)	0.80	(0.76)	0.18	0.17

**VII Maturity Profile of Defined Benefit Obligation**

	Year ended March 31, 2025	Year ended March 31, 2024
	Gratuity Unfunded	Gratuity Unfunded
Within the next 12 months	2.06	0.05
Between 2-5 years	9.47	2.68
Beyond 5 years	11.79	3.53

**39 CONTINGENT LIABILITIES**

	As at March 31, 2025	As at March 31, 2024
Claim against the company not acknowledged as debt		
- Income Tax	1.92	-
- Goods and Service Tax	-	-
- Customs	-	-
- Other matters including claims related to customers, labour and third parties, etc.	-	-

The Group has reviewed all its pending litigations and proceedings and has adequately provided for where provisions are required and disclosed as contingent liabilities where applicable, in its financial statements. The Group does not expect the outcome of these proceedings to have a materially adverse effect on its financial position.



**PI HEALTH SCIENCES LIMITED**

Notes to the Consolidated financial statements for the year ended March 31, 2025  
(All amounts in ₹ million, unless otherwise stated)

**40 OPERATING SEGMENT**

An operating segment is a defined as component of the entity that represents business activities from which it may earn revenues and incur expenses and for which discrete financial information is available. The operating segments are based on the group's internal reporting structure and manner in which operating results are reviewed by Chief Operating Decision Maker (CODM).

The Group has evaluated the applicability of segment reporting and has concluded that since the principal activities of the group are Manufacturing and/or trading, research and development of all kinds of Pharmaceuticals products, Pharma intermediates and related products accordingly the Company has one reportable business segment viz. Pharma Products.

**I Revenue****a Information about product revenues**

The amount of its revenue from external customers broken down by products is shown in the table below:

Particulars	For the year ended March 31, 2025	For the year ended March 31, 2024
Contract Research Development Organisation (CRDO)	363.50	373.03
Contract Manufacturing Organisation (CMO)	1,769.62	2,723.01
Others	17.84	52.59
<b>Total</b>	<b>2,150.96</b>	<b>3,148.63</b>

Contract Research Development Organization (CRO) that provides support to the pharmaceutical, biotechnology, and medical device industries in the form of research services outsourced on a contract basis and Contract Manufacturing Organisation (CMO) that serves other companies in the pharmaceutical industry on a contract basis to provide comprehensive services from drug development through drug manufacturing.

**b Geographical Areas**

The group is domiciled in India. The amount of its revenue from external customers broken down by location of the customers is shown in the table below:

Particulars	For the year ended March 31, 2025	For the year ended March 31, 2024
India	396.07	297.45
Europe	1,123.48	1,246.96
United States of America	503.83	1,400.29
Rest of the World	127.58	203.94
<b>Total</b>	<b>2,150.96</b>	<b>3,148.63</b>

The following is the carrying amount of non current assets by geographical area in which the assets are located:

Carrying amount of non-current assets	As at March 31, 2025	As at March 31, 2024
India	3,932.37	3,654.59
Europe	3,114.47	2,661.21
United State of America	134.43	140.90
<b>Total</b>	<b>7,181.27</b>	<b>6,456.70</b>

**Note:**

Non current assets exclude investments, goodwill, financial assets and deferred tax balance.

The revenue from transactions with one external customer exceeds 10% of the total revenue of the group for the year ended March 31, 2024.

**41 CAPITAL & OTHER COMMITMENT**

	As at March 31, 2025	As at March 31, 2024
Estimated Amount of Contracts remaining to be executed on capital account and not provided for {net of advances ₹ 6.35 (March 31, 2024 : ₹ 17.93)}	241.92	606.21

**42 LEASES - COMPANY AS A LESSOR****Operating lease**

The lease rentals recognized as income in these statements as per the rentals stated in the respective agreements:

Particular	For the year ended March 31, 2025	For the year ended March 31, 2024
<b>Lease rentals recognized as income during the year</b>		
- Variable lease rentals		
- Others	15.39	11.15

These assets relate to land and building subleased on account of idle space utilisation by subleasing it to respective customers.

Undiscounted Lease Payments to be received after the reporting date is ₹ 108.91.



**PI HEALTH SCIENCES LIMITED**
**Notes to the Consolidated financial statements for the year ended March 31, 2025**
**(All amounts in ₹ million, unless otherwise stated)**
**43 RELATED PARTY DISCLOSURES**

Related party disclosure, as required by Indian Accounting Standard-24, is as below:

**a) List of Related Parties:-**
**I. Enterprises which control the entity**

- (a) PI Industries Limited

**II. ENTERPRISES WHERE CONTROL EXISTS**
**Subsidiaries and their subsidiaries**

- (a) PI Health Sciences Netherlands B.V
- 
- (b) PI Health Sciences USA LLC
- 
- (c) Archimica S.P.A

**III. Fellow Subsidiaries**

- (a) PILL Finance and Investment Limited
- 
- (b) PI Life Science Research Limited
- 
- (c) PI Japan Co. Limited
- 
- (d) Jivagro Limited
- 
- (e) PI Fermachem Private Limited
- 
- (f) PI Bioferma Private Limited
- 
- (g) PI Industries Management Consultancies LLC
- 
- (h) Plant Health Care Ltd
- 
- (i) Plant Health Care, Inc., Nevada
- 
- (j) Plant Health Care (España) S.A, Spain
- 
- (k) Plant Health Care (UK) Limited
- 
- (l) Plant Health Care de Mexico S. de R.L. de C.V, Mexico
- 
- (m) Plant Health Care Insumos Agrícolas Ltd, Brazil

**IV. Key Managerial Personnel**

a) Mr. Narayan Keelveedhi Seshadri	Chairperson (Director)
b) Mr. Arunabha Raychaudhuri	Whole Time Director (w.e.f. July 05, 2024)
c) Mr. Mayank Singhal	Director
d) Mr. Rajnish Sarna	Director
e) Dr. Tanjore Soundararajan Balganesi	Director
f) Dr. Atul Kumar Gupta	Director (w.e.f. August 03, 2024)
g) Ms. Suman Gopalan	Director (w.e.f. August 03, 2024)
h) Mr. Anil Kumar Jain	Managing Director upto July 05, 2024
i) Mr. Ankit Nayyar	Chief financial officer
j) Mrs. Ruchi Sheth	Company Secretary

**V. Entities controlled by KMP with whom transactions have taken place**

- (a) PI Foundation

**b) The following transactions were carried out with related parties in the ordinary course of business:**

Nature of Transaction	2024-25		2023-24	
	Transaction during the period	Balance outstanding as Dr / (Cr)	Transaction during the period	Balance outstanding Dr / (Cr)
<b><u>Compensation to KMP</u></b>				
Short term employee benefits	23.63	-	61.76	-
Post employment benefits	1.80	-	7.98	-
Director sitting fees	0.39	-	0.45	-
Reimbursement on account of expenses incurred	0.09	-	9.27	(1.36)
Salary and other perquisites	17.91	-	6.28	-
<b><u>Transactions with PI Industries Limited</u></b>				
Issue of share capital	-	-	4,165.00	-
Issue of OFCD*	2,000.00	(7,500.00)	5,500.00	(5,500.00)
Loans received	-	-	3,910.00	-
Loans repaid	-	-	4,600.00	-
Interest paid on OFCD	32.86	(27.51)	5.05	(4.54)
Interest paid on loan	-	-	281.02	-
Rent paid	0.71	-	0.68	(0.06)
Consumable purchase	3.77	(1.60)	0.08	-
Cross charge	4.92	-	2.40	(2.59)
Reimbursement on account of expenses incurred	0.12	-	-	-
Purchase of Capital Asset	0.22	(0.03)	-	-
Sale of goods	18.57	10.20	2,063.53	-
Rent received	1.99	2.35	2,185.00	2,188.89
<b><u>Transactions with PI Foundation</u></b>				
Contribution towards CSR Activities	-	-	9.37	-

**Terms and conditions of transactions with related parties**

The sales and purchases / services rendered to and from related parties are made on terms equivalent to those that prevail in arm's length transactions. Outstanding balances at the year-end are unsecured and interest free and settlement occurs in cash. There have been no guarantees provided or received for any related party receivables or payables. For the year ended March 31, 2025, the Company has not recorded any impairment of receivables relating to amounts owed by related parties. This assessment is undertaken each financial year through examining the financial position of the related party and the market in which the related party operates.

\* As per Ind AS closing balance of OFCD is ₹ 7225.69 (March 31, 2024 ₹4937.69).





**44 FINANCIAL INSTRUMENTS****Financial instruments – Fair values and risk management****A. Financial instruments by category**

	As at March 31, 2025			As at March 31, 2024		
	FVTPL	FVTOCI	Amortised Cost	FVTPL	FVTOCI	Amortised Cost
<b>Financial assets</b>						
<b>Non-current assets</b>						
Investment	5.66	-	-	5.52	-	-
Security deposits	-	-	17.42	-	-	12.45
Derivative financial instrument	-	4.28	-	-	18.73	-
<b>Current assets</b>						
Trade receivables	-	-	933.22	-	-	1,285.39
Cash and cash equivalents	-	-	546.70	-	-	475.31
Bank balances other than cash and cash equivalent	-	-	11.48	-	-	11.56
Other financial assets	-	-	3.84	-	-	15.07
<b>TOTAL</b>	<b>5.66</b>	<b>4.28</b>	<b>1,512.66</b>	<b>5.52</b>	<b>18.73</b>	<b>1,799.78</b>
<b>Financial liabilities</b>						
<b>Non-current liabilities</b>						
Borrowings	-	-	7,988.19	-	-	5,554.25
Lease liabilities	-	-	63.88	-	-	71.45
Other financial liabilities	1,501.49	-	-	1,347.85	-	-
<b>Current liabilities</b>						
Borrowings	-	-	329.20	-	-	662.39
Lease liabilities	-	-	12.59	-	-	12.44
Trade payables	-	-	878.31	-	-	620.20
Derivative financial instrument	-	4.88	-	-	4.56	-
Other financial liabilities	70.62	-	522.32	-	-	551.96
<b>TOTAL</b>	<b>1,572.12</b>	<b>4.88</b>	<b>9,794.49</b>	<b>1,347.85</b>	<b>4.56</b>	<b>7,472.70</b>

**B. Fair value hierarchy**

This section explains the judgements and estimates made in determining the fair values of the financial instruments that are

(a) recognised and measured at fair value and

(b) measured at amortised cost and for which fair values are disclosed in the financial statements.

To provide an indication about the reliability of the inputs used in determining fair value, the company has classified its financial instruments into the three levels prescribed under the accounting standard. An explanation of each level follows underneath the table.

The fair value of cash and cash equivalents, bank balances other than Cash and cash equivalents, trade receivables, contract assets, current financial assets, trade payables and current financial liabilities approximate their carrying amount, largely due to the short-term nature of these instruments. Optionally fully convertible debentures has been recently floated to parent which resonates to its fair value as on reporting date. Fair value for security deposits (other than perpetual security deposits) and lease liabilities has been presented in the below table.

Following table present fair value heirarchy of assets and liabilities measured at fair value

	As at March 31, 2025			As at March 31, 2024		
	Level 1	Level 2	Level 3	Level 1	Level 2	Level 3
<b>Financial assets</b>						
Security deposits	-	-	28.51	-	-	21.53
Derivative asset	-	4.28	-	-	18.73	-
	-	<b>4.28</b>	<b>28.51</b>	-	<b>18.73</b>	<b>21.53</b>
<b>Financial liabilities</b>						
Deferred consideration	-	-	-	-	-	254.97
Derivative liability	-	4.88	-	-	4.56	-
Other financial liabilities	-	-	1,572.12	-	-	1,347.85
<b>TOTAL</b>	-	<b>4.88</b>	<b>1,572.12</b>	-	<b>4.56</b>	<b>1,602.82</b>

The valuation of purchase consideration payable is done using discounted cash flow method which considered the present value of expected future dates payments.



**Fair value hierarchy**

The table shown above analyses financial instruments carried at fair value, by valuation method. The different levels have been defined below:

Level 1 - This includes financial instruments measured using quoted prices.

Level 2 - The fair value of financial instruments that are not traded in an active market is determined using valuation techniques which maximise the use of observable market data and rely as little as possible on entity-specific estimates. If all significant inputs required to fair value an instrument are observable, the instrument is included in level 2. Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices).

Level 3 - If one or more of the significant inputs is not based on observable market data, the instrument is included in level 3.

**Valuation technique used to determine fair value:**

Specific valuation techniques used to value financial instruments includes:

- the use of quoted market prices
- the fair value of forward rate agreement is determined using forward interest rates at the balance sheet date
- the fair value of the remaining financial instruments is determined using discounted cash flow analysis.

The fair values for security deposits and deferred purchase consideration were calculated based on present values of cash flows and the discount rates used were adjusted for counterparty or own credit risk. They are classified as level 3 fair values in the fair value hierarchy due to the inclusion of unobservable inputs including counterparty credit.

**15 FINANCIAL RISK MANAGEMENT**
**Risk management framework**

The Group activities expose it to a variety of financial risks - credit risk, market risk and liquidity risk. The Group board of directors has the overall responsibility for the management of these risks.

This note explains the sources of risk which the entity is exposed to and how the entity manages the risk.

**i. Credit risk**

Credit risk is the risk of financial loss to the Group if a customer or counterparty to a financial instrument fails to meet its contractual obligation, and arises from the operating activities primarily (trade receivables) and from its financing activities including cash and cash equivalents, deposits with banks and other financial instruments. The carrying amount of financial assets represents the maximum credit exposure and is as follows:

**Trade receivables and contract assets**

The Group's exposure to credit risk is influenced mainly by the individual characteristics of each customer and the concentration of risk from the top few customers. However, management also considers the factors that may influence the credit risk of its customer base, including the default risk of the industry and country in which customers operate including the past trends on recoverability.

The group has established a credit policy under which each customer is analysed individually for creditworthiness before the Group's credit terms are offered. Credit risk is managed through credit approvals, establishing credit limits and continuously monitoring the creditworthiness of customers to which the Group grants credit terms in the normal course of business. Credit limits are established for each customer and reviewed periodically.

**Credit risk exposure**

The allowance for lifetime expected credit loss on customer balances recognized as on March 31, 2025 & March 31, 2024 is ₹231.00 and ₹ 23.73 respectively.

Particulars	As at March 31, 2025	As at March 31, 2024
Balance at the beginning	23.73	-
Change in loss allowance	207.27	23.73
Amounts written off	-	-
<b>Balance at the end</b>	<b>231.00</b>	<b>23.73</b>

The exposure to credit risk and expected credit loss on contract assets as at 31 March 2025 is insignificant and hence no loss allowance has been made.

**Cash and cash equivalents, deposits with banks:**

Credit risk from balances with banks and other financial instruments is managed by Group in accordance with its policy. Investments of surplus funds are made only with approved

counterparties and within credit limits assigned to each counterparty. Counterparty credit limits are reviewed by the management and may be updated throughout the year.

Impairment on cash and cash equivalents, deposits and other financial instruments has been measured on the 12-month expected credit loss basis and reflects the short maturities of the exposures. For financial assets which are long term in nature, the expected credit loss is insignificant.

Accordingly, based on the assessment there is no material allowance in the above financial assets.

**Derivatives**

The derivatives are entered with banks and financial institution counter parties which have low credit risk based on external credit ratings of counter parties.



**PI HEALTH SCIENCES LIMITED**
**Notes to the Consolidated financial statements for the year ended March 31, 2025**
**(All amounts in ₹ million, unless otherwise stated)**
**Exposure to credit risk:**

The gross carrying amount of financial assets, net of impairment losses (if any) recognized represent the maximum credit exposure. The maximum exposure to credit risk as at March 31, 2024 was as follows:

Particular	As at March 31, 2025	As at March 31, 2024
Trade receivables	933.22	1,285.39
Cash and cash equivalents	546.70	475.31
Other bank balances	11.48	11.56
Investment	5.66	5.52
Other financial assets	25.53	46.25
<b>Total</b>	<b>1,748.19</b>	<b>2,547.29</b>

**ii. Liquidity risk**

Liquidity risk is the risk that the Group will encounter difficulty in meeting the obligations associated with its financial liabilities that are settled by delivering cash or another financial asset. The Group's approach to managing liquidity is to ensure, as far as possible, that it will have sufficient liquidity to meet its liabilities when they are due, under both normal and stressed conditions, without incurring unacceptable losses or risking damage to the Group's reputation.

Management monitors rolling forecast of Group's liquidity position and cash and cash equivalents on the basis of expected cash flows. In addition, the Group's liquidity management policy involves projecting cash flows in major currencies and considering the level of liquid assets necessary to meet these and monitoring balance sheet liquidity ratios against internal and external regulatory requirements.

**a. Financing arrangements**

The Group had access to the following undrawn borrowing facilities at the end of the reporting period:

	As at March 31, 2025	As at March 31, 2024
Expiring within six months (Floating rate)	552.54	-

**b. Maturities of financial liabilities**

The following are the remaining contractual maturities of financial liabilities at the reporting date.

As at March 31, 2025	Contractual cash flows					
	Total	3 months or less	3-12 months	1-2 years	2-5 years	More than 5 years
<b>Financial liabilities</b>						
Borrowing	11,504.70	143.51	243.48	213.23	10,904.48	-
Lease liabilities	184.28	3.59	14.70	18.79	24.88	122.32
Trade payables	878.31	878.31	-	-	-	-
Other financial liabilities	2,628.95	607.46	14.61	630.99	1,375.89	-
<b>Total</b>	<b>15,196.24</b>	<b>1,632.87</b>	<b>272.79</b>	<b>863.01</b>	<b>12,305.25</b>	<b>122.32</b>

As at March 31, 2024	Contractual cash flows					
	Total	3 months or less	3-12 months	1-2 years	2-5 years	More than 5 years
<b>Financial liabilities</b>						
Borrowing	8,885.89	353.45	315.13	292.61	7,879.80	44.90
Lease liabilities	197.33	3.43	13.07	17.21	38.74	124.88
Trade payables	620.20	620.20	-	-	-	-
Other financial liabilities	3,003.88	268.33	340.16	701.07	811.16	883.16
<b>Total</b>	<b>12,707.30</b>	<b>1,245.41</b>	<b>668.36</b>	<b>1,010.88</b>	<b>8,729.70</b>	<b>1,052.93</b>

**iii. Market risk**

Market risk is the risk that changes in market prices - such as foreign exchange rates, interest rates and equity prices - will affect the Group's income or the value of its holdings of

financial instruments. The objective of market risk management is to manage and control market risk exposures within acceptable parameters while optimising the return.

The Group is exposed to market risk primarily related to foreign exchange rate risk (currency risk) and interest rate risk. Thus, the Group's exposure to market risk is a function of investing and borrowing activities and revenue generating and operating activities in foreign currencies.

**Foreign Currency risk**

The Group is exposed to foreign exchange risk arising from foreign currency transactions, primarily with respect to the USD and Euro. Foreign exchange risk arises from future commercial transactions and recognised assets and liabilities denominated in a currency that is not the Group's functional currency (₹).

**Foreign currency risk exposure -**

The currency profile of financial assets and financial liabilities as at reporting date expressed in Indian Rupees (₹) are as below:

**Financial assets**

	As at March 31, 2025				As at March 31, 2024			
	USD	EURO	GBP	Others	USD	EURO	GBP	Others
Trade receivables	51.74	-	-	-	781.15	116.22	-	-
Cash and cash equivalent (EEFC account)	26.53	-	-	-	16.39	-	-	-
	<b>78.27</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>797.54</b>	<b>116.22</b>	<b>-</b>	<b>-</b>

**Financial liabilities**

	As at March 31, 2025				As at March 31, 2024			
	USD	EURO	GBP	Others	USD	EURO	GBP	Others
Trade Payable	79.50	-	0.47	-	42.63	-	3.66	0.13
Creditors for capital purchase	1.59	-	-	-	17.71	0.07	3.66	0.13
	<b>81.09</b>	<b>-</b>	<b>0.47</b>	<b>-</b>	<b>60.34</b>	<b>0.07</b>	<b>7.32</b>	<b>0.26</b>
Spot exchange rate on reporting date	85.48	92.09	110.70	-	83.41	89.88	105.03	-



**Sensitivity analysis**

A reasonably possible strengthening (weakening) of the foreign currency at March 31 would have affected the measurement of financial instruments denominated in foreign currencies and affected equity and profit or loss by the amounts shown below. This analysis assumes that all other variables, interest rates, remain constant and ignores any impact of forecast sales and purchases. 1% increase or decrease is used when reporting foreign currency risk internally to key management personnel and represents management's assessment of the reasonably possible change in foreign currency rate.

Effect in INR	Profit or loss, net of tax		Impact on other components of equity, net of tax	
	Strengthening	Weakening	Strengthening	Weakening
<b>As at March 31, 2025</b>				
1% movement				
USD	(0.02)	0.02	-	-
EURO	-	-	-	-
GBP	(0.00)	0.00	-	-
<b>As at March 31, 2024</b>				
1% movement				
USD	7.37	(7.37)	-	-
EURO	1.16	(1.16)	-	-
GBP	(0.07)	0.07	-	-

**Interest rate risk**

The Group's main interest rate risk arises from term loan borrowings at variable rates for external borrowing. Group's investments are primarily in fixed deposits which are short term in nature and do not expose it to interest rate risk. The Group regularly evaluates the interest rate hedging requirement to align with interest rate views and defined risk appetite, in order to ensure most cost effective interest rate risk management. The Group has taken loan from parent Company carrying a fixed interest rate, hence there is no interest rate risk at the reporting date for loan taken from parent company.

**Exposure to interest rate risk**

The interest rate profile of the Company's interest-bearing financial instruments as reported to the management of the Group is as follows.

Particular	As at March 31, 2025	As at March 31, 2024
<b>Fixed-rate instruments</b>		
Financial liabilities	7,225.69	4,937.69
<b>Variable-rate instruments</b>		
Financial liabilities	1,091.69	1,278.95
<b>Total</b>	<b>8,317.38</b>	<b>6,216.64</b>

**Fair value sensitivity analysis for fixed-rate instruments**

The Company does not account for any fixed-rate financial assets or financial liabilities at fair value through profit or loss. Therefore, a change in interest rates at the reporting date would not affect profit or loss.

**Cash flow sensitivity analysis for variable-rate instruments**

A reasonably possible change of 50 bp in interest rates would have increased / (decreased) equity and profit or loss by the amounts shown below. This analysis assumes that all other variables, in particular foreign currency exchange rates, remain constant.

Effect in INR	Profit or loss, net of tax		Impact on other components of equity, net of tax	
	Strengthening	Weakening	Strengthening	Weakening
<b>As at March 31, 2025</b>				
Variable rate instruments	(5.46)	5.46	-	-
Cash flow sensitivity (net)	<b>(5.46)</b>	<b>5.46</b>	-	-
<b>As at March 31, 2024</b>				
Variable rate instruments	(6.39)	6.39	-	-
Cash flow sensitivity (net)	<b>(6.39)</b>	<b>6.39</b>	-	-

**Price risk**

The Group is not exposed to any price risk as at the reporting date.

**Impact of Hedging activities**

Disclosure of hedge accounting on financial position

Type of hedge and risk	As at March 31, 2025					
	No. of outstanding contracts	Nominal Value	Carrying value of hedging instrument *		Maturity date	Hedge Ratio
Interest Rate Option Contract	4	656.54	Financial Asset	4.28	May 2025 to September 2029	1:1
			Financial Liabilities	4.88		

Type of hedge and risk	As at March 31, 2024					
	No. of outstanding contracts	Nominal Value	Carrying value of hedging instrument *		Maturity date	Hedge Ratio
Interest Rate Option Contract	4	914.88	14.17		April 2025 to September	1:1



#### **46 BUSINESS COMBINATION**

During the current financial year there is no scheme of arrangement however in financial year 2023-24, the Group has acquired the following businesses:-

**(a) Acquisition of Therachem Research Medilab (India) Private Limited ("TRM India")**

PI Health Sciences Limited has entered into a share purchase agreement dated 27th April 2023 for the acquisition of 100% shareholding of "Therachem Research Medilab (India) Private Limited" which is now merged with the Company. On 2nd June 2023, PI Health Sciences Limited acquired 53,800 equity shares of face value ₹ 100 each for total purchase consideration ₹ 3,595.11.

The acquisition will enable the Company's plans of growth and expansion in pharmaceutical sector.

TRM India was engaged in the business of research, development and manufacturing of chemical compounds which are ultimately used for manufacturing of API (active pharmaceutical ingredients) and other pharmaceutical products.

**(b) Acquisition of Solis Pharmachem Private Limited ("Solis India")**

PI Health Sciences Limited has entered into a share purchase agreement dated 27th April 2023 for the acquisition of 100% shareholding of "Solis Pharmachem Private Limited" which is now merged with the Company.

On 2nd June 2023, PI Health Sciences Limited acquired 24,757,900 equity shares of face value ₹ 10 each for total purchase consideration ₹ 248.

The acquisition will enable the Company's plans of growth and expansion in pharmaceutical sector.

Solis Pharmachem is engaged in the business of research, development and manufacturing of chemical compounds which are ultimately used for manufacturing of API (active pharmaceutical ingredients) and other pharmaceutical products.

**(c) Acquisition of Archimica Spa ("Archimica")**

PI Health Sciences Netherlands B.V. ("PIHS BV") a wholly owned subsidiary of the Company, has entered into the share purchase agreement dated 26 April 2023 with existing shareholder of Archimica S.p.A. ("Archimica"), Plahoma Twelve GmbH, a private limited company incorporated under German law and the acquisition of 100% shareholding of Archimica was completed on 27 April 2023.

PIHS BV has acquired 16,463,115 equity shares of face value € 0.62 each for total purchase consideration € 34.2.

The acquisition will enable the Company's plans of growth and expansion in pharmaceutical sector.

Archimica is engaged in the business of manufacturing of API (active pharmaceutical ingredients) and other pharmaceutical products. Archimica is also engaged in the business of Contract Development and Manufacturing Organisation (CDMO).

**(d) Acquisition of business of Therachem Research Medilab, LLC ("TRM US")**

PI Health Sciences USA, LLC ("PIHS LLC"), a wholly-owned subsidiary of PIHS BV has entered into an asset purchase agreement (APA) dated 27 April 2023 with TRM US, Dr. PooranChand and Ms. Namita Bansal for acquisition of certain identified assets of TRM US.

As per APA, PIHS LLC has acquired certain movable, non-movable assets and employees of TRM US. On concentration test of these assets as specified in Para B7A of Ind AS 103, Business Combination, these assets didn't meet the required criteria.

Further, on assessment of elements of a business i.e., input, process and output, APA included an integrated set of activities and assets (i.e. input and a substantive process) which is significantly contributing to the ability to produce an output. Thus, it met the definition of business and therefore the substance of the APA is a business combination.

The assets acquisition will add new capabilities and will promote the Company's plans of growth and expansion in pharmaceutical sector.



**PI HEALTH SCIENCES LIMITED**
**Notes to the Consolidated financial statements for the year ended March 31, 2025**
**(All amounts in ₹ million, unless otherwise stated)**
**Assets acquired and liabilities assumed**

The fair values of the identifiable assets and liabilities as at the date of acquisition were:

<b>Assets</b>	<b>TRM India</b>	<b>Solis India</b>	<b>Archimica</b>	<b>TRM US</b>
Property, plant and equipment	288.50	236.75	2,169.24	142.16
Capital work in progress	0.20	-	215.35	-
Intangible assets	-	-	9.33	-
Trade receivables	6.13	22.95	879.62	-
Contract Asset	825.79	-	327.50	-
Cash and cash equivalents	566.95	2.23	111.30	-
Other bank balances	19.65	-	-	-
Other financial assets	13.66	4.58	-	-
Inventories	144.34	0.26	936.51	-
Current tax assets	97.29	-	-	-
Deferred tax assets	9.57	-	131.61	-
Other assets	54.11	12.38	98.53	-
<b>Total Assets (I)</b>	<b>2,026.19</b>	<b>279.15</b>	<b>4,878.99</b>	<b>142.16</b>
<b>Liabilities</b>				
Borrowings	-	-	1,034.25	-
Trade payables	30.77	8.57	771.25	-
Lease liabilities	3.72	-	3.72	-
Provisions	9.84	0.23	187.15	-
Deferred tax liabilities	-	1.22	-	-
Current tax liabilities	-	-	36.07	-
Other current liabilities	334.53	4.18	147.71	-
<b>Total Liabilities (II)</b>	<b>378.86</b>	<b>14.20</b>	<b>2,180.15</b>	<b>-</b>
Identifiable net assets at fair value (I-II)	1,647.33	264.95	2,698.84	142.16
Fair value of intangible asset identified on acquisition				
Customer contracts	1,661.00	-	-	-
Technical know-how	-	-	251.76	-
<b>Total net assets assumed</b>	<b>3,308.33</b>	<b>264.95</b>	<b>2,950.60</b>	<b>142.16</b>

**Purchase consideration**

Cash paid on business combination	2,732.80	248.00	3,043.12	413.89
Deferred purchase consideration on account of working capital acquired as per share purchase agreement	624.53	-	-	-
Additional deferred purchase consideration*	237.78	-	-	-

Contingent consideration of 15% of material margin earned for the date of acquisition till March 31, 2029\*\*

	-	-	-	1,196.00
<b>Total purchase consideration</b>	<b>3,595.11</b>	<b>248.00</b>	<b>3,043.12</b>	<b>1,609.89</b>

\* Additional deferred purchase consideration shall be paid after a period of 18 months from the date of acquisition, thereby, has been measured at fair value.

\*\* Contingent consideration is an additional amount payable by PIHS LLC to TRM US equivalent to fifteen percent (15%) of the sum of the material margin (revenue minus raw material cost) from the date of acquisition till 31 March 2029 on respective payment dates as per APA subject to maximum amount of \$25.

To determine the contingent consideration, PIHS LLC has estimated its obligation on respective payment dates and discounted it at 14% weighted average cost of capital with 100% probability.





**PI HEALTH SCIENCES LIMITED****Notes to the Consolidated financial statements for the year ended March 31, 2025****(All amounts in ₹ million, unless otherwise stated)****Calculation of goodwill**

	<b>TRM India</b>	<b>Solis India</b>	<b>Archimica</b>	<b>TRM US</b>
Purchase consideration	3,595.11	248.00	3,043.12	1,609.89
Less: Net assets assumed	3,308.33	264.95	2,950.60	142.16
Add: Deferred tax liability created on				
Fair value surplus on property, plant and equipment	39.00	2.49	271.17	-
Intangible asset identified on acquisition	418.04	-	64.78	-
Contract assets created on business combination	142.25	-	-	-
Exchange gain/(loss)	-	-	(4.54)	5.18
<b>Total goodwill</b>	<b>886.07</b>	<b>(14.46)</b>	<b>423.93</b>	<b>1,472.91</b>

TRM India and Solis India has been acquired as a part of single share purchase agreement having same parent and promoters, hence, capital reserve created on acquisition of Solis India has been netted off against the goodwill generated on acquisition of TRM India.

**Acquired receivables**

	<b>TRM India</b>	<b>Solis India</b>	<b>Archimica</b>	<b>TRM US</b>
Fair value of trade receivables	6.13	22.95	879.62	-
Fair value of contract assets	825.79	-	327.50	-
<b>Total fair value of acquired receivable</b>	<b>831.92</b>	<b>22.95</b>	<b>1,207.12</b>	<b>-</b>
Gross contractual amount of receivable	831.92	22.95	1,207.12	-
Contractual cash flows not expected to be collected	-	-	-	-

**Details of operational profit/loss**

	<b>TRM India</b>	<b>Solis India</b>	<b>Archimica</b>	<b>TRM US</b>
<b>Had acquisition occurred at the start of the year</b>				
Revenue from operations	326.83	34.63	2,743.41	NA
Loss before tax	(126.64)	(16.12)	(460.14)	NA
<b>From the actual date of acquisition</b>				
Revenue from operations	276.00	0.45	2,743.41	NA
Loss before tax	(123.62)	(24.80)	(460.14)	NA

**(e) Merger of TRM India and Solis India with PI Health Sciences Limited**

PI Health Sciences Limited had filed a Scheme of Amalgamation for the purpose of amalgamation of TRM India and Solis India businesses together with all the related assets, liabilities, and employees with PI Health Sciences Limited.

The said Scheme of Amalgamation has been approved by Hon'ble Regional Director, Ahmedabad, Ministry of Corporate Affairs vide its order dated 27th September 2023 under Section 233 read with rule 25 (5) of Companies Act, 2013 from effective date June 02, 2023. Accounting has been done in accordance with Indian Accounting Standard (Ind AS) 103 - Business Combinations.



**PI HEALTH SCIENCES LIMITED**

Notes to the Consolidated financial statements for the year ended March 31, 2025  
(All amounts in ₹ million, unless otherwise stated)

**47 ADDITIONAL INFORMATION REQUIRED UNDER PARAGRAPH 2 OF THE GENERAL INSTRUCTIONS FOR PREPARING OF CONSOLIDATED FINANCIALS  
STATEMENT TO SCHEDULE III TO COMPANIES ACT 2013**

**March 31, 2025**

Name of the entity	Net Assets i.e, total assets minus total liabilities		Share in profit or loss		Share in other comprehensive income		Share in total comprehensive income	
	As % of consolidated net assets	Amount (₹ Mns)	As % of consolidated profit or loss	Amount (₹ Mns)	As % of consolidated other comprehensive income	Amount (₹ Mns)	As % of consolidated total comprehensive income	Amount (₹ Mns)
<b>Parent</b>								
PI Health Sciences Limited	233.30%	3,945.35	35.52%	(871.99)	4.31%	4.20	36.81%	(867.79)
<b>Foreign Subsidiaries</b>								
PI Health Sciences Netherlands B.V	333.52%	5,640.13	2.81%	(68.91)	34.06%	33.16	1.52%	(35.75)
PI Health Sciences USA LLC	6.74%	113.94	11.90%	(292.05)	(2.15%)	(2.09)	12.48%	(294.14)
Archimica S.P.A	132.25%	2,236.48	48.77%	(1,197.37)	11.72%	11.41	50.30%	(1,185.96)
Consolidation adjustment and elimination	(605.82%)	(10,244.82)	1.01%	(24.80)	52.06%	50.69	-1.10%	25.88
<b>Total</b>	<b>100.00%</b>	<b>1,691.08</b>	<b>100.00%</b>	<b>(2,455.12)</b>	<b>100.00%</b>	<b>97.37</b>	<b>100.00%</b>	<b>(2,357.75)</b>

**March 31, 2024**

Name of the entity	Net Assets i.e, total assets minus consolidated net assets		Share in profit or loss		Share in other comprehensive income		Share in total comprehensive income	
	As % of consolidated net assets	Amount (₹ Mns)	As % of consolidated profit or loss	Amount (₹ Mns)	As % of consolidated other comprehensive income	Amount (₹ Mns)	As % of consolidated total comprehensive income	Amount (₹ Mns)
<b>Parent</b>								
PI Health Sciences Limited	119.74%	4,635.76	17.76%	(158.38)	1.44%	(0.45)	17.21%	(158.83)
<b>Foreign Subsidiaries</b>								
PI Health Sciences Netherlands B.V	50.26%	1,945.65	9.40%	(83.85)	109.14%	(34.03)	12.77%	(117.88)
PI Health Sciences USA LLC	2.04%	78.92	5.14%	(45.87)	(5.52%)	1.72	4.78%	(44.14)
Archimica S.P.A	78.54%	3,040.75	39.22%	(349.78)	90.80%	(28.31)	40.96%	(378.09)
Consolidation adjustment and elimination	(150.58%)	(5,829.62)	28.48%	(254.07)	(95.86%)	29.89	24.29%	(224.18)
<b>Total</b>	<b>100.00%</b>	<b>3,871.46</b>	<b>100.00%</b>	<b>(891.95)</b>	<b>100.00%</b>	<b>(31.18)</b>	<b>100.00%</b>	<b>(923.13)</b>



**PI HEALTH SCIENCES LIMITED**
**Notes to the Consolidated financial statements for the year ended March 31, 2025**
**(All amounts in ₹ million, unless otherwise stated)**
**48 OTHER STATUTORY INFORMATION**

- i) The Group does not have any transactions and balances with companies struck off.
- ii) The Group does not have any Benami property, where any proceeding has been initiated or pending against the Group for holding any Benami property.
- iii) The Group does not have any charges or satisfaction which is yet to be registered with ROC beyond the statutory period.
- iv) The Group has not traded or invested in Crypto currency or Virtual Currency during the financial year.
- v) The Group has advanced or loaned or invested funds to following entities, including foreign entities (intermediaries) with the understanding that the intermediary shall:

(a) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Group (ultimate beneficiaries) or

(b) provide any guarantee, security or the like to or on behalf of the Ultimate Beneficiaries

The details are as follows:

**For the year ending March 31, 2025**

Name of the intermediary to which the funds are loaned or invested	Type	Date of transaction	Amount (INR)	Ultimate beneficiaries
PI Health Sciences Netherland B.V	Loan	April 05, 2024	90.48	Archimica S.p.A and PI Health Sciences USA, LLC
	Loan	June 05, 2024	90.70	
	Loan	June 28, 2024	89.25	
	Loan	July 31, 2024	135.82	
	Loan	August 12, 2024	91.71	
	Loan	September 10, 2024	20.16	
	Loan	September 26, 2024	107.22	
	Loan	October 30, 2024	168.26	
	Conversion of loan to equity	October 31, 2024	(2,620.23)	
	Conversion of loan to equity	October 31, 2024	(452.37)	
	Loan	November 13, 2024	21.10	
	Investment	December 05, 2024	89.17	
	Investment	December 23, 2024	353.56	
	Investment	January 30, 2025	180.60	
	Investment	March 25, 2025	34.31	

Name of the ultimate beneficiary to which the funds are further loaned or invested by intermediary disclosed above	Type	Date of transaction	Amount
Archimica S.p.A	Investment	April 09, 2024	€ 10,00,000
	Investment	June 05, 2024	€ 10,00,000
	Investment	June 28, 2024	€ 10,00,000
	Investment	August 02, 2024	€ 15,00,000
	Investment	August 19, 2024	€ 10,00,000
	Investment	September 27, 2024	€ 11,50,000
	Investment	October 30, 2024	€ 18,00,000
	Conversion of loan to equity	October 31, 2024	€ (1,64,15,000)
	Investment	December 06, 2024	€ 10,00,000
	Investment	December 24, 2024	€ 32,50,000
	Investment	January 30, 2025	€ 10,00,000
	Investment	February 17, 2025	€ 10,00,000
PI Health Sciences USA, LLC	Loan repaid	April 05, 2024	\$ (50,000)
	Loan repaid	June 12, 2024	\$ (2,30,000)
	Loan	September 12, 2024	\$ 2,00,000
	Loan	September 12, 2024	\$ 2,00,000
	Loan	October 28, 2024	\$ 35,000
	Loan	November 14, 2024	\$ 2,50,000
	Conversion of loan to equity	November 30, 2024	\$ (26,23,015)
	Investment	December 31, 2024	\$ 5,50,000
	Investment	February 05, 2025	\$ 2,50,000
	Loan repaid	February 11, 2025	\$ (2,50,000)
	Investment	February 28, 2025	\$ 1,00,000
	Investment	March 19, 2025	\$ 40,000
	Investment	March 26, 2025	\$ 1,00,000



**PI HEALTH SCIENCES LIMITED**

Notes to the Consolidated financial statements for the year ended March 31, 2025  
(All amounts in ₹ million, unless otherwise stated)

For the year ending March 2024

Name of the intermediary to which the funds are loaned or invested	Type	Date of transaction	Amount (INR)	Ultimate beneficiaries
PI Health Sciences Nederland B.V.	Investment	April 21, 2023	2,063.53	Archimica S.p.A and PI Health Sciences USA, LLC
	Loan	April 21, 2023	1,175.39	
	Loan	May 18, 2023	134.38	
	Loan	May 31, 2023	413.69	
	Loan	October 18, 2023	61.64	
	Loan	February 26, 2024	129.92	
	Loan	March 05, 2024	179.99	
	Loan	March 26, 2024	90.00	

Name of the ultimate beneficiary to which the funds are further loaned or invested by intermediary disclosed above	Type	Date of transaction	Amount
Archimica S.p.A	Investment	April 26, 2023	€ 3,42,00,000
	Loan	May 10, 2023	€ 10,00,000
	Loan	June 05, 2023	€ 10,00,000
	Loan	October 11, 2023	€ 4,40,000
	Loan	October 11, 2023	€ 3,75,000
	Loan	October 19, 2023	€ 7,00,000
	Loan	February 06, 2024	€ 14,50,000
	Loan	March 05, 2024	€ 20,00,000
	Loan	March 26, 2024	€ 10,00,000
	Loan	March 26, 2024	€ 10,00,000
PI Health Sciences USA, LLC	Investment	April 26, 2023	\$ 15,00,000
	Loan	June 02, 2023	\$ 35,00,000
	Loan	June 02, 2023	\$ 10,000
	Loan	August 23, 2023	\$ 4,00,000
	Loan repaid	October 10, 2023	\$ (4,00,000)
	Loan repaid	March 21, 2024	\$ (8,41,985)

vi) The Group has received fund from following entity (funding party) with the understanding (whether recorded in writing or otherwise) that the Group shall:

(a) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party (ultimate beneficiaries) or

(b) provide any guarantee, security or the like on behalf of the ultimate beneficiaries

The details are as follows:

For the year ending March 31, 2025

Name of the funding party	Type	Date of transaction	Amount	Investment in other entities
PI Industries Limited	OFCDs	July 23, 2024	250.00	PI Health Sciences Nederland B.V.
	OFCDs	July 24, 2024	500.00	
	OFCDs	July 25, 2024	250.00	
	OFCDs	November 11, 2024	1,000.00	

For the year ending March 31, 2024

Name of the funding party	Type	Date of transaction	Amount	Investment in other entities
PI Industries Limited	Equity	April 10, 2023	4,165.00	PI Health Sciences Nederland B.V., Therachem Research Medilab (India) Private Limited & Solis Pharmachem Private Limited
	Loan	May 31, 2023	2,986.00	

vii) The Group has not been declared wilful defaulter any bank or financial institution or any other lender

viii) The Group has not revalued its property, plant and equipment (including right-of-use assets) or intangible assets or both during the current year except for asset acquired from business combination.

ix) The Group has complied with the number of layers prescribed under clause (87) of section 2 of the Companies Act, 2013 read with the Companies (Restriction on number of Layers) Rules, 2017.

x) The Group is maintaining its books of account in electronic mode and these books of account are accessible in India at all times and the back-up of books of account has been kept in servers physically located in India on a daily basis from the applicability date of the Companies (Accounts) Rules, 2014.

xi) The Group has no such transaction which is not recorded in the books of accounts that has been surrendered or disclosed as income during the year in the tax assessments under the Income Tax Act, 1961 (such as, search or survey or any other relevant provisions of the Income Tax Act, 1961).

xii) The Company has used accounting software for maintaining its books of account which has a feature of recording audit trail (edit log) facility and that has operated throughout the year for all relevant transactions recorded in the software, except that (a) the audit log at the application level, will not get generated in case of modification, if any performed by the users with certain specific privileged access; and (b) the audit trail feature at database level contains only the modified values to record any direct changes at the database level. During the course of performing our procedures, in respect of the audit trail feature enabled, we did not notice any instance of the audit trail feature being tampered with.



**PI HEALTH SCIENCES LIMITED**

Notes to the Consolidated financial statements for the year ended March 31, 2025  
(All amounts in ₹ million, unless otherwise stated)

**49 EVENTS OCCURRING AFTER THE BALANCE SHEET DATE**

No adjusting or significant non-adjusting events have occurred between the reporting date and date of authorization of these financial statements.

As per our report of even date

For S S Kothari Mehta & Co. LLP  
Chartered Accountants  
Firm Reg. No. 000756 / 500441

**AMIT GOEL**  
Partner  
Membership Number: 500607



Place: New Delhi  
Date: May 12, 2025

For and on behalf of the Board of Directors  
PI Health Sciences Limited

**Arunabha Raychaudhari**  
Director  
DIN: 10685547

**Rajnish Sarna**  
Director  
DIN: 06429468

**Ankit Nayyar**  
Chief Financial Officer

**Ruchi Jayesh Sheth**  
Company Secretary